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Abstract 
Biocatalytic processes are gaining significant focus in frontiers where they offer unique advantages 
(selectivity and mild operating conditions) over chemical catalysts. It is therefore not surprising that there 
have been many industrial biocatalytic processes implemented.  
Despite past successes, the implementation of a new biocatalytic process still presents some challenges 
(demands placed on the biocatalyst) in terms of the requirements to make a viable industrial process. In 
order for a biocatalytic process to be economically successful, it is necessary that certain a set of target 
metrics (product titre, biocatalyst yield or space time yield and reaction yield) are achieved. Hence, the 
biocatalyst must be able to work at high substrate and product concentrations. Such constraints that arise 
from the biocatalyst are classified as biocatalyst-related limitations. In addition, other limitations can arise 
from the reaction species (substrate and product volatility for example) and the process (such as oxygen 
supply, ability to control pH) and are classified as reaction-related and process-related constraints 
respectively. Although the development of biocatalyst and process engineering tools offers a number of 
solutions to overcome the limitations, it is often complicated to identify the key limitation of the system 
that prevents economic scale-up. Hence, development of a systematic method for identifying the 
limitations during early-stage development of a biocatalytic process and potentially the order in which they 
need to be tackled would offer a valuable tool for process development.  
Biocatalytic oxidations are potentially of great value because of the selective chemistry that they offer, 
resulting in higher yields compared to those achievable through chemical catalysis. Oxidases are 
particularly interesting biocatalysts because they use a mild oxidant (oxygen) as a substrate as opposed to 
their chemical counterparts which use strong oxidants such as permanganates. A class of oxidases called 
monoamine oxidases has been used as the central case study for the thesis. The rationale for choosing this 
system is that it has been shown to exhibit the potential for resolution of racemic amines, and is capable of 
producing industrially interesting imines which are rather difficult to synthesize by chemical routes.  
An important aspect for biocatalytic reactions would be the implementation of monitoring and control 
systems that allow for rapid data collection to gain process knowledge. For oxidase-based biocatalysis, 
oxygen is consumed in stoichiometric amounts for the reaction. Therefore, oxygen sensors which can 
measure the oxygen concentration can be a valuable tool for monitoring of the process. The thesis 
exemplifies the use of novel solvent-resistant oxygen sensors as supporting technology for oxidase-based 
reactions using a glucose oxidase reaction system as an example.  
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Implementation of biocatalytic oxidation at scale still requires process knowledge which includes the 
limitations of the system and the knowledge about the potential solutions available to alleviate these 
limitations. This thesis presents a methodology for development of oxidase-based biocatalytic processes. A 
particularly important aspect of the methodology includes the use of in silico analysis where property 
prediction tools have been used to identify the potential limitations to the reaction system prior to 
experimentation. Such an analysis presents the opportunity to direct experimental work and therefore 
reduce the time and effort spent on process development, by eliminating unfeasible routes. The example 
chosen for the development of the methodology was a specific monoamine oxidase-based syntheses for 
the production of a pharmaceutical intermediate.  This particular reaction system was chosen because of 
the potential use of the product of the biocatalytic reaction as a pharmaceutical intermediate. However, 
there was little information on the reaction system in the literature for the use of this biocatalyst for 
synthesis of chemicals. Therefore, early stage process understanding was required. The chapters of the 
thesis identify the potential limitations for the reaction system by systematic evaluation of the reaction 
system through the use of property prediction tools as well as experiments. The results obtained from the 
experiments are then used to identify the bottleneck for the implementation at scale. Furthermore, a 
discussion of the limitations and the order which they need to be tackled is presented. 
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Dansk Resumé 
Fokus på biokatalytiske processer er øget betydeligt på grund af deres unikke fordele (selektivitet og milde 
reaktionsbetingelser) i forhold til kemiske katalysatorer. Det er derfor heller ingen overraskelse at mange 
biokatalytiske processer allerede er blevet implementeret industrielt. 
Til trods for den hidtidige succes er det stadig en udfordring at sikre en bæredygtig industriel proces, når en 
ny biokatalytisk reaktion skal implementeres på industriel skala. Det er nødvendigt at en række mindstemål 
for processen (mht. produkt koncentration, biokatalysator udbytte, volumetrisk udbytte og reaktion 
udbytte) er opnået for at sikre økonomisk succes for en biokatalytisk proces. Det er derfor nødvendigt at en 
given biokatalysator fungere selv ved høje substrat- og produktkoncentrationer. Proces restriktioner der 
fremkommer på grund af biokatalysatoren er klassificeret som biokatalysator-relaterede begrænsninger. 
Ydermere kan der fremkomme begrænsninger grundet reaktions specier (for eksempel substrat og produkt 
flygtighed) samt selve processen (så som oxygen tilførsel eller evnen til at kontrollere pH), hvilke er 
klassificeret som henholdsvis reaktions- og proces-relaterede begrænsninger. Ingeniørværktøjer til 
forbedring af både biokatalysatorer og kemiske processer gør det muligt at afhjælpe system 
begrænsningerne, men det er oftest kompliceret at identificere nøgle-begrænsningerne der forhindre en 
økonomisk forsvarlig opskalering. Det er derfor nødvendigt at udvikle systematiske metoder der gør det 
muligt at identificere disse begrænsninger i en tidlig udviklingsfase af en biokatalytisk proces og potentielt 
også rækkefølgen som disse begrænsninger skal afhjælpes i.  
Biokatalytiske oxidationer er potentielt meget værdifulde på grund af den høje kemiske selektivitet de 
tilbyder, hvilket resulterer i højere udbytte sammenlignet med det opnåeligt med kemiske katalysatorer. 
Oxidaser er særligt interessante biokatalysatorer, da de udnytter et mildt oxidationsmiddel (oxygen) som 
substrat modsat deres kemiske modstykker der bruger stærke oxidationsmidler så som permanganater. 
Monoaminoxidaser, en klasse af oxidaser, er i denne afhandling brugt som det primære case study. 
Rationalet for valget af netop dette system er at enzymklassen kan bruges til resolution af racemiske 
aminer samt industriel produktion af interessante iminer, som ellers er meget svære a syntetisere via 
kemiske ruter.  
Implementering af måle- og kontrolsystemer der muliggør hurtig data indsamling vil være et vigtigt aspekt 
for biokatalytiske reaktioner. Oxidase-baseret biokatalyse forbruger oxygen i støkiometriskmængde. 
Oxygensensorer der kan måle oxygenkoncentrationer kan derfor udgøre et værdifuldt måleinstrument til at 
følge processen. Afhandlingen giver eksempler på brugen af moderne oxygensensorer der er 
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modstandsdygtige overfor organiske solventer der kan benyttes til at følge eksempelvis en glukoseoxidase 
katalyseret reaktion.  
Implementeringen af biokatalytisk oxidation på industrielskala kræver proceskendskab som inkluderer 
systembegrænsninger og viden der gør det muligt afhjælpe disse begrænsninger. Denne afhandling 
præsenterer en metodologi for udviklingen af oxidase-baserede biokatalytiske processer. Et specielt vigtigt 
aspekt i metodologien inkluderer brugen af in silico analyse hvor værktøjer til forudsigelse af kemiske 
egenskaber er brugt til at identificere de potentielle systembegrænsninger før eksperimenter. En sådan 
analyse giver muligheder for at give retningslinjer for efterfølgende eksperimentelt arbejde og derved 
reducere mængden a tid og ressourcer brugt på procesudvikling ved at udelukke urealiserbare alternativer. 
En monoaminoxidase baseret syntese af et intermediært lægemiddel blev benyttet som eksempel i 
udviklingen af metodologien. Dette reaktionssystem blev valgt specifikt på grund af den potentielle 
anvendelse af produktet som et vigtigt intermediært lægemiddel. Informationer i den videnskabelige 
litteratur omkring brugen af denne biokatalysator og det pågældende reaktionssystemet var dog yderst 
begrænsede, hvilket gjorde tidlig procesforståelse uundværligt. Kapitlerne i denne afhandling identificerer 
de potentielle begrænsninger i reaktionssystemet ved hjælp af systematisk evaluering af systemet gennem 
brugen af værktøjer til forudsigelse af kemiske egenskaber samt eksperimenter. Resultaterne opnået 
gennem det eksperimentelle arbejde er derefter brugt til at identificere flaskehalsene for 
implementeringen af processen på industrielskala. Ydermere bliver systembegrænsninger og rækkefølgen 
de skal afhjælpes i diskuteret grundigt. 
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Abbreviations and Nomenclature 
 
 
Abbreviation Description 
AAO Amino acid oxidase 
ACA Amino cephalosporanic acid 
AMBA Alpha methylbenzyl amine 
CE Crude-enzyme 
CPME Cyclopentylethyl ether 
DO Dissolved oxygen 
E.C. Enzyme commission 
E. coli Escherichia coli 
e.e. enantiomeric excess 
FAD Flavin adenine dinucleotide 
FDA Food and drug administration 
FDH Formate dehydrogenase 
FIA Flow injection analysis 
FMN Flavin mononeucleotide 
FTIR Fourier transform spectroscopy 
GC Gas chromatography 
gcdw Gram cell dry weight 
GMO Genetically modified organism 
GOx Glucose oxidase 
h Hour(s) 
HCV Hepatitis C virus 
ISPR In situ product removal 
ISSS In situ substrate supply strategy 
KPi Potassium phosphate buffer 
LC/MS Liquid chromatography/mass spectrometry 
LB Luria Bertani 
LED Light emitting diode 
M Molar 
MAO Monoamine oxidase 
MAO-N Monoamine oxidase from Aspergillus niger 
MTBE methyl tertbutyl ether 
MTQ 1-methyl-1,2,3,4-tetrahydroisoquinoline 
N.A.  Not applicable 
N.D. Not determined 
NMR Nuclear magnetic resonance  
NIR Near infrared  
pET 16 Vector containing N-terminal His Tag and a T7 expression region 
PQQ Pyrroloquinoline quinone 
rpm Rotations per minute 
7
 vi 
 
TB Terrific broth 
TTN Total turnover number 
WC Whole-cells 
WT Wild type 
 
Nomenclature Description Unit 
ccritaq Critical concentration of inhibitor in aqueous phase M 
fi Constant (=25 for liquids at room temperature) Dimensionless 
LogP Octanol-water partition coefficient  Dimensionless 
LogPi Octanol-water partition coefficient of inhibitor  Dimensionless 
OD600 Optical density at wavelength of 600 nm Dimensionless 
pKa Acid dissociation constant Dimensionless 
siaq Aqueous solubility of inhibitor M 
T Temperature ˚C 
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 Thesis Introduction 1.
1.1 Background  
Chemical industries have been producing value-added products which include a plethora of chemicals 
(which can broadly be classified into pharmaceuticals, fine chemicals, speciality chemicals and bulk 
chemicals).  The need for such chemicals combined with the realisation of the impact of civilization on the 
environment has driven chemical industries towards manufacturing such commodities through green 
chemistry. To this effect, the first principles of green chemistry were promoted by Anastas and Warner1. 
Green chemistry, in principle consists of processes that are considered to use raw materials (preferably 
renewable) effectively, generate less waste, and do not use toxic/hazardous materials in the production2. 
Consequently, bioprocesses (consisting of fermentation and biocatalysis) that use renewable materials and 
specific catalysts to produce the target molecule have seen rapid development in the past few years.  
Fermentation involves growing of cells and using their innate metabolic pathway to produce the product of 
interest (Figure 1-1). The products could include enzymes, peptides, feed for animals and chemicals such as 
propane diol, butanol, succinic acid, citric acid among others.  Fermentation has been used to produce cells 
which contain the enzyme of interest; however, fermentation is not in the scope of the thesis and will not 
be discussed in detail. 
Fermentation
Off-gas
Media
Innoculum
Oxygen
Product
(e.g. enzymes, acid,
animal feed etc.)
 
Figure 1-1: Schematic representation of batch fermentation.  
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Government policies and public pressure have contributed to the adoption of biocatalysis for greener 
manufacture3. Biocatalysis is a class of bioprocesses that are based on the use of enzyme(s) (either in free 
or immobilized forms) or whole-cells (growing or resting cells) as a catalyst4,5.  In Figure 1-2 biocatalysis 
using extracellular enzyme has been depicted. The focus of the thesis will be on biocatalytic processes.  
 
Fermentation
Waste (cells)
Extracellular enzyme
Cell
separation Biocatalysis
Substrate
Oxygen
Off-gasMedia
Innoculum
Biocatalysis using extracellular enzymes
Product
Enzyme
concentration
Conc. enzyme
Waste
Biocatalyst production BiocatalysisBiocatalyst formulation
 
Figure 1-2: Biocatalysis with an extracellular enzyme. 
 
1.2 When to use biocatalysis for chemical synthesis 
Selectivity is an important trait for catalysts employed in the production of chemicals. A catalyst which can 
be highly selective ensures a higher yield compared to a non-selective process (because a low selectivity 
would result in the loss of substrate by converting them into other undesirable products). Reactions 
catalysed with chemical catalysts often suffer from low selectivity, especially when chiral molecules are 
being produced. In order to selectively add a functional group using a chemical catalyst, the substrate 
molecule is often protected prior to the reaction and de-protected after the desired functional group has 
been added6.  These additional steps involve some losses in the reaction yield (i.e. gram of product 
produced per gram of substrate consumed) and generate more waste, thus going against green chemistry 
principles. Biocatalysis has gained importance in part due to their selectivity (regio- and stereo-selectivity) 
and the unique chemistry (compared to their chemical counterparts) that they offer7. Due to the highly 
selective nature of the biocatalysts, biocatalysis offers a much greater yield/atom economy over 
conventional chemistry.  
18
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Enzymes in general work very well at temperatures close to the natural environment of the organism from 
which the enzymes are isolated8. Because of this, it is not surprising that these catalysts are active at 
temperatures around 30 oC.  Biocatalysts thus additionally offer the advantage of operating at fairly low 
temperatures. Operating at low temperatures with high catalytic activity (which can easily be achieved 
through biocatalysis) can come in handy when using substrates that are less stable at high temperature. 
One such substrate that has benefited from biocatalysis is docosahexaenoic acid which is prone to 
oxidation9. 
Furthermore, enzymatic systems can operate well in aqueous media making the use of organic solvents 
unnecessary. However, since they generally operate in dilute systems, the requirement of downstream 
processing and the energy costs that come with it needs to be considered. Hence, operating at aqueous 
environment doesn’t necessarily make the process green. However, in case of reactions where oxygen or 
gases need to be supplied, use of organic solvents can cause handling difficulties and explosion hazards. In 
such cases, working in aqueous media can prove to be advantageous.  
Owing to these advantages it is not surprising that biocatalytic reactions not only have a major importance 
in the pharmaceutical industry but have also been extended to other areas of the chemical industry that 
include fine and bulk chemistry10-13. Biocatalytic reactions using hydrolases and transaminases have been 
established over the past few years7,14-17. Current focus has been shifted to employing enzymes capable of 
catalysing oxidation-reduction reactions and formation of C-X or C-C bonds. This is because carbon-carbon 
and carbon-functional group bond formation offers the backbone for generating several organic molecules. 
However, use of conventional chemistry for formation of C-C or C-X bonds can often be difficult and involve 
the use of additional agents for protecting and de-protecting the functional groups. Therefore, avoiding 
these agents and producing the chemical intermediate of interest has potential. Thus, enzymatic reactions 
have been identified and consequently there has been an increase in enzyme development (to cope with 
the conditions required for the application of the biocatalyst for synthesis) that has allowed for novel C-C, 
C-X bond formations through biocatalysis18,19. 
Of these reactions, oxidations are particularly interesting because they form the cornerstone for 
transformation in organic chemistry. Oxidation reactions offer access to different functional groups and can 
therefore offer functionalization of building blocks used in synthesis. Although the focus on green 
chemistry has moved traditional chemical oxidations from being catalysed by toxic catalysts, such as 
chromates, towards the use of milder transitional metal catalysts, the chemical route still suffer from issues 
of low selectivity20,21. The low yield and selectivity obtained from chemical catalysis combined with the high 
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selectivity offered from biocatalysts has caused a paradigm shift towards the use of biocatalytic 
oxidations22. Industrial implementations of biocatalytic oxidations are now available23,24 
Biocatalytic oxidations will be discussed further in this chapter leading up to the scope of the thesis. 
1.3 Biocatalytic oxidations 
Oxidizing enzymes can be broadly classified as dehydrogenases (EC 1.1.1.x), oxygenases (EC 1.13.x.x), 
oxidases (EC 1.1.3.x) and peroxidases (EC 1.11.1.x). Oxygenases are a class of enzymes that use oxygen as a 
substrate and introduce one or two oxygen molecules in the substrate25,26. Peroxidases use hydrogen 
peroxide as electron acceptor and produces water as a product27. Oxidation reactions, in principle, are also 
accessible by alcohol and amino acid dehydrogenases28. However, these enzymes require expensive and 
often unstable cofactor NADH. Additionally, co-factor regeneration systems need to be employed29,30. An 
example of alcohol dehydrogenase catalysed reaction has been depicted in Scheme 1-1. 
Oxidations of alcohols and amines represent two important oxidation reactions in synthetic chemistry and 
both these reactions can be catalysed by oxidases24.  Oxidases are a class of enzyme which uses oxygen as a 
terminal electron acceptor for catalysing the oxidation of the substrate molecule24. The major focus of this 
thesis is on biocatalytic oxidations catalysed by oxidases. 
 
Scheme 1-1: Example of alcohol dehydrogenase catalysed reaction. 
Alcohol and amine oxidases, which catalyse C-O and C-N oxidations, respectively, and depend on metal or 
flavin groups for catalytic activity, have consequently become an important class of biocatalytic oxidations. 
Therefore, biocatalytic oxidations of alcohols and amines are gaining focus for chemical synthesis and some 
examples will be discussed in the following sections. Of these oxidations, oxidations of amines are very 
difficult using chemical synthesis and more easily accessed by biocatalysis. Therefore, they are the central 
goal of the thesis. 
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1.3.1 Alcohol oxidases 
Alcohol oxidases (E.C. 1.1.3.x) catalyse the oxidation of alcohols by using molecular oxygen as electron 
acceptor and produce hydrogen peroxide (Scheme 1-2). This class of enzyme can further be classified as 
primary and secondary alcohol oxidases.  
 
Scheme 1-2: Alcohol oxidation catalysed by alcohol oxidases. 
Primary alcohol oxidases 
Primary alcohol oxidases can catalyse the oxidation of aliphatic or aromatic alcohols. Aliphatic alcohol 
oxidases (eg. from Candida boidinii) have been used to catalyse the oxidation of primary alkanols to the 
aldehyde to generate hydrogen peroxide31-34. Oxidation of racemic mixtures to obtain optically pure 
aldehyde have been achieved35.  
A significant example of a primary alcohol oxidase is the galactose oxidase which converts the sugar 
galactose to galactohexodialdose (Scheme 1-3). Wild type enzyme is highly selective to D-galactose and D-
talose36. However the substrate spectra has been increased towards other sugars such as glucose and 
fructose through protein engineering37. Galactose oxidase has found applications in sensor development38 
as well as in synthetic chemistry.   
 
Scheme 1-3: Conversion of galactose by galactose oxidase. 
Application of galactose oxidase in synthesis includes stereospecific oxidation of glycerol39, kinetic 
resolution of D-threose and the conversion of 3-halo-1,2- propane diols to the corresponding aldehyde. 
However, preparative-scale oxidations with galactose oxidase is slow and often results in low yields29. 
Secondary alcohol oxidases 
Secondary alcohol oxidases include the most studied catalyst of the oxidase family - glucose oxidase. Other 
oxidases that fall in this group would include pyranose oxidase, glycolate oxidase and cholesterol oxidase.  
21
Thesis Introduction 
6 
 
Glucose oxidase 
Glucose oxidase is used for conversion of glucose to gluconolactone which spontaneous hydrolyses to 
gluconic acid (Scheme 1-4). The reaction scheme is depicted in Scheme 1-4. The enzyme has been used 
widely in the food industry for making bread and for development of sensors40,41. The high substrate 
specificity towards glucose has made the application scope for this biocatalyst rather limited29,42. However, 
the enzyme has been widely studied and often used as a model system to represent the oxidase family.  
 
 
Scheme 1-4: Oxidation of glucose by glucose oxidase. 
 
Glycolate oxidase 
This class of oxidases is dependent on flavin mononeucleotide (FMN) and converts glycolic acid to glyoxylic 
acid. The biocatalyst has been employed for oxidation of 2-hydroxy acids to 2-keto acids and for 
deracemization of 2-hydroxy acids by using the enzyme in combination lactate dehydrogenase and formate 
dehydrogenase43 (Scheme 1-5).  
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Scheme 1-5: (a) Oxidation by glycolate oxidase (b) Use of glycolate oxidase/lactate dehydrogenase (LDH) and formate 
dehydrogenase (FDH) for the production of optically pure dehydroxy acid (Adopted from Kroutil et. al.29). 
Pyranose oxidase 
Pyranose oxidase converts glucose into its corresponding ketose (the oxidation occurs at the C-2 position).  
The enzyme has been applied synthetically for the production of optically pure fructose from glucose as 
well as in the production of 5-keto-D-fructose44,45. From a clinical perspective, it has been used for the 
detection of glucitol in diabetic patients (glucitol is a marker for glycemia)46. 
 
Scheme 1-6: Production of D-fructose by chemo-biocatalysis. 
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1.3.2 Amine oxidases 
Amine oxidases catalyse the oxidation of amines (primary, secondary or tertiary) to their corresponding 
aldehydes (in case of conversion of terminal amines) or ketones. These reactions are catalysed by flavin 
dependent oxidases. These conversions are central to synthetic chemistry because the conventional 
traditional routes to achieve C-N oxidations are, if not impossible, at least very difficult. These oxidations 
require rather aggressive oxidants and consequently suffer from low selectivity24. These challenges faced by 
chemical catalysis provide opportunities for biocatalytic C-N bond oxidations. Therefore, amine oxidase was 
chosen to form the central focus for this thesis. Therefore, a separate chapter on amine oxidases, in 
particular monoamine oxidase is dedicated for this system (Chapter 2).  
1.4 Scope of the thesis 
Oxidase-based biocatalysis as mentioned previously is gaining significant focus due their selectivity as well 
as the access they provide to oxidation reactions that are difficult to achieve using chemical synthesis. 
Implementation of biocatalytic process at scale presents some challenges and process development is often 
not straightforward. Therefore, it could be a valuable tool to arrive at a systematic methodology for process 
development. Hence, this thesis, in part, was aimed at characterising an oxidase-based system in a 
systematic manner and using the characterization to make suggestions for process development.  
For developing a methodology for process characterisation of an oxidase-based process an amine oxidase 
(monoamine oxidase) based reaction system has been selected as the case study. The product of this 
reaction provided access to a pharmaceutical intermediate that potentially increases the yield by 
decreasing number of steps involved in the production of the drug molecule. However, there are only a few 
publications (patents and journal articles) available for the use this biocatalyst in synthetic route (most 
focus in the past decade has been on this particular biocatalyst for deracemization of amines). Because 
relatively few studies are available for using this enzyme in a synthetic route, the studies conducted focus 
on several early stage characterisation experiments for process development. The characterisation involved 
the use of property prediction tools and literature review for identifying potential limitations to the system. 
Following this, process characterisation was carried out through experiments with the purpose of 
quantifying the limitations that were identified through literature. Furthermore, process limitations that 
prevent economic feasibility of the reaction were identified and improvements were suggested to enable 
the system to reach the economic targets.   
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The second goal of the thesis involved the implementation of monitoring tools. Implementation of tools for 
monitoring allows for rapid data collection and thereby contributes to rapid acquisition of process 
knowledge. To this end, oxygen sensors were tested for their applicability. Novel oxygen sensors that were 
capable of working in organic solvents were tested for this purpose. Also since it was desired to use a well-
characterised system for demonstrating the applicability of these sensors, a glucose oxidase based-reaction 
system was selected. 
1.5 Structure of the thesis 
The thesis is divided into 12 Chapters, which are grouped into 5 main parts. Part I, containing chapters 1-3 
form introduction to the thesis, the case study (which focuses on biocatalysis by monoamine oxidase) and 
an introduction to oxygen sensors as supporting tools for biocatalytic oxidations. In Part II (consisting of 
Chapter 4), the applicability of oxygen sensors as tools for oxidation reactions has been established. In Part 
III made up of chapters 5-7 the analysis of potential limitations to the system and experimental work to 
quantify these limitations are presented. Part IV describes more experimental work to identify the key 
limitations of the reaction system, the order of the limitations and the implications for scale-up. Finally, the 
last 3 chapters (Part V) form the discussion, conclusion and future perspectives.  
The different chapters can be split into 5 parts.  
Part I - Background 
The first part (Chapters 1, 2, 3) forms the background for oxidative biocatalysis and involves the use of 
literature to identify potential challenges for the target systems.  
Chapter 1 provides an introduction and background to biocatalysis and oxidase based biocatalytic 
processes. It also presents the scope of this thesis.  
Chapter 2 deals with the introduction to amine oxidases and biocatalytic reactions catalysed by amine 
oxidases have been presented. Furthermore, the motivation for selection of the said case has been 
presented.  
Chapter 3 describes the use of oxygen sensors as tools for operating oxidase-based biocatalytic processes. 
A review of the most commonly used applications of advanced oxygen sensors has been presented. 
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Part II – Oxygen sensors as supporting tools for oxidase-based biocatalysis 
The second part consists of chapter 4, where supporting technologies for oxidation reactions are explained. 
Here, the use of solvent resistant sensors for Kla measurements have been demonstrated using a glucose 
oxidase catalysed reaction system. The results presented in this chapter along with results from sensor 
calibration in collaboration with TU Graz and PyroScience have made the basis for a manuscript. 
Part III – Analysis of process limitations of monoamine oxidase based biocatalytic process 
The third part (Chapters 5-9) focuses on the characterization of a biocatalytic oxidation reaction which 
involve experimental validations of the limitations identified in system in part I of the thesis. 
In Chapter 5, literature review has been presented which help identify the potential challenges for the 
target amine oxidase processes. Following these identifications, a list of potential solutions for 
corresponding challenges has been identified. 
Chapter 6 focuses on the limitations that are arising from the reaction species that is the substrate and the 
product. This includes issues with pH shift caused due to the product, mass balances of the reaction and 
product toxicity. The chapter further introduces an ISPR technique to cope with the toxicity. 
In Chapter 7, biocatalyst-related limitations which include interactions of reaction species with the 
biocatalyst (for example substrate and (co-)product inhibition and toxicity) have been identified and 
quantified. This chapter also deals with test for oxygen limitations for the system. Here, oxygen 
requirement for the target reaction system has been discussed.  Major part of the results from this chapter 
is reported in Paper I. 
Part IV – Analysis of process limitations for implementation at scale 
The fourth part (consisting of Chapter 8 and 9) contains more experimental work that has been conducted 
to analyse the various process limitations of the target system and their implications for implementation of 
the reaction system at scale.  
Chapter 8 presents an introduction to important process metrics for successful implementation of 
biocatalytic reactions. This further presents the interactions between process metrics and presents the 
effect of overcoming process limitations. 
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Chapter 9 deals with the handling of biocatalyst downstream of fermentation prior to biocatalysis. This 
chapter forms an extension of Chapter 5 in terms of the limitation arising from the handling of the 
biocatalyst. The results in this chapter with additional results from another partner from the EU project 
consortium are presented in paper II which is in preparation for submission. 
Part V – General discussion and conclusions 
The fifth part (Chapter 10-12) present the general discussion and conclusions from the work presented in 
the thesis.  Future directions for the work are presented in the last chapter. 
Chapter 10 presents general discussions on the two case studies. A methodology that was established for 
process characterization.  
Chapter 11 lists the most significant conclusions from the work are stated. 
In Chapter 12, few directions for future work and directions following the work in this thesis have been 
discussed in this chapter. 
1.6 Contributions 
Results from several stages of the project were presented in conferences and some of the experimental 
work has been published as manuscripts. The feedback obtained at these conferences and EU meetings 
greatly enriched the project’s outcome.  Besides the mentioned publications and conference presentations, 
bi-annual presentations were made at internal BIONEXGEN meeting with the collaborating partners and 
additional work-package meetings that were held during the course of the project. 
Journal articles 
The following journal articles were drafted from parts of this thesis.  
Published 
Ramesh, H., Woodley, J.M. (2014) Process characterization of a monoamine oxidase. J. Mol. Biocat. B, 
106:124-131. 
 This paper is based on the material presented in Chapter 7. 
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In preparation 
Ramesh, H., Zajkoksa, P.; Rebros, M.; Woodley, J.M.; biocatalyst washing paper  
This paper is based on material presented in Chapter 9. 
Ramesh, H., Mayr T., Krühne U., Woodley J.M.; Use of oxygen sensors as tools for oxidase-based biocatalytic 
processes.  
 This paper forms the basis for discussion in Chapter 4. 
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 Introduction to the target reaction 2.
system  
The previous chapter introduced oxidation reactions and further the importance of role of C-N bond 
oxidation through biocatalysis. Often, the oxidation of C-N bond is difficult to achieve through conventional 
chemistry and biocatalysis provides a valuable alternative. In this chapter, amine oxidases will be 
introduced and further the motivation for the target reaction system presented.  
2.1 Amine oxidases 
Amine oxidases (EC. 1.4.3.x) form a class of enzymes from the oxidoreductase family that catalyses the 
oxidation of amines. Amine oxidases are found in a wide range of organisms (consisting of both prokaryotes 
and eukaryotes). While they are found in the mitochondria in eukaryotes and are membrane bound, in 
prokaryotes they are not membrane bound. The primary function of the amine oxidase is to provide the 
prokaryotic organism with nitrogen by breaking down amines to form ammonia.  
 As with the other enzymes in the oxidase family, amine oxidases do not incorporate molecular oxygen in 
the target molecule but instead use oxygen as a terminal electron acceptor in the oxidation of an amine to 
an imine. The by-product of this reaction is hydrogen peroxide47. The general reaction scheme 
(corresponding to conversion of primary amines) for amine oxidases is shown in Scheme 2-1. In the case of 
primary amines, the imine product that is formed is often hydrolysed to form the corresponding aldehyde 
or ketone depending on the position of the amine group. Scheme 2-2 represents the oxidation of a primary 
terminal amine to an aldehyde. 
 
Scheme 2-1: Amine oxidase catalysed oxidation of primary amines. 
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Scheme 2-2: Hydrolysis of primary amine to an aldehyde. 
2.1.1 Types of amine oxidases 
Two types of amine oxidases have been identified viz. type I and type II amine oxidase. Type I amine 
oxidases are copper containing enzymes that additionally require a co-factor (such as pyrroloquinoline 
quinone (PQQ)) for the activity of the enzyme. This class of enzyme is prevalent in bacteria, fungi and 
plants. The use of this class of enzyme for biocatalysis is limited - there is only one documented application 
for this system48. The authors reported a low E value (E=15) for this process and suggested that this 
example could be used as a basis for future biocatalyst development. However, a previous study on the 
catalytic mechanism of this enzyme suggests that an imine can covalently bind to the active site of the 
enzyme49. This phenomenon will cause irreversible inhibition of the enzyme making successful 
implementation in biocatalytic applications difficult. Such irreversible binding of molecules to enzymes is 
not uncommon to enzymatic reactions, and the molecules are generally referred to as inactivating agents.  
For biocatalytic applications, significant focus (over the past decade) has therefore been on the latter type 
of amine oxidase (type II). Type II amine oxidases are flavin-dependent enzymes (use flavin adenine 
dinucleotide (FAD) as a co-factor). FAD participates in the catalytic conversion of the substrate to the 
product and is tightly bound to the active site of this enzyme, making the biocatalyst more favourable for 
synthetic purposes. The FAD acts as a redox partner by either accepting an electron or donating it to 
generate a free imine molecule.  
One of the important enzymes of type II amine oxidase is a monoamine oxidase, which has shown promise 
in several industrial applications. The mechanism of the conversion of amine to imine by monoamine 
oxidase A and B has been discussed by Millers and Edmondson50 (Figure 2-1).  
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Figure 2-1: Mechanism of conversion of a primary amine by MAO. (Adopted from Miller & Edmondson, 
199950). 
2.2 Monoamine oxidase-N (MAO-N) 
Lerch and Schilling were the first to identify MAO-N in Aspergillus niger about 2 decades ago51. Following 
identification, the enzyme was cloned into E. coli through a pET3 vector containing a T7 promotor enabling 
the formation of soluble protein inside the cells52. Later, MAO-N was identified as a soluble protein and we 
have confirmed that the protein is constitutive (Appendix III). This development opened up the possibility 
to using this enzyme for biocatalytic applications. Simple amines (e.g. butlyamines) have been reported as 
the preferred substrate for the wild type enzyme53. To enable the use of the oxidase as a synthetic catalyst 
(of industrial relevance), further development of the biocatalyst was required (including improved 
applicability towards industrially relevant amines). Turner and co-workers have successfully combined 
random mutagenesis together with a rapid screening strategy to select mutants of interest 54. While the 
initial mutants were developed to improve the spectra for primary amines28, several rounds of 
development led to the usability of MAO-N for more complex amine molecules, including secondary and 
tertiary amines55-60. A list of the amines that have been used and the corresponding kcat values (when 
available) have been listed in Table 2-1. It is noteworthy that the kcat values reported in literature for the 
same mutant is quite different – sometimes as much as an order of magnitude of difference is seen (for 
example in the case of L-AMBA). Such differences could arise from the differences in the experimental 
method adopted for kcat measurements. Nevertheless, these kcat values can be used to show the substrate 
spectra has been improved and one can infer that the catalyst has a high specific activity. These 
developments have opened up the possibility of applying this class of enzyme for industrially relevant 
reactions. Examples of the use of monoamine oxidase in the past years will be discussed in the following 
section. 
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Table 2-1: Substrate spectra for MAO-N and the mutants.  
Substrate Wild 
Type/ 
Mutant 
Mutation detail (if available) kcat (s-1) 
Amylamine WT N.A. 44551 
WT N.A. 8153 
WT N.A. 16.728 
Mutant Asn336Ser 228 
Mutant Asn336Ser 1.262 
Mutant Asn336Ser/Ile246Met 1.2162 
L-AMBA WT N.A. 0.0328 
Mutant Asn336Ser 0.128 
Mutant Asn336Ser 2.533 
Mutant Asn336Ser/Ile246Met 2.1333 
D-AMBA WT N.A. 1.6*10-4 28 
Mutant Asn336Ser 0.00128 
Benzylamine WT N.A. 19951 
WT N.A. 23.353 
WT N.A. 6.228 
Mutant Asn336Ser 3.228 
Crispine A Mutant Ile246Met/Asn336Ser/Met348Lys/ 
thr384Asn/Asp385Ser 
not available56 
1-Cyclohexyl-N-
methoxyethanamine 
Mutant not available 10.261 
S- 1-MTQ Mutant Asn336Ser 1.162 
Mutant Asn336Ser/Ile246Met 662 
R-1-MTQ Mutant Asn336Ser 0.0662 
Mutant Asn336Ser/Ile246Met 0.0862 
2-phenylpyrrolidin Mutant Asn336Ser 6.0162 
Mutant Asn336Ser/Ile246Met 762 
4-chloro-
benzhydrylamine 
Mutant Ile246Met/Asn336Ser/Met348Lys/ 
thr384Asn/Asp385Ser/Trp430Gly/ 
Phe210Met/Leu213Thr/Met242Gln
/Ile246thr 
not available58 
1-phenyl 
tetrahydroisoquinoline 
Mutant Ile246Met/Asn336Ser/Met348Lys/ 
thr384Asn/Asp385Ser/Trp430Gly/ 
Phe210Met/Leu213Thr/Met242Gln
/Ile246thr 
not available58 
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2.2.1 MAO-N structure 
MAO-N was first crystallised by Atkin and co-workers in 2008 which opened up the possibility of studying 
the structure and it’s implication for biocatalysis63. Wild type MAO-N and two different mutants were 
successfully crystallized and reported in this paper. While the wild type enzyme is a tetramer in solution 
with a molecular weight of approx. 55 kDa, MAO-N-3 and MAO- N-5 exist as two tetramers and a dimer 
respectively. The crystallization consequently helped in decoding the presence of two channels 
(hydrophobic in nature) leading to the active site containing the FAD. The volume of these channels 
dictates the size of the substrate molecules that can enter the active site and consequently the substrate 
spectra of the biocatalyst. MAO-N-5 structural studies also indicate that each monomer contains 495 amino 
acid residues. The co-factor FAD is found to be in the oxidised form and held in the active site by non-
covalent bonding64. The implication of a tightly bound FAD to the enzyme is that the biocatalyst will be 
catalytically active outside the cell membrane without additional cofactor being added to facilitate the 
reaction. This opens up the possibility of using this enzyme as a crude extract or in the purified form in an 
economical way.  
2.3 MAO-N Application 
Once the substrate spectra for MAO-N was increased, its potential has been explored for three different 
purposes. The stereo-selectivity of the biocatalyst has been exploited for (i) dynamic resolution of racemic 
mixtures, (ii) synthesis of aldehydes from amines and (iii) synthesis of optically pure oxidation product 
(imine). The reason for using pure stereoisomer is that the regulatory authorities have mandated that 
pharmaceutical industry use optically pure compounds as drug molecules. All three reactions are discussed 
in the following section. 
2.3.1 Synthesis of optically pure amines using MAO 
Regulatory agencies such as FDA and consequently the pharmaceutical industry have been moving away 
from using racemic mixtures as drugs to using an optically pure compound. The reason for this is that only 
one of the enantiomer is usually the active drug component. The other enantiomer is either 
pharmacologically inert or could even have undesirable properties65.  
Turner and co-workers first established the deracemization reaction involving MAO-N in the year 2000. 
MAO-N has been used for the separation of a single stereoisomer from the racemic mixture by using the 
biocatalyst to oxidize one of the racemates to its corresponding imine. Following the oxidation step, a non-
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specific chemical reduction (using a chemical catalyst) is carried out to convert the imine into the racemic 
mixture. These steps are carried out for several cycles until one racemate is concentrated. Scheme 2-3 
represents the general deracemization reaction. MAO-N can catalyse deracemization of several amines, 
some of which are depicted in Scheme 2-5 (Adapted from56,58,62). 
 
 
Scheme 2-3: Deracemization using MAO. 
2.3.2 Synthesis of aldehyde from amines 
Synthesis of aldehydes from amines is carried out in two steps, the first of which is catalysed by MAO. 
Following the conversion of primary amines to imines, the imine hydrolyses (spontaneously) to the 
corresponding aldehyde (Scheme 2-4). Therefore, this type of conversion is limited to primary amines 
because secondary and tertiary imines are less prone to hydrolysis. This type of reaction can be catalysed 
by wild type enzyme. 
 
Scheme 2-4: Conversion of amine to aldehyde. 
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Scheme 2-5: Deracemization of (a) nicotine, (b) hydroxylamine and (c) Crispine A catalysed by different 
mutants of MAO-N (Adapted from56,58,62). 
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2.3.3 Synthesis of imine from amines 
As mentioned earlier, MAO has been extensively used for deracemization reactions. However, several 
competing biocatalytic technologies (eg. using transaminases, lipases, imine reductases) are available for 
the synthesis of an optically pure compound15,66,67. Hence, the true potential of a monoamine oxidase lies in 
its application towards synthesis, rather than deracemization. Herein, the selectivity of the biocatalyst can 
be exploited to produce the target imine in a single step, which would otherwise require multiple steps 
using synthetic chemistry. The use of MAO in synthetic chemistry was first established by Köhler and co-
workers, who used MAO for the synthesis of pyrroline residues57. Subsequently, the authors identified that 
the pyrroline residue produced could be used for the synthesis of drugs for the treatment of Hepatitis C. 
A recent study reported that around 200 million people are affected by Hepatitis C. Of these, some of them 
do not respond to the treatment available today due to mutated virus and/or adverse effects of the drug. 
As a result, new drugs have been identified and recently have got FDA approval. Following this, two 
industrially relevant examples have been identified for production of drug intermediates (for the treatment 
of Hepatitis C) using MAO as the biocatalyst68,69. One of these examples is implemented in a joint work by 
Merck and Codexis which is discussed further.  
Boceprevir intermediate 
The first industrial example is from a recent joint publication from Merck and Codexis for the production of 
Boceprevir intermediate, which is a drug used for the treatment of Hepatitis C patients with HCV 
genotype69. The companies were able to produce a 500 Kg batch of the Boceprevir intermediate with a 66% 
yield and >99% ee. The production of the intermediate with a high enatio-selectivity and yield resulted in 
reduction in the cost of the process.  The authors have successfully established a chemo-enzymatic route 
for the production of Boceprevir intermediate, where the key enzymatic reaction is the oxidation of a cyclic 
amine by MAO-N (Scheme 2-6). Several developments have been achieved by the authors. Firstly, the 
enzyme has been evolved by directed evolution to improve the activity and the stability of the biocatalyst, 
thereby decreasing the cost contribution of the biocatalyst. Additionally, the process limitations such as 
oxygen supply (through head space aeration under pressure), substrate (via feeding) and product inhibition 
have been addressed. The report also contains an elegant in situ product removal (ISPR) technique 
involving the degradation of the imine to the sulfonate form using bisulphite to remove the inhibitory 
compound. It should be noted that since the bisulfite reaction also uses oxygen, the use of ISPR results in a 
higher oxygen demand in this process. Additionally, it might be necessary to have a stoichiometric excess of 
the bisulfite to account for the competing reactions. The excess of bisulfite used could contribute to a 
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decrease in the efficiency of ISPR technique which increased oxygen demand adds to the cost of the 
process. This is the first example of a process that has been established at industrial scale using MAO-N. A 
process flow-sheet for the industrial process is depicted in Figure 2-2. 
 
 
Scheme 2-6: Production of Boceprevir intermediate (Drawn based on process described in Li et. al., 
2012). 
 
 
Figure 2-2: Production of Boceprevir intermediate. The process flow-sheet was drawn based on the 
description in the supplementary material from Li and co-workers69. 
2.5 Motivation for case study 1 
Köhler et.al. first indicated that MAO can be used for oxidation of pyrollidines, and subsequently the 
potential to produce the drug intermediate for treatment of Hepatitis C was identified57. Telaprevir has 
been shown to have a more sustained response compared to Boceprevir for treatment, making this 
example particularly interesting70. Chemical synthesis of Telaprevir consists of lengthy steps which involves 
protection and deprotection of functional groups71. Following this, a new and improved synthesis method 
was suggested where the authors reduced the number of steps required for producing Telaprevir68. The 
imine formed by the biocatalytic oxidation of a cyclic secondary amine could then be used in a 3 
component chemical synthesis to produce the drug molecule, Telaprevir, which is also used for the 
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treatment of Hepatitis C68. In this thesis, the imine intermediate was produced by oxidation of amine to 
reduce the number of steps involved in the production of the molecule. From a process stand point, use of 
biocatalysis to produce the imine product reduces the number of steps involved in the production of the 
final molecule, consequently reducing the process cost for the drug molecule. Scheme 2-7 represents the 
biocatalytic route for production of the Telaprevir intermediate.  
The past studies that involve this particular system have only been a proof of concept and the system has 
not been quantified. Therefore, it is of interest to evaluate this system by identifying the limitations to the 
system for process development and scale-up. The Boceprevir process cannot be used directly for the 
process development for this system because of the potential differences in the interaction of the substrate 
and product with the biocatalyst as well as the differences in the physiochemical properties of the reaction 
species. This target reaction will be discussed further in Chapters 5 through 9.  
 
Scheme 2-7: Production of Telaprevir intermediate using MAO-N. 
In order to evaluate the reaction system for industrial implementation, the status of the reaction in terms 
of economic metrics (product concentration and biocatalyst yield in particular) were assessed. Also, 
improvement of the reaction system on the economic metrics by alleviating the process limitations was 
assessed. 
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 Oxygen sensors as supporting tools 3.
for oxidase based biocatalysis 
Oxygen plays a central role as an electron acceptor in oxidase-based biocatalysis. Oxygen is required in 
stoichiometric quantities for a reaction. It is therefore advantageous to measure oxygen concentrations in 
the reaction system. Some oxidase-based reactions operate in a two-liquid phase system that contains a 
solvent to aid in substrate solubilisation. In such cases, use of conventional oxygen electrodes become 
complicated because solvent can cause the membrane (often made of silicone polymers) to swell, resulting 
in measurement errors. Advanced solvent-resistant sensors have been developed recently which could be 
useful for such applications.  
This chapter gives a short review on the implementation of monitoring tools and introduces the uses of 
advanced oxygen sensors. 
3.1 Introduction 
As mentioned in a previous chapter, oxidase-based biocatalytic processes are gaining importance and are 
increasingly being implemented at industrial scale. In order to develop a process for an oxidase-based 
reaction, it is often desired to collect kinetic data for the biocatalytic system (similar to the ones that will be 
discussed in Chapter 7). However, conventional methods of analysis are prone to errors. Firstly, there exists 
an error introduced by manual handling of the components and secondly a systemic method arising from 
analytical instrument. Of these errors, the systemic error cannot be completely avoided. Therefore lots of 
efforts have been focused on developing automated, high-throughput systems for data collection in 
biocatalytic systems72,73. Consequently, the need for sensors and other high-throughput detection methods 
which can be employed for online monitoring and control for use in systems has increased74. Several online 
measurement devices are available for data collection including NIR, FT-IR and LC/MS75,76.  
One field within bioprocessing where these sensors are being employed successfully for monitoring and 
control is fermentation. A list of sensors used for fermentation is given in a paper77. Conventional oxygen 
and pH probes have been successfully employed for several years. It is also possible to use flow cytometry 
in combination with fermentation to obtain online monitoring of cell structure (a recent publication has 
shown the application of flow cytometry for identification of yeast budding states78).    
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Biocatalysis is another field which could benefit greatly from online sensors and measurements. Oxidation 
reactions in particular offer an interesting possibility owing to the consumption of oxygen during the course 
of the reaction. Coupling an oxidation reaction with a measurement device (oxygen probe), consumption of 
oxygen can be traced and potentially be used as a measure for the degree of reaction. This type of 
application is similar to using an oxygen electrode in fermentation for measuring dissolved oxygen 
concentration and controlling the feeding rate of the substrate.  
3.1.1 Online sensors for oxygen measurements 
Oxygen sensors are very useful for fermentation processes and other applications where monitoring of 
dissolved oxygen is necessary. Conventionally, oxygen measurements are carried out by amperometric 
Clark-type electrodes79. The principle of measurement is electrochemical in nature80. The construction and 
working principle of such electrodes have been described in a review81. In such sensors, often the limiting 
step is the transfer of oxygen from the bulk solution through the membrane81.  This would cause increased 
response times of such sensors. Also, these electrodes are required to be polarised by applying a certain 
voltage for a few hours before they can be used.  These limitations have led to effort being placed on more 
robust sensors. 
Modern sensors are optical sensors which consist of an oxygen-sensitive membrane, a light source (laser or 
light emitting diode), optical fibres and a detector82,83. Micro-sensors with similar principle of operation 
have now been developed for use in high-throughput systems110. Development of such versatile oxygen 
sensors have led to interesting studies with biocatalytic systems84-86.  All these studies have looked into 
interesting aspects of oxygen transfer and application of the sensors have led to increased process 
understanding.   
3.1.2 Applications for advanced oxygen sensors 
Three important, recent applications which have led to improved process understanding (including mass 
transfer in microreactors, through immobilized beads etc.) are discussed in this section.  
Oxygen transfer in micro-channels 
Oxygen transfer in micro-channels determines the kinetics of oxygen-requiring reactions occurring in these 
reactors. It is therefore desirable to measure the oxygen concentrations at different positions within a 
microchannel. Measurements of oxygen in micro-channels have been studied by phosphorescence and 
fluorescence. These studies indicated measuring oxygen concentrations in microfluidic channels might be 
valuable87,88.  
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In another study employing microreactor, oxygen concentrations were measured by having luminescent 
nanoparticles (245 nm) in the influent aqueous stream, using a LED to trigger the excitation and camera to 
image the luminescence on-line. Glucose oxidase (GOx) was used as a model system. This study compared 
experimental results to modelling and showed that in a typical Y-shaped microchannel, steady state can be 
accurately described by disregarding diffusion by convection86. 
Measurement of intra-particle oxygen gradient in solid supports used for immobilization 
Immobilization of oxidation biocatalysts are often limited by the low specific activity of the immobilized 
biocatalyst when compared to free enzyme. The low specific activity observed is often attributed to the lack 
of availability of oxygen within the immobilized particles. Oxygen sensors have been used to identify the 
concentration gradient from the bulk solution and the internal environment. In a particular study, the 
authors used a methacrylic polymer (which is often used for immobilization). These beads were labelled 
with ruthenium complex (oxygen sensitive dye) and the biocatalyst was immobilized onto the particles. 
Phase shift between the excitation and the luminescence in the presence of oxygen was used to study the 
oxygen concentrations within the particle. GOx was used as the model system. The study indicated that the 
drop in oxygen concentration was related to the biocatalyst concentration. The authors indicate that such 
measurements could be valuable for selection of resins for immobilization as they affect oxygen 
concentration available by affecting the diffusivity84.  
This study was extended to an amino acid oxidase system where the authors have identified that pore 
diffusion (in the immobilized particles) is responsible for mass transfer resistance. In the same study, the 
authors have successfully established in situ measurements of oxygen concentration to measure the 
success of immobilization technique. Measurement of specific activity of the biocatalyst immobilized in two 
different modes (covalent and non-covalent immobilization) of immobilization indicated that covalent 
immobilization led to more loss in activity of the biocatalyst89.  
Measurement of oxygen transfer rates in a solvent system 
Advanced oxygen sensors have been applied in high-throughput systems or in systems where process 
understanding is desired (two examples have been discussed in the previous section). Oxygen plays a 
central role in oxidase-based biocatalytic process as an electron acceptor. The reaction rates are affected 
by the availability of oxygen. However, solubility of oxygen in aqueous phase is low (7.95 mg/L in water at 
30 oC90). Therefore, is desirable to improve the availability of oxygen in the system. One of the suggestions 
in literature for improved oxygen supply is to couple aeration with an oxygen-vector (commonly a solvent) 
which is capable of solubilizing more oxygen than water (this method has been adopted for improving 
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oxygen transfer in fermentations). By using a solvent, the oxygen availability in the reactor is improved and 
consequently aids as an oxygen supply strategy. However, the oxygen transfer rates reported are usually 
coupled to the overall mass transfer in the system rather than mass transfer from the solvent phase to the 
aqueous phase. A publication by McLellen and co-workers have included the difference in solubility of 
oxygen in aqueous and organic phases and reported the transfer rates91. However, this was done for a two-
phase, well-mixed aerated system. Decoupling of oxygen transfer rates from air to solvent phase and 
subsequently from solvent to aqueous phase could provide a valuable insight for process understanding of 
the limiting step for oxygen transport. Also, by doing this, it is possible to assess the feasibility of using a 
solvent for enhanced oxygen supply. Separation of the transfer rates of oxygen from air to solvent and 
solvent to aqueous phases can be achieved by using a Lewis cell where the aqueous and organic phases are 
separated. However, conventional Clark type electrode contains a membrane made of polymers and they 
are seldom stable with exposure to pure solvents. Development of luminescence-based oxygen sensors (by 
PyroScience) has opened up the opportunity of sensing oxygen concentrations in pure solvents as well as in 
two-phased systems.  
Some work done in this thesis (Chapter 4) has exemplified the use of solvent-resistant oxygen sensor for 
the measurement of KLa (oxygen mass transfer rates) in a solvent phase of a Lewis cell. These experiments 
goes to validate the use of the sensor for measuring the oxygen transfer rates in pure solvent which can be 
highly advantageous as it helps to understand the process. One could in extension also use the sensors for 
measuring the reaction rates or as a tool for solvent selection for two phase reactions as one could 
potentially track the reaction progress with the sensors.  
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 Measurement of oxygen transfer in 4.
organic solvents using optical sensors 
The previous chapter provided a brief overview of the applicability and uses of oxygen sensors and 
introduced novel oxygen sensors. 
This chapter describes the use of advanced-oxygen sensors developed which are capable of working in the 
presence of organic solvents. Conventional Clark type electrodes used for oxygen measurements are not 
suitable for use in the presence of pure organic solvents. This is because the membrane in these sensors is 
prone to swelling in the presence of organic solvents and consequently lead to errors in measurement. 
Consequently, development of sensors that can be used in the presence of organic solvents present an 
important advance in the development for oxygen sensors. To demonstrate the applicability of such 
solvent-resistant oxygen sensors, separate experiments were conducted in a Lewis-cell (where the sensors 
were used in the presence of diisononyl phthalate-water and heptane-water systems). The experiments 
describe the first efforts towards characterising the oxygen sensors and measuring oxygen concentrations 
in organic solvents.  
4.1 Introduction 
Molecular oxygen has been established as a benign and powerful oxidant for performing synthetic 
chemistry24. However, green chemistry using oxygen suffers from selectivity issues21,92. Biocatalysis has 
provided a valuable tool to overcome the selectivity issues since enzymes are usually highly selective23,24,93. 
Consequently implementation of biocatalytic oxidations in fine chemical production has seen rapid 
increase17,69,94-96. One of the requirements for oxidation reactions is the supply of oxygen to meet the 
demand of the biocatalysis. Oxygen supply rate (from the gas to liquid) at scale is limited to 100 mmol/L/h 
when supplying with air97. Oxygen demand is a function of biocatalyst concentration as the rate of the 
reaction is affected by the catalyst concentration and the oxygen is required in stoichiometric amounts. 
Therefore, improvement in oxygen supply strategies may be required when high rates are required (for 
example, when high biocatalyst concentrations are used)98. Use of an auxiliary phase as an “oxygen vector” 
has been suggested previously especially in fermentations where the oxygen demand for the growth of the 
cells is critical91,99. This strategy for oxygen supply can therefore be extended for biocatalytic reactions 
requiring oxygen. Oxygen supply using solvents take advantage of the high solubility of oxygen in the 
solvents as opposed to the solubility in aqueous phase100,101. However, the amount of oxygen in the system 
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is limited to the saturation concentration of the oxygen in the solvent and aqueous phase. Therefore, the 
limitation to such a system would occur from the mass transfer rates of oxygen between the different 
phases (i.e., gas to liquid and liquid to liquid).  It is therefore interesting to measure the transfer rates 
between the different phases and the effect of using a solvent phase on the extent of a biocatalytic 
reaction.  
Conventionally, oxygen concentration is measured using Clark-type electrodes79. Such electrodes consist of 
a membrane usually made of a silicone polymer which is prone to swelling when exposed to organic 
solvents. Therefore, the measurements from such sensors become less reliable. Recently, PyroScience has 
developed solvent-resistant oxygen sensors which work based on fibre-optics. Following this development, 
accurate, high-throughput data collection of oxygen concentration was made possible, which is highly 
relevant for the purpose of this study.  
In order to assess the oxygen transfer rates in solvents for a biocatalytic reaction, a model system was 
required. A system with a highly stable biocatalyst which has been extensively studied and is easily 
accessible was desired for such a purpose. It is for this reason, glucose oxidase (E.C. 1.1.3.4) was chosen as 
a model system. Glucose oxidase is an oxido-reductase which catalyses the conversion of glucose to 
gluconolactone which is spontaneously hydrolysed to gluconic acid. The reaction uses oxygen as a substrate 
and produces hydrogen peroxide as a by-product (Scheme 1)102. Glucose oxidase is a well characterised 
system which has been used for several applications, e.g. in the food industry and in the development of 
sensors for glucose detection (for clinical and biochemical purposes)103,104.   
 
Scheme 4-1: Conversion of glucose catalysed by glucose oxidase. 
The paper discusses the use of glucose oxidase in a Lewis cell in the presence of two organic solvents for 
testing the effect of using a solvent phase on the biocatalytic reaction. Furthermore, oxygen transfer 
coefficient (Kla) measurements were conducted. Finally, other applications for solvent resistant sensors 
have been suggested. 
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4.2. Materials and methods 
Potassium di- and mono-hydrogen phosphate and glucose were purchased in technical grade from Sigma 
Aldrich (Steinhiem, Germany) and used as purchased. Solvents used in the study were purchased in 
analytical grade, also from Sigma Aldrich. GOx was kindly donated by Novozymes A/S (Bagsværd, Denmark). 
The solvent-resistant oxygen sensors were procured from PyroScience (Aachen, Germany) and the 
FirestingO2 was purchased from PyroScience. The software for data collection (Oxygen logger v.3.1) was 
downloaded from PyroScience website (http://www.pyro-science.com/downloads.html). 
4.2.1 Reactors 
The experiments were carried out in a 250 mL stirred tank reactor equipped with two Rushton turbines (6 
blades, diameter 2.4 cm, width of the baffle was 0.6 cm and height 0.5 cm) and two baffles (of 1 cm width). 
The height of the impeller and the stirring speeds are adjustable.   
4.2.2 Calibration of oxygen sensor 
A 2-point calibration was made for the oxygen sensors by exposing them to air (for 100% DO) and 1% 
sodium sulphite (for 0% DO).  
4.2.3 Kla measurements 
Kla measurements were made using dynamic gassing out technique105 using nitrogen for gassing out and 
head space aeration as a means of oxygen supply.  
Kla measurement for aqueous phase 
To a stirred tank reactor, 40 mL of 200 mM phosphate buffer (at pH 7.0) and 10 mL of glucose (at 50 g/L) 
was dispensed. The reactor was stirred at a speed of 72 rpm at 37 oC. The buffer was sparged with nitrogen 
until the oxygen concentration stabilizes at 0. Following this, nitrogen was stopped and the reactor the 
oxygen transfer measured using the sensors. Two sensors were used at opposite either sides of the reactor 
(close to the baffles).  
Kla measurement for organic phase 
50 mL of heptane was taken in the stirred tank reactor (stirred at 72 rpm at 37 oC) and the head space 
aerated with nitrogen until the oxygen concentration in the aqueous phase stabilized at 0. Following this, 
nitrogen gas flow was stopped and the reactor left stirring to equilibrate with oxygen in the head space and 
the increase in oxygen concentration documented with two oxygen sensors (one attached to each baffle).  
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Kla measurement for two phase system 
To simulate a two phase Lewis cell system, 40 mL of phosphate buffer, 10 mL of 50 g/L glucose and 50 mL 
of heptane were taken in a reactor which was maintained at 37 oC at 72 rpm. Stirring was maintained such 
that the aqueous and organic phases existed as two separate layers. Nitrogen was supplied through head-
space aeration until the oxygen concentration in both the aqueous and organic phase stabilized at zero. 
Following this, the flow of nitrogen was stopped and the increase in oxygen concentration measured with 
one sensor in each phase. The experiment was repeated to get a duplicate measurement. 
4.2.4 Biocatalysis 
Glucose oxidase (GOx) based biocatalysis was carried out to convert glucose to gluconic acid. The oxygen 
concentration was measured using the solvent-resistant oxygen probes. The reaction was carried out in 250 
mL stirred tank reactors at 37 oC. Biocatalysis in such reactors were operated in both single and two-phase 
systems. 
Substrate inhibition 
To the reactor different volumes of 50 g/L glucose stock was dispensed with buffer (200 mM, pH 7.0) such 
that the concentration of glucose was 2, 4, 8, 12, 24 g/L.  1 mL of 0.1 g/L GOx was added to get a final GOx 
concentration of 0.01 g/L. The rate of oxygen consumption was measured with two oxygen sensors, each 
placed at one baffle.  
Biocatalysis in Lewis-cell 
All biocatalysis in Lewis cell was carried out at a substrate concentration of 10 g/L. The working volume of 
the aqueous phase was 50 mL and the pH was maintained at 7.0 by 200 mM phosphate buffer. The reactor 
was maintained at 37 oC and 72 rpm. To the aqueous phase, 50 mL of the organic phase (depending on the 
experiment, it was heptane or diisononyl phthalate) was added. Two impellers were used for stirring (one 
in the aqueous phase and one in the organic phase). When the oxygen concentration measurements were 
stabilized, biocatalyst at a concentration of 0.01 g/L was added to the aqueous phase through a feed pipe. 
The oxygen depletion in each phase was measured with the oxygen sensor. 
4.3 Results and discussion 
Use of oxygen sensors has only been exploited for measuring the oxygen concentration in the reaction 
system. However, it can be used for several other applications that involve characterising oxygen requiring 
reactions. In this paper, oxygen sensors that are resistant to solvents were used to demonstrate their 
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applicability as tools for oxidase-based biocatalysis. One of the scopes of this study was to test the 
applicability of the oxygen sensors for measuring initial rates of the reaction system. Secondly, the effect of 
adding a second phase on the oxygen transfer in the system has been studied.   
4.3.1 Substrate inhibition 
Substrate inhibition for biocatalytic reactions is a common occurrence. In order to assess substrate 
inhibition, the initial reaction rate at varying substrate concentration is measured (Initial rate was 
calculated over the first 30 s after addition of the enzyme). The sensor that has been used in this particular 
study can record the oxygen concentration every second making the analysis more accurate. The 
consumption of oxygen is measured as partial pressure from the oxygen sensor. Partial pressure can then 
be converted to concentration using Henry’s Law. Henry’s constant for oxygen in aqueous phase is assumed 
to be 1.16. The study Figure 4-1 indicates that inhibition of the biocatalyst by the substrate is evident at 
concentrations of 80 mmol/L and higher.  The results are in line with substrate inhibition that has been 
reported previously106.  
Conventional methods often incorporate the use of standard analytical equipment for measuring the 
substrate and product profile over a period of time. The downside of adopting this technique is that it is 
time consuming and often includes errors arising from sampling (manual handling of the samples). One 
could reduce the analysis time by implementing online oxygen sensors while also improving data quality by 
sampling more often. Therefore, use of such sensors for initial rate measurements can prove to be a useful 
tool for fast data collection. 
 
Figure 4-1: Substrate (glucose) inhibition profile for a glucose oxidase system. 
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Substrate inhibition curve obtained has been used to obtain the optimum substrate concentration for the 
reactions with a two-phase system. For the following studies with a two phase system, substrate 
concentration where the reaction rate is not limited by substrate inhibition was chosen in order to maintain 
the highest possible reaction rate in the aqueous phase. Therefore, a concentration of 60 mmol/L of 
glucose was used. 
4.3.2 Solvents as vectors for oxygen transfer 
In order to test for the oxygen supply through the use of solvents, two solvents whose LogP > 4 and were in 
the list of environmentally safe solvents from the GCI solvent selection guide were chosen107. Solvents with 
Log P greater than 4 were chosen because they are less toxic to the biocatalyst. The solvents chosen for the 
test were heptane and diisononyl phthalate.  
Biocatalysis in a Lewis-cell 
A modified Lewis cell108 where two liquid phases were present such that the aqueous phase was at the 
bottom and the organic phase was at the top was used in the experiments conducted in this study (Figure 
4-2).  Lewis cells have been previously used in two-liquid phase reactions where the solvent phase was used 
as a substrate reservoir and/or remove product from the aqueous phase109,110. Mixing in each phase was 
achieved by use of a Rushton turbine mounted on a shaft propelled by an overhead motor. Since the two 
stirrers were mounted on the same shaft, the stirring speeds in the aqueous and organic phases were kept 
a constant and the Rushton turbine was placed such that it was placed in the middle of each phase. A 
Lewis-cell was used instead of a well-mixed system so that the surface area available for oxygen transfer 
between the organic and the aqueous phase could be maintained a constant (and could be calculated) 
irrespective of the solvent used. 
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Figure 4-2: Depicts a Lewis cell with two liquid phases. In this particular example, the substrate and product are highly soluble in 
aqueous system and the oxygen transfer occurs from the solvent phase to the aqueous phase through the interface present. 
 In this particular example, the conversion of substrate to product occurs at the aqueous phase. The solvent 
phase acts as a reservoir for oxygen and oxygen transfer occurs from the headspace to the solvent phase 
and subsequently from the solvent phase to the aqueous phase.  The oxygen concentrations were 
measured at the aqueous phase and the organic phase simultaneously and recorded to give an idea of the 
reaction rates. Oxygen concentrations were measured as partial pressure and depicted in Figure 4-3. The 
figure indicates that the oxygen concentration is almost constant in the organic phase whilst there is a rapid 
reduction in the oxygen concentration in the aqueous phase.  
From the rate of oxygen consumption, the rate of the reaction can be calculated. Reaction rates were also 
calculated in the absence of solvent and compared to the reaction rates obtained in the presence of an 
organic solvent. The relative rates obtained in a Lewis cell was compared to that of an aqueous phase and 
reported in Table 4-1. 
53
Oxygen sensors as supporting tools for oxidase based biocatalysis 
38 
 
 
Figure 4-3: Partial pressure of oxygen in a Lewis cell-system using an aqueous phase together with an organic phase of either 
diisononyl phthalate (represented by black line) and heptane (represented by grey line). The dotted lines represent the oxygen 
concentration in the organic phase and the solid lines represent the concentration in aqueous phase.  
Table 4-1: Relative rates obtained for reactions run with an organic phase to the rate obtained from a reaction without solvents. 
Solvent Relative 
activity 
None 1 
Heptane 1 1.10 
Heptane 2 1.02 
Diisononyl 
phthalate1 
1.02 
Diisononyl 
phthalate2 
0.93 
From Table 4-1, it can be seen that the presence of a solvent phase does not cause an increase in the 
reaction rate. It has also been observed that the oxygen concentration in the solvent phase is almost a 
constant through the reaction. This indicates that the rates of oxygen transfer could be a limiting factor in 
the reaction. To validate this theory, the oxygen transfer rates from the headspace to the organic phase 
and the organic phase to the aqueous phase was measured by dynamic method. Nitrogen was flushed 
through the aqueous phase, and when an organic phase was present, the oxygen concentration was 
depleted by sweeping the headspace with nitrogen. This was done to decrease evaporation of the organic 
phase. The oxygen saturation phase was obtained through headspace aeration to mimic the transfer rates 
in the Lewis cell when a biocatalytic reaction is carried out. In principle, when the nitrogen sweeps out the 
oxygen from the system, the oxygen concentration becomes zero. When headspace aeration is then 
started, oxygen concentration rises in the system until it reaches saturation (as seen in Figure 4-4). It is 
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important that the sensors used for Kla measurements have a low response time in order to avoid the 
errors involved in measurement111. 
 
Figure 4-4: Dynamic method for determination of oxygen transfer rates from the headspace to heptane system. 
From the results obtained in Figure 4-4, the oxygen transfer rate (Kla) can be calculated for heptane. Kla 
represents the mass transfer of oxygen where Kl represents the rate constant and a represents the surface 
area per unit volume. Kla was calculated from the partial pressures obtained by the oxygen sensor since the 
concentration is related to the partial pressure by Henry’s law. Therefore, Kla can be calculated using the 
following expression: 
݀ܲ
݀ݐ ൌ ௦ܲ௔௧ െ ௦ܲ௔௧
כ כ ݁ି௄௟௔כ௧ 
Where dP/dt represents the rate of change of partial pressure, Psat is the partial pressure, Psat* represents 
the partial pressure at saturation concentration of oxygen, Kla represents the mass transfer coefficient and 
t represents the time.  
 Duplicates were obtained by using two oxygen sensors within the reactor at the same position on the 
baffles. After the Kla were calculated, the values were used to simulate the data points to validate the fit 
for the duplicates. This showed a good correlation to the experimental result (results not shown).  
Furthermore, since the area available for oxygen transfer in the Lewis cell is fixed by the diameter of the 
reactor (6.5 cm) and the total volume of the aqueous phase (50 mL), Kl values can be calculated from the 
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measured Kla.  Table 4-2 gives the Kla values and calculated Kl values for transfer of oxygen from the 
headspace in a single phase and two phase system. Oxygen transfer from air to aqueous phase was 
measured for comparison and reported in the table. The Kl values reported for a two phase system in a 
similar Lewis cell experiments by Woodley and co-workers is in the same order of magnitude as the ones 
obtained in this study109.  
Table 4-2: Kla and Kl values obtained for single- and two-phase systems. 
Particulars Kla (h-1) Kl (mh-1) 
Air Æbuffer containing glucose 7.2 5.4*10-2 
Air Æ heptane 4 3.0*10-2 
heptane Æbuffer containing glucose 3.5 2.6*10-2 
 
Based on the Kla values reported in Table 4-2, it can be seen that the limiting transfer rate is between the 
liquid phases. It should be noted that the oxygen transfer from the organic phase to the aqueous phase is 
the limiting factor.  
The factor limiting the improvement in reaction rate by use of a solvent in this case can therefore be 
concluded to be the transfer of oxygen from the organic phase to the aqueous phase. This can also be seen 
in Figure 4-3, where the oxygen concentrations in the organic phase hardly decrease. Therefore, it might be 
interesting to test the oxygen transfer rates in a well-mixed system where the organic phase is dispersed 
through the aqueous phase.  
4.3 Applications for oxygen sensor in oxidase-based processes 
This paper has indicated the use of advanced-oxygen sensors for rapid measurement of oxygen transfer 
rates in a solvent-based system. The sensors are particularly interesting for Kla measurements because they 
exhibit high stability in high vapour pressure organic solvents, have a low response time and can record the 
oxygen concentration as frequently as every second. Reduction in the response time as well as the increase 
in the frequency of recording improves the quality of the measurements making it possible to obtain more 
accurate oxygen transfer rates.  
Also, the developed oxygen sensor was applied to the characterisation biocatalyst inhibition profile through 
the measurement of initial rates. It is noteworthy that care should be taken when adopting this method of 
analysis for quantitative assessments. This is because several reaction characteristics affect the oxygen 
concentration. For example, most glucose oxidase preparation contains catalase. If catalase is present, the 
hydrogen peroxide produced in the system is broken down to water and oxygen. Therefore, the oxygen 
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concentration measured will be a net effect of the oxygen consumed by the reaction and the oxygen 
produced from the degradation of hydrogen peroxide. The presence of catalase and the rates of 
degradation of hydrogen peroxide relative to the reaction should be characterised through separate 
experiments and accounted for.  
Initial rate measurements can also be used for screening purposes. For example, the oxygen sensors can be 
used for screening oxidases from different sources for catalysing a select reaction. Also, solvents for 
applicability in two phase systems could be screened by measuring the oxygen consumption during the 
reaction. 
Since stoichiometric amount of oxygen is consumed by an oxidase system (non-whole cell based processes 
which do not contain catalase), the rate of oxygen consumption can be used for feeding a substrate to the 
reaction system. As an extension, the sensors can be used for online monitoring of the reaction progress. 
However, this needs to be done in combination with standard analytical methods to obtain quantitative 
information on the reaction yields. For instance, the oxygen sensors can be used to give an idea about 
whether the reaction has reached completion or not. However, the reaction yield can only be obtained 
when the substrate and product concentrations are analysed. Application of such sensors becomes 
particularly interesting in continuous oxidations. Oxidation reactions at steady-state would contain a said 
oxygen concentration. An increase in oxygen concentration would be observed when the catalyst loses its 
stability. Therefore, stability of a biocatalyst can be assessed on-line.  
4.4 Conclusions 
In this chapter, advanced oxygen sensors were used for measuring volumetric mass transfer coefficients in 
an organic phase. The study indicated that these sensors can be used for quick and high-throughput data 
collection.  The application of such sensors in a two-phase system in a Lewis-cell has been used as a case 
study to investigate the several options for the use of the solvent-resistant sensors. The results indicated 
that operating an oxidase reaction that is as fast as a glucose oxidase in a Lewis cell is not advantageous 
because liquid-liquid mass transfer is the limiting. Finally, other potential uses for the sensors have been 
identified. In the following chapters, a different oxidase based biocatalytic process has been discussed. The 
oxygen sensor used in this investigation can potentially be used in the following case study. 
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 In silico Analysis of Potential 5.
Limitations  
To successfully scale-up of a process, its characteristics and limitations (if any) need to be identified. This 
knowledge is the basis for a pragmatic methodology to overcome said limitations and also suggest where 
the efforts for improvements need to be placed (for example, biocatalyst development through protein 
engineering, process improvement through ISPR etc.). Constraints to the system can be broadly classified as 
process-related (such as change in pH, oxygen supply etc.), reaction-related (pertaining to the 
physicochemical properties of the substrate(s) and product(s)) and biocatalyst-related (inhibition, stability 
of the enzyme, specific activity etc.). Often, knowledge of the process is gained through experimentation 
that requires a large investment of time and effort. However, some process limitations can be identified by 
taking a closer look at the target reaction system. By analysing the physicochemical properties and the 
targets required for a given reaction, it is often possible to identify which experiments have a higher 
priority, reducing the load on the time and effort placed on process development.  
In the Part I, the motivation behind selecting a monoamine oxidase based syntheses was presented. This 
chapter describes the efforts towards identifying potential bottlenecks for the MAO case study prior to 
experimentation. By doing this exercise, the experimental load can be focussed on the expected limitations 
and help in arriving at smart solutions. 
5.1 Introduction 
Biocatalytic reactions are becoming increasingly popular in industrial processes because of the selectivity 
and the diverse chemistry they can offer. However, biocatalysts are often operated in conditions that differ 
from their natural environment112. Based on the reaction characteristics and targets, several process 
options (which include choice of reactor, mode of operation, development of biocatalyst among other tools 
employed in the process such as in situ product removal, substrate feeding strategy etc.) can be used to 
achieve the set goal (eg. product concentration, reaction time etc.) for a given process. The choice of a 
particular process option (for the given process) would depend on the knowledge of the reaction and/or 
the constraints (time and financial) faced by the industry. However, complete knowledge of the reaction 
system is seldom available due to the lack of integration of product and process discoveries and 
experimentation is required to gather relevant data. In order to reduce the time and investment spent on 
experimental development of the process, it would be useful to make some pragmatic choices on the 
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number of process options that are worth investigating for a particular reaction, based on its 
characteristics. It is with this purpose in mind that an in silico analysis of potential process limitations was 
carried out. The analysis serves to direct experiments to select conditions and help reduce experimental 
load. 
5.2.1 Process limitations 
A simplistic view of a biocatalytic reaction can be explained by the binding of the substrate to the active site 
of the biocatalyst (forming an enzyme-substrate complex), conversion of the substrate to the product 
(formation of enzyme-product complex) and release of the product from the active site.  Over the course of 
the three steps several constraints can arise.  
First of these is the availability of the substrate for binding with the biocatalyst. Factors that affect the 
availability of the substrate are dictated by the substrate properties such as its solubility, volatility, melting 
and boiling point among others. In cases where an immobilized biocatalyst or a whole-cell biocatalyst is 
used, it is likely that the availability of substrate is further limited by its mass transfer. 
Another constraint arises from the binding of the substrate to the active site of the biocatalyst. For 
example, the substrate can irreversibly inactivate the biocatalyst (when the substrate binds irreversibly to 
the biocatalyst such that it prevents the formation of product), a phenomenon referred to as substrate 
inactivation.  
A further constraint that can arise is attributed to the dissociation of the product molecule from the active 
site. Herein, the uncoupling rate dictates the rate of product formation. If the product binds irreversibly to 
the biocatalyst or causes modifications in the biocatalyst, it is said to be toxic. If the product molecule 
produced binds to the enzyme such that it prevents binding of new substrate molecule to the active site, it 
is said to be inhibitory.   
Other characteristics of the product can also cause product loss or loss of biocatalyst stability. For example 
the reaction could be endo- or exo-thermic causing the reaction to slow down or the biocatalyst to lose its 
stability unless the temperature is controlled. The product could be volatile causing product loss.  
Finally, limitations can also arise that are related to the reactor or process which include supply of oxygen, 
control of pH etc.  
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In a broad perspective, the limitations to a reaction system can be classified into biocatalyst-related 
limitations (eg. inhibition, toxicity, stability), reaction-related (affected by physiochemical properties of the 
substrate and product) and reactor-related (such as need for oxygen supply or pH control). Figure 5-1 
depicts some examples of reaction constraints that cause potential limitations to implementing a target 
process. 
 
Figure 5-1: Factors contributing to limitations of reaction system. Examples of limitations are listed in each category. 
In the following sections, in silico analyses of the potential limitations for the target system and the 
corresponding solutions are discussed.  
5.3 Biocatalyst-related limitations 
Biocatalyst-related limitations arise either from factors inherent to the biocatalyst (such as stability, 
requirement of co-factors and catalyst formulation) or from interaction of the reaction species with the 
biocatalyst. In the following section, analysis of biocatalyst-related limitations for the target system will be 
discussed.  These limitations can arise from non-specific effects and/or specific effects in terms of inhibition 
and toxicity caused by the substrates (amine and the oxygen) and the products (imine and hydrogen 
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to reaction 
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peroxide). These limitations will be discussed based on the literature available and is extended to the 
specific case study whenever possible.  
5.3.1 Non-specific inactivation of the biocatalyst 
For successful implementation of biocatalytic reactions, it is desired that high concentrations are produced 
to maintain high process intensity. Consequently, the biocatalysts used for synthetic applications are often 
exposed to high concentrations of substrates and products as opposed to the mild conditions that the 
biocatalyst would be exposed to in nature. As a result, often they are susceptible to inhibition and/or 
toxicity113.   
Octanol-water partitioning (Log P) has been used for evaluating the toxicity of solvents to the biocatalysts. 
It is argued that the biocatalyst is stripped of water by solvents with low Log P values (typically below 2). 
For a whole-cell system, however, the toxicity arises from the integrity of the cell membrane being lost114. A 
study of biocatalysis with whole-cells and immobilized whole-cells indicated that solvents were toxic when 
their Log P was over 4115. Straathof reported a methodology for predicting such toxicity based on the 
solubility and logP values of the reactants and products.  
The assumptions that go with the estimation developed by Straathof include that the reaction is not limited 
by thermodynamics, it is not mass transfer limited and phase toxicity is neglected.  After extensive study, 
they have shown that this estimation is valid only when the solubility of the product in water is between 
0.3 and 200 mM.  The concentration which causes the biocatalyst to lose most or all of its activity can be 
calculated using the following equations116: 
݈݋݃ݏ௜௔௤ ൌ ͲǤͷ െ ͲǤͲͳሺ ௜݂ െ ʹͷሻ െ ݈݋݃ ௜ܲ 
݈݋݃ܿ௖௥௜௧௔௤ ൌ ͲǤ͹ͻ݈݋݃ݏ௔௤ െ ͲǤ͹Ͷ 
where siaq is aq solubility, fi =25 for a liquid at room temperature otherwise is the melting point in ˚C. 
For the target reaction, the assumptions of the methodology rule out its applicability for one of the 
substrates (oxygen) and the product (imine). This is because oxygen offers a second phase which could lead 
to potential phase toxicity and the imine has a low aqueous solubility. The methodology is not tested for 
hydrogen peroxide because of the potential interference by catalase present in whole-cell (it has been 
shown that intracellular specific catalase activities for degradation of hydrogen peroxide are relatively 
high117). However, the methodology can potentially be used to estimate the concentrations at which the 
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substrate (amine) reaches critical concentrations. The solubility and logP values of the substrate can be 
estimated by EPA’s online software (EPI Suite, http://www.epa.gov/opptintr/exposure/pubs/episuite.htm), 
which makes the solubility prediction. Many such types of software for property prediction are available 
and can also be used118. By applying the values to the equations, the critical concentration of the amine was 
estimated to be 100 mM.  For an economically scalable process, the processing intensity has to be high and 
consequently the biocatalyst is exposed to high concentrations of substrate and therefore there is a high 
likelihood that the substrate for the target system at these concentrations are affected by the toxicity. 
Inactivation of the biocatalyst by the product has not been analysed by the above mentioned methodology, 
but can be expected since a similar imine was found to be toxic to a monoamine oxidase69. 
5.3.2 Specific interaction of the substrate and product with the biocatalyst 
While substrate and product inhibition has not been assessed in silico, it can be expected since the 
biocatalyst will be exposed to high concentrations. Inhibition of a monoamine oxidase by substrate and 
product has been seen in the Boceprevir example69.  
Inhibition of the substrate and the product can be overcome by improving the biocatalyst (at industrially 
relevant conditions)119,120 and/or employing process development tools such as in situ product removal 
(ISPR)112,113,121,122 (in cases where product inhibition/toxicity is present) and substrate feeding or in situ 
substrate supply (ISSS)123-125 (in cases where substrate inhibition or toxicity is prevalent). In some cases, it is 
desired that the substrate supply and product removal are carried out simultaneously. Use of auxiliary 
phases (solvents, resins) will provide an opportunity for this kind of supply126,127.  
Overcoming substrate and product  inactivation 
Available Substrate feeding strategies are discussed in detail in a review125. It should be noted that feeding 
of substrate should be in such a way that it matches the rate of the reaction in order to prevent the 
reaction from operating at substrate limited regimes. In cases of solids, it is desired to use a co-solvent to 
solubilize the substrate or feed the substrate as a solid. In both these cases, the availability of the substrate 
is limited by the solubility (when implementing solid feeding strategy) or mass transfer across the phases 
(when co-solvent was used). Also, adding a co-solvent can cause loss in stability of the biocatalyst. Solid 
feeding strategy has been implemented in a biocatalytic process catalysed by Mycobacterium128. 
While substrate inhibition is easily overcome by feeding strategies, implementation of ISPR techniques is 
rather difficult. This is because the substrate and product molecules of a biocatalytic reaction are often very 
similar. It is important to consider the selectivity of the product removal technique for the product over the 
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reactants. It is necessary to carefully consider the limitations of the type of substrate and product removal 
techniques employed.  
5.3.3 Inactivation (toxicity) by reactive co-product 
Common phenomenon to oxidase-based biocatalysis is the formation of hydrogen peroxide as a by-
product. Once the hydrogen peroxide is produced, its interaction with the biocatalyst determines the effect 
of hydrogen peroxide on the biocatalyst. Hydrogen peroxide is known to cause chemical modifications on 
proteins. For example, methionine residues in the catalyst can easily be oxidised. These oxidations could in 
turn lead to lowered stability of the enzyme129. Other residues that have been seen to be affected by 
exposure to hydrogen peroxide include cysteine, tyrosine, and phenyl alanine among others. Protein 
fragmentation had been observed by Törnvall et al. on exposure to hydrogen peroxide 130. Therefore, 
removal of hydrogen peroxide from the microenvironment of the catalyst desired. It can either be done 
with chemical catalysts or by using catalase in the system131. The use of catalase is preferred as they are 
specific and produce benign products (oxygen and water). This potentially opens up the opportunity to use 
the oxygen produced as the substrate for the oxidase reaction117.  
For the monoamine oxidase used for the current study, the active site residues consist of serine, aspargine, 
methionine and tyrosine residues close to the active site64. Therefore, it is likely that hydrogen peroxide 
mediated inactivation can occur causing the loss in stability of biocatalyst. 
5.3.4 Inactivation by oxygen 
Supply of oxygen is critical for oxidase-based reactions; however, oxygen supply can potentially cause 
deactivation of the catalyst. Proteins are often affected by the presence of interfacial effects (such as the 
ones occurring in the presence of gas-liquid interface which is constantly coalescing and breaking up in the 
reactor)132. While shear effects could cause inactivation in soluble enzymes, use whole-cells can offer more 
protection to the enzyme and this effect can be neglected. Another way of deactivation is that the amino 
acid residues in the enzyme can be oxidized by the formation of reactive oxygen species133,134.  It is 
therefore essential to supply oxygen in such a way that the stability of the biocatalyst is not 
compromised135. Stabilization effects by immobilization and/or protein engineering could help overcome 
this limitation. 
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5.4 Reaction species-related limitations 
5.4.1 pH shift during the reaction 
When the substrate and product for a reaction system have difference in pKa values, a change in pH during 
the course of the reaction is expected. Therefore, looking at the pKa values of the susbtrate and the 
product would give valuable insight into the pH shift that can be expected and consequently the buffer 
strength needed for the reaction can be assessed. The pKa values of the substrate and product can be 
determined from a property prediction software (EPI 4.0).  
Amines are highly basic, and the corresponding imines are less basic. Therefore, a decrease in pH can be 
expected. For the target system, the pKa values of the substrate and product are 8.2 and 11.6 respectively. 
Therefore, there an acidic shift in pH can be expected as the reaction progresses. Consequently, pH control 
becomes critical to the process and the final product concentration that can be achieved. pH control is a 
process-related challenge and is discussed later.  
5.4.2 Degradation of the substrate and product by hydrogen peroxide 
Hydrogen peroxide could potentially cause adverse effect on the reaction by modifying the substrate or the 
product of the target reaction136. For example, in the production of 7-aminocephalosporanic acid (7-ACA) 
from cephalosporin C using an amino acid oxidase, the hydrogen peroxide produced during the reaction 
spontaneously decarboxylates the product to Gl-7-ACA. Gl-7-ACA in turn is used by another enzyme, 
acylase, as a preferred substrate for the production of 7-ACA (Scheme 5-1)137.  
 
Scheme 5-1: Spontaneous decarboxylation by hydrogen peroxide (Scheme adopted from 137) 
Similarly, oxidation of the substrate (amine) by hydrogen peroxide is possible and literature was used to 
verify the possibility of such reactions. Although oxidation of tertiary amine by hydrogen peroxide is well 
known, they require high temperature (60-65 ˚C)136. Oxidation of secondary amine, like the substrate in the 
target reaction system, by hydrogen peroxide requires the presence of a catalyst138. Both these scenarios 
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are not relevant to the process conditions at which MAO reaction occurs. No such reports on oxidation of 
tertiary imines have been found. 
5.5 Process-related limitations 
5.5.1. pH control 
As mentioned before, a pH shift can be expected for the target reaction system. pH shift can be overcome 
by using a buffer at concentration that can cope with the pH change or by coupling the reactor to a pH stat. 
Another approach to pH control could be to feed the substrate at a sufficient rate (below inhibition levels) 
and compensate for the difference with an addition of base. This would reduce the base consumption and 
the dilution effects on the system. 
5.5.2 Oxygen supply strategies 
For an oxidase based reaction, one mole of oxygen is required to convert one mole of substrate into the 
product. However, oxygen supply at scale is limited to 100 mmol/L/h when air is used to supply oxygen to 
the reactor97,139. Therefore, the next potential challenge for the system is development of an oxygen supply 
strategy to achieve the desired concentrations at a relatively economic way. Some potential means of 
achieving high KLa (mass transfer of oxygen) include the use of modified aeration strategies or reactors for 
example, the use of bubble column reactors140,141, supplying air with a higher surface area (by reducing the 
bubble sizes)142 etc. Oxygen can also be supplied at a higher rate when oxygen is used instead of air or by 
increasing agitation rates143. However, these strategies would incur additional costs. Also, care should be 
taken when introducing oxygen into the reactor because gas-liquid interfaces and oxygen concentration 
could leave to loss in stability of the biocatalyst as mentioned previously. 
Since it is not possible to assess the amount of oxygen required by a target system without initial rate 
measurements experiments were conducted to assess oxygen requirement of the target reaction are 
discussed in Chapter 7.  
In summary, the potential limitations of the target MAO system can be classified as biocatalyst-, reaction 
species- and process-related limitations and is represented in Table 5-1. In the table, potential solutions 
have also been listed. Each of these solutions comes with a certain limitations for implementation. Such 
limitations should be considered while implementing a particular solution. These comments have also been 
stated in this Table.  
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In the following chapters, experimental evaluations of the identified limitations are conducted in order to 
assess the presence or absence of a particular limitation.  
5.6 Conclusions 
Based on the literature survey and in silico analysis for the reaction system, several potential limitations 
have been identified. Through such analysis before starting the experimental work, important information 
about how the process should be operated can be identified. For example, by looking at the 
physicochemical properties of the substrates and products one can identify the limitations such as potential 
volatility, solubility issues. Therefore, it is a good practice to consider the properties of the reaction system 
prior to experimentation. 
Table 5-1 summarizes the potential challenges identified by such analysis and the potential solutions to 
overcome these challenges for the target system. However, the extent of the limitation and the 
applicability of the solutions have to be assessed experimentally. The presence or absence of the 
limitations and the quantification of the limitations present have been identified through experimentation 
and will be discussed in Chapters 6-8.  
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 Reaction Species-Related Limitations 6.
In the previous chapter, the potential limitations to the target system arising from the reaction-species, 
biocatalyst and process were identified. The limitations that arise solely from the nature of the reaction 
species, i.e. the physiochemical properties of the substrate and the product are illustrated in this chapter.  
For the monoamine oxidase case study, the first of such limitation arises from the product (imine) having a 
lower pKa value (pKa = 8.2) than the substrate (amine, pKa = 11.6). During the course of the reaction, as the 
imine is produced, there will be a pH shift. Such a pH shift will cause the reaction to either slow down (if the 
biocatalyst is active over a wide range of pH) or in some cases when the enzyme has a steep pH optimum, 
the reaction can terminate before the biocatalyst has been exploited to its full potential. 
Also, Köhler and co-workers reported that the imine formed (from the target reaction) can co-exist in 
solution as a trimer. This would imply that the process can’t be followed by the formation of product (since 
the trimer is not detected in the gas chromatography).  
Additionally, for a similar biocatalytic system, the product imine was found to be volatile69. This could be 
the case for the target system and needs to be evaluated.  
This chapter deals with analysing these product-related limitations and goes on to confirming or validating 
the presence of one or more of these limitations through experimentation. Finally, some tools to overcome 
the limitations have been suggested (which would further affect the design considerations for the process). 
Product-related limitations can arise from the physicochemical properties of the product (pKa value, 
volatility, stability at reaction conditions) or from the interaction of the product with the biocatalyst (e.g. 
toxicity).In the following sections, the product-related limitations that have been assessed from literature 
have been presented. 
6.1 Introduction 
In the following sections, product-related limitations identified in the previous chapter are quantified.  
6.1.1 pH shift 
Since the pKa of the imine of the target system is lower than that of the substrate amine, a pH shift 
(reduction in pH as conversion increases) over the course of the reaction is to be expected. In order to cope 
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with the pH shift, buffers are generally employed at lab-scale. The strength of the buffer dictates the 
buffering capacity.  The pH shift of using a buffer of a certain buffering capacity can be calculated by using 
the Henderson–Hasselbalch equation. The pH shift expected can be calculated and compared to that of a 
buffer with a higher buffering capacity (Figure 6-1). It can be seen that a pH shift of 1 unit would be 
expected when as little as 80 mM of the substrate is converted. It is therefore critical to maintain the pH of 
the reaction in order to utilise the full capacity of the biocatalyst. 
 
Figure 6-1: Shift in pH for 100 mM (blue) and 500 mM (red line) phosphate buffer as imine is produced 
Overcoming pH shift 
In a laboratory-scale preparation, buffers are often used to maintain pH. However, at scale, pH is commonly 
maintained by acid/base titration. However, to cope with the feed-back controls, the reaction is often 
started with a low concentration of buffer and pH maintained by titration. It is desired that high 
concentrations of acid and base are used for titration in order to avoid diluting the reaction mixture. 
However, this practice could lead to deactivation of the biocatalyst as some biocatalyst will be exposed to a 
very high concentration of base/acid for a short time (i.e. before mixing comes into effect)144. Therefore, 
the success of the method is often subjected to the mixing efficiencies and the biocatalyst stability to 
alkaline environment. 
Although the pH shifts quite rapidly in a buffer with a low buffering capacity, the effect of the pH shift on 
the reaction depends on the pH profile of the biocatalyst. Therefore, the pH-activity profile was studied and 
a reaction was run at both 100 mM and 500 mM phosphate buffer and compared to understand the effect 
of the pH shift in the reaction.  
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In the previous sections, product-related limitations for the system have been identified to be product 
toxicity and pH shift (See also Chapter 5). In the following sections in this chapter, experiments were 
conducted to identify the extent of influence on these parameters through experimentation. Results and 
conclusions have been drawn and explained. 
6.2 Materials and methods 
All chemicals and reagents were bought from Sigma Aldrich unless specified and used as purchased.  
6.2.1 Biocatalyst preparation 
Plasmid  
Plasmids (pET 16b vector) containing 3 different mutants of MAO genes derived from Aspergillus niger 
(wild-type)52  were kindly donated by University of Manchester (Professor N. J. Turner). 
LB broth and plates 
LB broth was made with 10 g/L tryptone (Nordic biolabs AB, Täby, Sweden), 5 g/L yeast extract (Nordic 
biolabs AB, Täby, Sweden) and 10 g/L sodium hydroxide. To this, 2% (w/v) agar was added for making 
plates. The broth was autoclaved and ampicillin (filter-sterilized) was added to the broth (100 μg 
ampicillin/mL media) prior to use and the agar just prior to plating (100 μg ampicillin/mL media). 
Preparation of competent cells  
A starter culture was used to inoculate 5 mL of LB broth and the cells were incubated at 37˚C to grow the 
cells to an OD600 of approx. 0.6. 2 mL of cells were transferred to Eppendorf tubes and incubated in ice for 
20min. The cells were then centrifuged at 6000 rpm for 10 min and the pellet was re-suspended in ice-cold 
water. The centrifugation step followed by re-suspension in water was repeated and centrifuged to obtain 
pellet. The pellet was re-suspended in 500 μL of 10% glycerol and centrifuged for 10 min. The supernatant 
was discarded, the pellet re-suspended in glycerol. The cells were stored as 100μL aliquots until further use. 
Plasmid transformation 
Plasmids (3 mutants) obtained from University of Manchester were transformed into competent E. coli 
BL21 by electroporation. To 50 μL of electro-competent cells, 0.5 μL of the respective plasmid was added 
and transferred to an electroporation cuvette (BIORAD, Copenhagen, Denmark) and exposed to a short 
pulse of high voltage. Following the electroporation, 950 μL of LB medium was added to the cuvette and 
incubated for 1h at 37 ˚C. 50 μL of the cell suspension was plated onto a LB plate containing ampicillin. 
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A colony was picked from the transformation plate, streaked onto a new plate and, incubated at 37 ˚C 
overnight. 5 mL of LB broth containing ampicillin was inoculated with a colony and allowed to grow to an 
OD600 of 0.6. This culture was then stored in 10% glycerol to obtain glycerol stocks. The stocks were stored 
at -80 ˚C until further use.   
Production of biocatalyst 
LB plates and pre-culture 
From the glycerol stock, cells were streaked onto an LB plate containing 100 μg/mL ampicillin. The plate 
was incubated at 37 ˚C overnight. 5 mL of LB broth containing 100 μg/mL of ampicillin was inoculated with 
a colony from the LB-Amp plates. The culture tube was incubated at 30 ˚C in a shaker at 150 rpm for about 
4 hours. 
Fermentation 
All fermentations were carried out in un-baffled shake flasks. To 500 mL of LB broth containing ampicillin, 5 
mL of pre-culture was added (1% inoculum). The flask was incubated at 30˚C, 150 rpm. Cells were 
harvested after 18 h of growth by centrifugation at 4000 rpm, 20 min.  The harvested cells were re-
suspended in 100 mM phosphate buffer containing mono and di-basic potassium salts at pH 7.6 (25 ˚C) and 
used for biocatalysis. Fermentation was carried out prior to each biocatalytic reaction. 
6.2.2 pH shift 
pH-activity profile 
Phosphate buffer with different ratios of mono- and di-basic potassium phosphate salts were prepared to 
obtain buffers at pH 6.5, 7, 7.7 and 8.2. Biocatalysis was carried out in baffled shake-flasks with a final 
working volume 20 mL of reaction mixture (2.9 g/L substrate and 5.6 gcdw/L biocatalyst suspended in 100 
mM phosphate buffer) incubated at 37 ˚C and 150 rpm. The substrate, aza-bicyclo-octane HCl was procured 
from AK Scientific, (Union city, CA, USA). The sampling frequency was t= 0, 15, 30, 45 min, 1 h, 2h, 4h, 6h 
and 24 h.  Samples were prepared and analysed using GC145. The pH profiles were made using a single batch 
of cells.  
Effect of pH control 
A reaction with 14.8 g/L of substrate amine was converted using 5.6 gcdw/L of cells. The reaction was 
carried out in both baffled shake-flasks (with phosphate buffer of 100 mM and 500 mM, pH 7.8) and a small 
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reactor (MiniBio, Applikon purchased from Holm & Halby A/S, Brøndby, Denmark) that was equipped with 
a 6-blade Rushton turbine, and, a pH and temperature control unit. The reactor has an internal diameter of 
13 cm, with a maximum working volume of 250 mL and contains 2 baffles. The reactor was maintained at 
37 oC and stirred at 800 rpm. pH was maintained at 7.8 (comparable to shake-flask experiments) by base 
titration (with 5M NaOH). The progress of the reaction was tracked using a GC.  
6.2.3 Test for presence of trimer and product volatility 
Biocatalysis was carried out with a substrate (amine) concentration of 2.96 g/L and biocatalyst 
concentration of 5.6 gcdw/L. The reaction was tracked over time by sampling and analysed using GC. The 
product solution obtained after conversion of all of the substrate was collected in a falcon tube and 
sonicated twice with 40% amplitude and 0.5 s cycles for 7 min. Following the sonication, cells were 
removed by centrifugation at 6000 rpm for 20 min. The supernatant was collected and used for testing 
product volatility. 
20 mL of the supernatant was dispensed to baffled shake-flasks and incubated at 37 oC. To one of the shake 
flasks, E. coli cells were added (fermented in the same batch of cells as used for the biocatalysis). Samples 
were taken over a period of time and the product concentration monitored with GC. Similarly, 50 mL of the 
supernatant was poured in two stirred-tank reactor (MiniBio, Applikon, Holm & Halby A/S, Brøndby, 
Denmark) and to one of them E. coli cells was added. The reactor was maintained at 37 °C. The product 
concentration was monitored.  Additionally another experiment was set up where the reactor was filled 
with 50 mL of the product solution and nitrogen (set at an over pressure of 0.5 bar) was bubbled through 
the reactor.  
Rotary evaporation 
A reaction with a biocatalyst concentration of 5.6 gcdw/L and 14.8 g/L of substrate (amine concentration) 
was carried out. Complete conversion was verified by measuring substrate concentration with the GC. 
Following the reaction, the reaction mixture was sonicated and the cells separated by centrifugation at 
4000 rpm for 30 min. To the supernatant 2 mL of 10 M NaOH was added. Following this, the supernatant 
was dispensed in 5 falcon tubes (each containing 10 mL) and extracted with 20 mL MTBE three times and 
the extracts were pooled together and evaporated in a rotary evaporator. The temperature of the rotary 
evaporator was set to 30 0C and pressure of 100 mbar was used. The condensate was collected and was 
analysed to test for traces of product. The solid obtained from evaporation was yellow crystals and were 
used for 1H NMR analysis. 
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6.3 Results and discussion 
Reaction species related constrains that were identified were product related. The product causes a pH 
shift in the reaction mixture, is potentially volatile and can form a trimer. Therefore, these constraints were 
studied in this Chapter and the results are discussed further. 
6.3.1 pH optima for MAO 
Phosphate buffer at different pH was used to study the pH optima. Since the pKa value of the buffer is 7.2, 
it is reasonable to use the buffer for testing the effect of pH at pH values between 6.2 and 8.2. Since the 
product produced would cause an acidic shift, the activity measurements were made only for pH at and 
below the reaction pH (~pH 8.0). Duplicates of the activity were measured and plotted (Figure 6-2). Activity 
of the biocatalyst at a particular condition was measured by obtaining the initial rate of the reaction over 
the first 30 min of the reaction. The results indicate that MAO has steep reaction optima where 50% of the 
activity is lost with a pH shift of 1 unit. These results correlate with an experiment made with MAO-B from 
both the microsome and mitochondria146.  
 
Figure 6-2: Effect of pH on biocatalyst activity. Substrate concentration 1.48 g/L, biocatalyst concentration of 5.65 gcdw/L. 
Duplicate experiments were performed and plotted. 
6.3.2  Effect of  pH shift on the reaction profile 
From calculations of buffering capacity, it was inferred 500 mM buffer maintains the pH of the reaction 
mixture fairly well when converting substrate of a concentration of ~15 g/L. Therefore, in order to validate 
the effect of pH on the reaction profile, a reaction with 100 mM and 500 mM phosphate buffer was run and 
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the reaction profile was compared (Figure 6-3). The results indicate that the pH change which is quite 
significant in the 100 mM buffer causes a notable change in the final product concentration achieved. From 
Figures 6.3 and 6.4 we know that with 50 mM of imine produced, the pH is shifted by 1 unit and the activity 
of the biocatalyst is significantly reduced (approximately halved). These explain the deviation in the 
reaction profile between the two buffers. 
 
Figure 6-3: Comparison of reaction profile carried out in baffled-shake flask with 100 mM (▲) and 500 mM (■) phosphate buffer. 
Concentration of the biocatalyst was 5.65 gcdw/L 
The shift in pH indicates that the pH control for the process has to be reliable. At large scale operations, this 
can particularly be a challenge because there might be zones of the reactor where the mixing is not 
homogeneous. Also, at the zone where the inlet for the base is placed, the cells will be exposed to high 
concentrations of the base for a short period of time which might cause deactivation. The inhomogeneity of 
pH and the effect of adding strong neutralising agents on the cells have been studied for 
fermentations147,148, but this effect can be extended to biocatalysis as well.  One should keep these 
considerations in mind when the process is developed.  
A reaction was also run in a reactor where pH was controlled by titration of 10 M NaOH. The reactor 
experiments were conducted to compare the reaction profile obtained with a pH stat to that of a buffered 
shake-flask system (Figure 6-3). If catalyst deactivation by addition of base was present, it would be 
noticeable in the reaction conducted in the reactor. Additionally, changes in mass transfer between the 
stirred-tank reactor and the shake-flasks could be noticed in the reaction profile as well. 
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Figure 6-4: Biocatalysis performed with 5.6 gcdw/L in a buffered shake-flask system (■) and in a pH controlled stirred tank 
reactor (♦) 
From Figure 6-4, it can be seen that the reaction profiles between the buffered shake-flask system and the 
reactor are similar indicating that the biocatalyst is not significantly deactivated during the reaction span. 
Also, mass transfer in the stirred tank reactor is similar to that of the shake-flask reactor.  
These set of experiments indicate that the first product-related limitation to the system is pH shift and that 
the reactions should be carried out under a well-buffered system or in the presence of pH stat.  
In order to test for the next identified product-related limitation, tests were carried out to test for the 
volatility of the product and will be discussed in the following section. 
6.3.3 Product volatility and trimerization 
A reaction carried out with 1.48 g/L of the substrate and a biocatalyst concentration of 5.65 gcdw/L was 
plotted as relative response of the substrate and product (Figure 6-5). Relative responses were plotted 
because the product could not be purchased and consequently, a standard curve for it could not be made. 
Also, in order to be able to compare the substrate and product in the same scale, both the substrate and 
product was represented it terms of their relative response obtained by the detection method. Relative 
response of the substrate is the ratio of the substrate to the area of the internal standard (1% PEA) and 
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similarly, the relative response of the product is the ratio of the product peak to that of the internal 
standard. Figure 6-5 indicates that there is a miss-match between the amount of substrate consumed and 
the product formed. The reasons for this could either be that the product is lost due to volatility, consumed 
by the cells or forms a trimer which is not traceable by the GC.  
 
Figure 6-5 : Relative response of the substrate (♦) and product (■) plotted as a function of time. Relative response of the 
substrate is the ratio of the area of the substrate peak to that of the internal standard and similarly that of product is the ratio of 
the area of the product peak to that of the internal standard. 
In order to check for product loss via volatility or by consumption to the cell, product solution was 
incubated in a 250 mL shake-flask flask (with 20 mL working volume) in the presence and absence of cells. 
The product concentration was monitored (Figure 6-6). Relative response was plotted and calculated as 
previously explained. A control of product solution was kept in a sealed falcon tube at room temperature 
and the product concentration was tracked at different time intervals.  
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Figure 6-6: Test for volatility vs. consumption by the cells. The product solution was incubated in shake-flask with cells at 37 ˚C 
(■), without cells at 37 ˚C (▲) and incubated in falcon tubes at room temperature (●). 
From Figure 6-6, it can be seen that the product profile with and without cells are very similar indicating 
that the consumption of the product by the E. coli cells is very unlikely. The product concentration reduces 
in a falcon tube maintained at room temperature but the reduction observed is not significant. This 
indicates that the product is not likely to be degraded over time.  
In order to further test for volatility, the product solution was incubated in reactors and sparged with 
nitrogen. If the product was volatile, sparging with nitrogen will strip the volatile compounds from the 
reaction mixture. Since the flow rate of nitrogen was not measured, the rate of evaporation cannot be 
calculated. However, a comparison to the shake-flask experiments can still be made.  
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Figure 6-7: Test for evaporation of product in a reactor. The product solution did not contain cells. Nitrogen was sparged through 
with an over pressure of 0.5 bar (●) and a control experiment (▲) where the product was incubated in shake-flask is 
represented.  
From Figure 6-7 it can be seen that the sparging nitrogen seems to have less impact on the product 
concentration than the shake-flask experiment (product concentration was found to reduce a lot more in 
the shake flask compared to the reactor). If the product was volatile, the volatility would be observed 
easier in a stirred reactor system with gas bubbling through it. This test therefore indicates that the product 
is not volatile. Additionally, in a different experiment where isolation of product was attempted using a 
rotary evaporator using reduced pressure, no product was observed in the condensate obtained after 
evaporation of excess solvent (MTBE) further indicating that the product is not lost in evaporation. It can 
also be seen from the predicted vapour pressure for the product (0.8 mmHg at 25 oC) that volatility can be 
neglected. From the above tests, volatility and product degradation by the cells can be neglected. 
6.3.4 Trimer formation 
Köhler and co-workers had shown that the product exists as a trimer and this is not traceable by the GC57. 
To confirm this, a 1H NMR was made for the substrate, product and the reaction mixture after 4 h of 
reaction and 24 h of reaction (See Appendix VI). By doing this, the presence of the trimer and the extent of 
trimerization can be studied. The NMR confirmed the presence of a trimer. Integration of the peaks for 
quantitative response seemed unrealistic because several unidentified and overlapping peaks apart from 
the peaks corresponding to the substrate and product were seen. Further experimentation is required for 
confirming if these peaks are from the impurities from solvent and the salt used for product extraction or if 
they are degradation peaks from the product.  
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From the previous experiments, product trimerization has been confirmed. Polymerization of a similar 
imine has been reported previously149. It has been reported in this paper that the monomer and trimer 
exists in equilibrium and the equilibrium formation is almost instantaneous. In order to check for this, the 
reaction was run with different biocatalyst concentration and the relative response of the substrate and the 
product were plotted.  
 
Figure 6-8: Relative response of the substrate (open symbols) and product (closed ymbols) plotted for biocatalyst concentrations 
of 2.5 gcdw/L (■), 5 gcdw/L (▲), and 10 gcdw/L (●). Substrate concentration for the reaction was 6.7 g/L. Relative response of 
the substrate is the ratio of the area of the substrate to the area of the internal standard. Relative response of the product is the 
ratio of the area of the product to the area of the internal standard 
From Figure 6-8, it can be seen that the trimer formation does not seem to be instantaneous. If the 
reaction is fast enough (as in the case with the reaction with a biocatalyst concentration of 10 gcdw/L), all 
of the substrate converted is traceable as a monomer and then the trimerization begins. Additionally, 
trimer formation seems to be related to the presence of the substrate. The presence of the substrate 
seems to slow down the trimer formation (can be seen in reaction with 5 gcdw/L and 10 gcdw/L). This 
could perhaps be because the concentration of the monomer is driving the formation of the trimer.  
6.4 Conclusions 
In this chapter, product-related limitations have been identified. pH shift has been confirmed and this 
affects the final conversion achieved in a batch. pH maintenance by pH stat seems to overcome this 
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limitation. The product was identified to be non-volatile and the formation of trimer has been validated 
through NMR analysis. The rate of formation of trimer seems to depend on the cell concentration.  
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 Biocatalyst-related limitations –7.
Characteristics of the biocatalyst 
Summary 
Redox biocatalysis is currently gaining focus because it offers exquisite selectivity using mild oxidants. This 
includes oxygen, which is also environmentally benign. However, it is often challenging to implement 
oxidative reactions at scale due to the low activity and stability of the biocatalyst under industrial 
conditions. By identifying the bottlenecks for a specific oxidation reaction, it becomes possible to prioritise 
development efforts in the critical areas, i.e, on biocatalyst development (e.g. improvement of expression 
levels), process development (e.g. improved oxygen supply, product removal strategies) or biocatalyst 
stabilization (e.g. through immobilization or directed evolution). This chapter describes the first efforts to 
characterize the target reaction system for potential process limitations.  
The biocatalyst-related limitations that were identified in Chapter 5 were validated and quantified through 
experiments in this chapter. Suggestions for implementing a product removal strategy for overcoming 
inactivation of biocatalyst by the product have been discussed. 
A modification of this chapter has been published (Paper I).   
7.1 Introduction 
To develop a process, it is crucial that it be characterised and its limitations and targets identified. This 
chapter indicates the first efforts towards characterisation of the target reaction system (represented in 
Chapter 2). A systematic approach has been used to characterize the biocatalyst-related limitations. First, 
different mutants expressing the enzyme were screened for and then the best mutant was adopted for 
identifying the mass transfer of the substrate and product across the cell membrane, inhibition (reversible) 
of the biocatalyst by the substrate and (co)product, and inactivation (irreversible) of the biocatalyst by the 
substrate and (co)product Also, the inactivation of the biocatalyst due to reaction conditions (in the 
absence of substrate or product) also affects the reaction and has to be assessed. These limitations are 
quantified in this chapter. 
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7.1.1 Mass transfer across the cell membrane 
Cell membranes are designed in nature to allow the transport of nutrients into the cell and keep the toxic 
substances outside. Therefore, the cell-membrane is often referred to as being semi-permeable.  However, 
this permeability is often a disadvantage for employing the cells for biocatalysis150. For a whole-cell based 
biocatalytic process the substrate must be transported within the cell and made available to the enzyme. 
Following this, the product formed from the enzymatic reaction needs to be transported outside the cell.  If 
the substrate is unable to enter the cell, the reaction will not occur. Furthermore, the rate of the reaction 
catalysed by the enzyme and the rate of transport across the membrane play a central role to how fast the 
reaction occurs. If the rate of transport of the substrate is faster than the biocatalytic reaction, one could 
consider that there is no mass transfer limitation with respect to the transport of the substrate across the 
cell membrane. This is the ideal case. However, at times, the rate of substrate transport is impeded by the 
presence of the cell membrane. Therefore, substrate availability has to be evaluated.  
Similarly, for the ease of recovery of the product, the product has to be transported outside the cell. The 
transport of product across the cell membrane becomes particularly important when the product is toxic to 
the biocatalyst or the cell. 
7.1.2 Stability of the biocatalyst 
Biocatalysis as mentioned earlier is being implemented in many industrial processes. However, one central 
challenge that prevails is to deal with the biocatalyst stability. Biocatalyst stability can be affected by 
process conditions (such as temperature, buffer composition and salt concentrations) and chemicals 
reacting with the biocatalyst (eg. inactivation by the substrate or the product). The loss in stability by these 
can be addressed through different solutions. While the stability to reaction conditions can be varied 
depending on the process conditions chosen (i.e by operating at a different temperature, pH etc.).  Stability 
loss due to the chemical species of a said reaction can be improved by process technology (ISPR, feeding 
etc.).  
Inhibition and Inactivation of the biocatalyst 
One of the desirable properties of an industrial biocatalyst is that it is stable at high product 
concentrations151. The requirement of stability at high product concentrations arises from the need for 
achieving a certain concentration of the product in order to facilitate easy and cost-effective downstream 
processing. However, since most biocatalysts in nature operate at low concentrations of substrate and 
product, they are seldom tolerant to high product concentrations. Consequently, this leads to substrate 
and/or product inhibition and toxicity, which is common to many biocatalytic systems.  
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Substrate toxicity, if present, can easily be overcome by feeding the substrate. The by-product of the target 
reaction is hydrogen peroxide which can potentially cause inactivation of the enzyme152. It is therefore 
necessary to remove the peroxide as it is formed to maintain the enzyme stability and it is hypothesised 
that this can be achieved by the use of another enzyme, catalase (EC 1.11.1.6).  Finally, product toxicity 
becomes a critical factor to overcome and strategies to overcome that is discussed in the following section.  
7.1.3 Overcoming product inhibition and toxicity 
As mentioned previously, in order to achieve high productivities required by the target biocatalyst, the 
reactions are operated in such a way to obtain high product concentrations. This is important to reduce the 
downstream processing cost of the process. Consequently, inhibition and toxicity of the biocatalyst by the 
product becomes inevitable. 
 Inhibition and inactivation of the biocatalyst by the product can be overcome by protein engineering or by 
adopting the so called in situ product removal strategies119,122,153,154. In situ product refers to a set of 
techniques adopted to remove the products in the site of the reaction. Several methods of product removal 
are available for use by a process engineer. While the techniques are known, it is often not straight forward 
to apply the strategies. A successful ISPR exploits the difference in the physiochemical properties of the 
product of interest from the rest of the reaction mixture. However, the substrates and products in most 
biocatalytic reactions have very similar physicochemical properties which complicate the implementation 
of ISPR. Additionally, the selectivity of the ISPR is dependent on its driving force (which is the concentration 
of the product) and the determining factor for separation of the molecules (for example, if resins are 
employed, the capacity of the resins, its selectivity towards the product over the substrate, the rate of 
adsorption of the product/desorption of the substrate with respect to the rate of the reaction are some of 
important factors).  Consequently, concentration profiles of the substrate and the product (that needs to 
be removed) affects the ISPR efficiency.  
For the target reaction system, the substrate and product molecules have different pKa values and 
therefore, this difference can be exploited in order to obtain a successful ISPR technique. It is possible to 
determine the charge of the substrate and the product molecules at a given pH based on their respective 
pKa values. Furthermore, a plot of the ratio of uncharged molecules can be plotted (Figure 7-1). As the 
substrate becomes uncharged, the ratio of the substrate to product becomes higher, when both the 
substrate and the product become uncharged, the ratio becomes 1 (pH> 13). 
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Figure 7-1: Ratio of uncharged substrate to uncharged product for the target reaction system as a function of pH. 
Figure 7-1 indicates that at pH<10, the ratio of the substrate to product is almost zero indicating that most of 
the substrate is uncharged. However, it is only at pH 9 that all of the product molecules are uncharged (See 
appendix IV). Therefore, there is a flexibility of operating the ISPR at different pH (Figure 7-2). 
 
Figure 7-2: Flexibility in operating ISPR for the target reaction. The points represent the various options for operating the ISPR 
and the reaction. (▲) represents operating at pH optimum for the reaction, (■) represents operating at pH optimum for ISPR and 
(●) represents operating the ISPR at different pH. 
As depicted in Figure 7-2, the pH of the ISPR can be set to the optimum pH for the biocatalytic reaction or 
the operated at the pH optimum for the ISPR. In both these cases, there is certain trade-off. The ideal 
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operation would be to catalyse the reaction at a pH that is optimum for the reaction and have an external 
loop for the ISPR where the pH can be adjusted to the pH optimum for separation. This would be operating 
the reaction at pH of 7.8 and the ISPR at pH 9 (represented by ● in Figure 7-2).  
Since the charge is the separating factor, two of the most common ISPR techniques, i.e. solvent extraction 
and ISPR using resins can be employed155,156. When resins are used, the product is immobilized on the 
resins and thereby separated from the reaction mixture (from the site of the biocatalyst). Solvent 
separation involves a use of a two-phase reaction system where the solvent forms a separate organic phase 
and the biocatalyst is present in the aqueous phase. The reaction therefore takes place in the aqueous 
phase and the product molecules that are uncharged are extracted onto the solvent phase. However, 
solvent extraction may cause additional concerns with respect to the biocatalyst stability. Therefore, in this 
study use of resins for ISPR was tested. 
The advantage of using a resin for absorption or adsorption (adsorption is a surface phenomenon, where 
the product gets attached to the resins through non-covalent bonding, while absorption occurs over the 
entire volume of the resin) is that the kinetics is rather fast. Moreover, the capacity offered by absorptive 
resins is higher compared to adsorptive resins. It was therefore chosen to operate a resin-based ISPR for 
this process. The resins can also be re-used after the extraction of the product. Several types of resins are 
available in the market for separation purposes.  
In the following sections, the constraints of the system were outlined above were tested and quantified. 
The constraints were identified systematically where both reversible binding (inhibition) and irreversible 
binding (toxicity) of the substrates, product and co-product were studied. The results from this chapter 
form the basis for understanding that is required for analysing the process limitations for the target system 
for scale-up. 
7.2 Materials and methods 
All chemicals unless specified were purchased at Sigma Aldrich (Steinhiem, Germany) and used as 
purchased.  The solvents were GC grade while the salts were analytical grade. Absorbent resins were kindly 
donated by Professor Daugulis (Queens University, Canada).  
7.2.1 Plasmid  
Plasmids (pET 16b vector) containing 3 different mutants of MAO genes derived from Aspergillus niger 
(wild-type)52  were kindly donated by University of Manchester (Professor N. J. Turner). 
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7.2.2 LB broth and plates 
LB broth was made with 10 g/L tryptone (Nordic biolabs AB, Täby, Sweden), 5 g/L yeast extract (Nordic 
biolabs AB, Täby, Sweden) and 10 g/L sodium hydroxide. To this, 2% (w/v) agar was added for making 
plates. The broth was autoclaved and ampicillin (filter-sterilized) was added to the broth (100 μg 
ampicillin/mL media) prior to use and the agar just prior to plating (100 μg ampicillin/mL media). 
7.2.3 Preparation of competent cells  
A starter culture was used to inoculate 5 mL of LB broth and the cells were incubated at 37˚C to grow the 
cells to an OD600 of approx. 0.6. 2 mL of cells were transferred to Eppendorf tubes and incubated in ice for 
20min. The cells were then centrifuged at 6000 rpm for 10min and the pellet was re-suspended in ice-cold 
water. The centrifugation step followed by re-suspension in water was repeated and centrifuged to obtain 
pellet. The pellet was re-suspended in 500 μL of 10% glycerol and centrifuged for 10 min. The supernatant 
was discarded, the pellet re-suspended in glycerol. The cells were stored as 100 μL aliquots until further 
use. 
7.2.4 Plasmid transformation 
Plasmids (3 mutants) obtained from University of Manchester were transformed into competent E. coli 
BL21 by electroporation. To 50 μL of electro-competent cells, 0.5 μL of the respective plasmid was added 
and transferred to an electroporation cuvette (BIORAD, Copenhagen, Denmark) and exposed to a short 
pulse of high voltage. Following the electroporation, 950 μL of LB medium was added to the cuvette and 
incubated for 1 h at 37 ˚C. 50 μL of the cell suspension was plated onto a LB plate containing ampicillin. 
A colony was picked from the transformation plate, streaked onto a new plate and, incubated at 37 ˚C 
overnight. 5 mL of LB broth containing ampicillin was inoculated with a colony and allowed to grow to an 
OD600 of 0.6. This culture was then stored in 10% glycerol to obtain glycerol stocks. The stocks were stored 
at -80 ˚C until further use.   
7.2.5 Fermentation 
LB plates and pre-culture 
From the glycerol stock, cells were streaked onto an LB plate containing 100 μg/mL ampicillin. The plate 
was incubated at 37 ˚C overnight. 5 mL of LB broth containing 100 μg/mL of ampicillin was inoculated with 
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a colony from the LB-Amp plates. The culture tube was incubated at 30 ˚C in a shaker at 150 rpm for about 
4 hours. 
Fermentation 
All fermentations were carried out in un-baffled shake flasks. To 500mL of LB broth containing ampicillin, 5 
mL of pre-culture was added (1% inoculum). The flask was incubated at 30˚C, 150 rpm. Cells were 
harvested after 18 h of growth by centrifugation at 4000 rpm, 20 min.  The harvested cells were re-
suspended in 100 mM phosphate buffer containing mono and di-basic potassium salts at pH 7.6 (25 ˚C) and 
used for biocatalysis. Fermentation was carried out prior to each biocatalytic reaction. 
7.2.6 Biocatalysis 
Biocatalysis was carried out in baffled shake flasks with a final working volume 20mL of reaction mixture 
(substrate and biocatalyst suspended in 100 mM phosphate buffer, pH 7.6) incubated at 37 ˚C and 150 rpm. 
The substrate, aza-bicyclo-octane HCl was procured from AK Scientific, (Union city, CA, USA). The sampling 
frequency and duration varied depending on the experiment. Samples were prepared and analysed as 
described in the following section. Similar experiments were performed with the same batch of cells (to 
avoid variation between batches). In most reactions, unless specified, the biocatalyst concentration used 
was 5.6 gcdw/L.  
Screening of MAO mutants 
3 different mutants of MAO expressed in E. coli BL21 were used for biocatalysis with 2.96 g/L substrate 
(amine) and a biocatalyst (whole-cell) concentration 11.3 gcdw/L. Conversion after 6 h was measured using 
a gas chromatography according to sample preparation and chromatography protocol and compared. 
Conversion is obtained from the amount of substrate consumed in 6 h. 
Mass transfer of substrate and product across the membrane 
Two biocatalytic reactions with a substrate concentration of 6 g/L and biocatalyst concentrations of 13.5 
gcdw/L and 20.5 gcdw/L were carried out at 37 oC. Samples were taken at different time points, and cells 
isolated from the reaction mixture by centrifugation at 4000 rpm for 2 min. Following this the supernatant 
was separated from the pellet. The samples from the supernatant were extracted as explained in the 
sample preparation section and analysed in the GC. Similarly, at the same time, another sample containing 
the reaction mixture including cells was extracted and analysed in the GC. 
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Substrate (amine) inhibition studies 
Substrate (amine) inhibition was studied by carrying out the biocatalytic reaction at different substrate 
concentrations and measuring the initial rate and reaction progress. Initial rate was obtained by fitting a 
second order polynomial to the first 6 hours  of the reaction and taking the derivative to this curve at t=0 
min. In order to identify catalyst inactivation, 2 mL of cell suspension (~60 gcdw/L concentration) was 
added to the reaction mixture containing 5.92, 8.8 and 11.84 g/L of substrate after 24 h. Samples were 
taken at 3 h and 6 h after the addition of catalyst to monitor conversion. 
Fed-batch reaction 
A reaction with 2.96 g/L of substrate was initiated and 1.48 g/L of substrate was added step-wise at time 
t=2 h, 4 h, 6 h and 8 h. The reaction progress was monitored with GC and compared to a batch reaction 
with 60 mM substrate.  
Product (imine) inhibition 
In order to obtain product for product inhibition tests, a reaction with a substrate concentration of 2.96 g/L 
and a catalyst concentration of 5.65 gcdw/L was run to completion. The reaction mixture was sonicated to 
break open the cells. The cell lysate was stored at room temperature for a week prior to use. Different 
volumes of the reaction mixtures were diluted appropriately with phosphate buffer (100 mM, pH 7.6) to 
obtain various concentrations of product required for the inhibition studies. 
Product (imine) toxicity 
In order to test the inactivation of the biocatalyst by the imine, 0.27 g/L of the product was added to a cell 
suspension containing at a concentration of 5.65 gcdw/L. The mixture was then incubated at reaction 
conditions (37˚C, 150 rpm) for 24h. To this, amine (1.46 g/L) was added and the progress of the reaction 
monitored. 
Also, biocatalyst at the concentration of 5.65 gcdw/L was exposed to product of concentrations 0.44 g/L 
and 0.87 g/L and was incubated at 37 oC for 150 rpm. Reactions were started at t= 0, 2, 5 and 24 h by 
adding substrate such that the concentration was 2.96 g/L and the initial rate was measured. Relative 
activity was calculated and plotted.  
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Co-product (hydrogen peroxide) inhibition  
3% hydrogen peroxide solution purchased from Sigma was used for these studies. The concentration of 
hydrogen peroxide in the solution was confirmed by spectrophotometric absorbance at 240 nm using a 
quartz cuvette. To the reaction mixture containing 2.96 g/L of the amine, hydrogen peroxide was added at 
concentrations of 2.5, 5, 20 mM and initial rate calculated as explained previously.  
Co-product toxicity  
For testing the inactivation of MAO by hydrogen peroxide during the course of the reaction, catalase from 
bovine liver was added to reaction mixture containing 14.8 g/L of substrate catalysed by both whole cells 
and crude extracts such that the final concentration of catalase was 2.5 mg/mL.    
Preparation of crude extract 
Following fermentation, the cells were harvested by centrifugation as mentioned previously. The cells were 
then re-suspended in potassium phosphate buffer (100 mM). The cell suspension was sonicated in an ice 
bath at an amplitude of 20% with 0.5 second cycles for 7 min. The extract was directly used for biocatalysis 
after sonication. 
Biocatalyst stability at reaction conditions 
Whole-cells from fermentation was re-suspended in 500 mM phosphate buffer and dispensed in baffled-
conical flasks such that the final concentration of the biocatalyst would be 5 gcdw/L. The conical flasks were 
incubated at 37oC and 150 rpm for 0, 24, 48 and 52 hours. Substrate was added at these time points such 
that the concentration of substrate in the shake-flasks was 2.96 g/L and the reaction followed by GC. 
Test for oxygen limitation 
In order to test for oxygen limitation, a reaction containing 14.8 g/L of substrate was catalysed with whole 
cells at concentrations of 1.25, 2.5, 5.65, 11.3 and 16.9 gcdw/L. 
ISPR using absorbent resins 
The resin capacity was evaluated by incubating the product in the presence of different concentrations of 
the absorbent resin (1, 3, 5 % (m/v)) at a pH 7.7 and at pH 9.5. GC was used to analyse the product 
concentration in the solution.  
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To test for the ISPR during the reaction, resins at a concentration of 10% (m/v) was tested in a batch set-up. 
The target biocatalytic reaction was carried out with a biocatalyst concentration of 5 gcdw/L and 100 mM 
substrate concentration and pH was maintained at 7.7 with 500 mM KPi.  
7.2.7 Sample preparation  
200 μl of reaction mixture was added to an eppendorf tube containing 10 μL of 10 M sodium hydroxide and 
100 μL of 1% (v/v) 1-phenyl ethylamine (PEA) (Merck, Germany). To this, 1 mL of methyl tert butyl ether 
(MTBE) was added, vortexed for ~20 seconds and centrifuged (Eppendorf, Horsholm, Denmark) at 14100 
rpm for 5 min. The supernatant was then transferred to another eppendorf tube and dried with sodium 
sulphate. This was then vortexed and centrifuged. 200 μL of the organic phase was then transferred to GC 
vials for analysis.  
7.2.8 Gas Chromatography 
The organic substrate and product were analysed in a J&W CAM column (Agilent Technologies, Horsholm, 
Denmark) by Clarus 600 GC-FID (Perkin Elmer, Skovlunde, Denmark) with a split injection, using a split ratio 
of 50:1. An isothermal method with column, injector and detector temperatures of 110 ˚C, 250 ˚C and 250 
˚C, respectively, was used. The carrier gas (nitrogen) flow-rate was set to 1.6 mL/min. Flow rates of 350 
mL/min and 45 mL/min were used for the detector gases air and hydrogen, respectively. 
7.3 Results and discussion 
7.3.1 Mass transfer across the membrane 
By isolating the supernatant and the cell fractions during the biocatalytic reaction and analysing each of 
these fractions for the substrate and the product, the partitioning of the substrate and the product can be 
identified.  
Partitioning of the substrate 
Partitioning of the substrate inside and outside the cell has been quantified for two different cell 
concentrations and plotted (Figure 7-3). 
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Figure 7-3: Represents the fraction of substrate in the supernatant for reactions catalysed by cell concentrations of 13.5 gcdw (■) 
and 20.25 gcdw/L (●).  Duplicates for each cell fraction are plotted. 
Figure 7-3 was obtained by measuring the distribution of the substrate during the course of the reaction. 
From the figure, it can be seen that the irrespective of the cell concentration, approximately 10% of the 
substrate is present in the cell fraction and 90% is present in the supernatant. Therefore, at the current 
situation, the rate of the reaction is lower than the rate of transport of substrate across the cell membrane. 
However, if the activity of the enzyme or the expression level of the protein is increased it is possible to 
observe a mass transfer limitation. Therefore, it is probably advantageous to operate the system without a 
cell membrane. However, the integrity of the cell membrane would contribute to the stability of the 
biocatalyst and need to be assessed.  
Partitioning of the product 
Similarly product distribution in the cell fraction and supernatant can be plotted. However, for this case 
study as depicted in Chapter 5, only the monomeric part of the product can be analysed by GC. Therefore 
the plot depicted here is a representation of only part of the product formed. Nevertheless, an idea about 
the distribution of the product can still be gained. From Figure 7-4, it can be seen that the product 
concentration in the supernatant is only about half the total product concentration. This indicates that 
about 50% of product is associated with the cell fraction and this is irrespective of the cell concentration. 
This result is similar to what has been observed in another E. coli system expressing a monooxygenase 
system157.  
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A 50% distribution of the product in the pellet does not necessarily imply that it is present in the vicinity of 
the enzyme. Therefore product inhibition and toxicity values obtained from a whole-cell system are only 
apparent in the sense that the absolute values are not predictable. 
Also, if product removal techniques are introduced, it might be desired that the ISPR is operated in 
conjunction with a biocatalyst which is either in the form of a lyophilized cells or as free enzymes. With 
either of these cases, the cost of the biocatalyst is a little higher than the cost for whole-cell operation. 
However, the benefits obtained (higher final product concentration) might be able to justify the additional 
cost. A cost-benefit analysis would be useful to assess the catalyst formulation required for this process. 
 
Figure 7-4: Representation of the fraction of total monomeric product molecules present in the supernatant for cell 
concentrations of 13.5 gcdw/L (▲) and 20.5 gcdw/L (♦). 
 
7.3.1 Inhibition by the substrate (amine) 
Reaction progress curves were obtained for the reaction and were used to obtain the initial rates at 
different conditions. While the extent of the reaction gives an idea about the reaction equilibrium and gives 
an insight about the presence/absence of toxicity to the biocatalyst (Figure 7-5), the initial rate gives an 
idea about substrate inhibition (Figure 7-6). Thermodynamic equilibrium is not expected to be limiting in 
this reaction since complete conversion for reactions at low substrate concentration is often observed 
(Figure 7-5). In these studies that initial rate measurements were made over the first 45 minutes of the 
reaction. Samples were taken at t=0 min, 10 min, 20 min, 30 min and 45 min.  
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Figure 7-5: Reaction progress curves for MAO-N-D5 catalysed reaction at different substrate concentrations. (▪) – 15 g/L,  (▲) – 
14 g/L, (●)- 8 g/L, (♦)- 5 g/L, (○) – 2.5 g/L, (Δ) – 1.5 g/L, (◊) – 0.78 g/L.  
 
 
Figure 7-6: Initial rate for reactions at different substrate concentration. 
From the initial reaction rates (Figure 7-6), it can be observed that substrate inhibition (caused by amine) 
becomes apparent at concentrations above 5 g/L and at a concentration above 14 g/L, it is seen to be more 
severe. This is in accordance with toxicity calculations that were made for the amine using the method 
described by Straathof (described in Chapter 5)116. Although the authors argue that the primary reason for 
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product toxicity is membrane disruption, this is not seen to affect the target reaction (as seen from the 
reaction profile using crude lysate in Figure 7-9). The authors also state that there are other causes for 
toxicity which involve specific effects such as inactivation of enzyme by toxic compounds. Therefore, it is 
interesting that this method could be used for predicting the toxicity effects in this system considering 
membrane disruption was not the source of the toxicity.  Since the methodology, by its assumptions is 
limited to substances with an aqueous solubility of up to 0.2 M, this methodology was only tested for the 
substrate. The critical concentration is calculated on the basis of the aqueous solubility (52.45 g/L for the 
amine), and its logP (0.74). The solubility of the imine was calculated using the EPI software from EPA 
(http://www.epa.gov/opptintr/exposure/pubs/episuite.htm).  
From Figure 7-5, it can be seen that when the substrate concentration is higher than 5 g/L, complete 
conversion is not achieved in 24 h. A sample taken after 30 h of starting the reaction indicated no further 
conversion (results not shown). Addition of more catalyst allowed the reaction to further proceed 
indicating that the reaction had stopped due to a loss in catalytic activity (Figure 7-7). It is interesting that 
the conversion rate when fresh catalyst is added is slower and we suspect that the reason for the same is 
the presence of product inhibition and/or an effect of pH change during the reaction (Figure 7-7). This 
result is in accordance with the one obtained by Codexis, where the authors also see that conversion is 
marginally improved when fresh catalyst is added69. The possible reasons for the loss of catalyst activity are 
inactivation by (i) substrate (amine) (ii) hydrogen peroxide (iii) product (imine) and (iv) inactivation due to 
process conditions.  
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Figure 7-7: In a reaction run with an amine concentration of 14 g/L, the conversion has stopped after 24 h. This can be seen from 
the conversion points between 24 and 30 h. Addition of fresh catalyst at 31.5 h indicates that conversion is resumed albeit 
slowly.  
7.3.2 Inhibition by product (imine) 
Since the product (imine) is not commercially available, it needs to be synthesised prior to the inhibition 
tests. The product was synthesized as described in the materials and methods section. This method of 
imine synthesis was chosen because of its simplicity. Likewise, it circumvents the time consuming steps of 
purification and recovery (including extraction into solvent and drying with a rotary evaporator) that is 
involved in the chemical synthesis of the compound. In addition, when the product is synthesised using the 
chemical route, the imine obtained is in the form of a trimer which is not soluble in water. In order to 
solubilize the trimer, an alkali of an equivalent strength needs to be added to enable dissolution. It is 
therefore advantageous to produce the imine by biocatalysis as the product solution can be used directly 
after production. The cell suspension was sonicated to release the product from within the cells and the 
suspension was stored at room temperature for a week to ensure removal of residual MAO activity. The 
initial rate was used as an indication of product inhibition (Figure 7-8). The initial rate was obtained by 
following the substrate conversion since the product can co-exist (in equilibrium) as a monomer and a 
trimer, consequently complicating the analysis. Trimer formation has also been observed for another 
similar pyrroline molecule149. From the figure, it can be seen that the biocatalyst is inhibited by the imine 
with almost 50% of the activity being lost at a concentration of 0.7 g/L.  
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Figure 7-8: Initial rates for reactions at different product concentrations. The graph represents duplicates made with the same 
batch of biocatalyst. 
7.3.3 Inhibition by co-product (hydrogen peroxide) 
Inhibition studies using hydrogen peroxide indicated that there is a reduction in the initial rate when 
hydrogen peroxide is added to the system (Figure 7-9). It is also noteworthy that the reduction in reaction 
rate is very low (i.e from 0.92 g/L/h to 0.83 g/L/h). Also, the reaction progress (for reaction containing 2.9 
g/L of substrate) indicated that the reactions proceeded to completion at the end of 24 h. This indicates 
that inhibition by hydrogen peroxide is present, at the conditions tested, but because the cells contain 
catalase, the MAO is stable enough to facilitate the reaction to completion. The presence of catalase was 
qualitatively assessed when hydrogen peroxide was added to the cells causing effervescence (caused due 
to production of oxygen when hydrogen peroxide is degraded).  As to whether this is a function of catalyst 
turn over number (inherent to the number of active sites of catalase in the cells) remains to be tested.  
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Figure 7-9: Inhibition by hydrogen peroxide. 
7.3.4 Biocatalyst stability (Inactivation of the biocatalyst) 
As can be seen from Figure 7-7, the catalyst is inactivated (irreversible loss in activity) after 24 h when 
converting substrates at concentrations over 5 g/L. The reason for the inactivation could be due to the 
substrate(s) and/or the product(s) and the inherent stability of the biocatalyst. Since oxygen is not supplied 
by sparging (but supplied by head-space aeration), shear forces that can be caused by gas-liquid interface is 
minimal. Hence, inactivation by oxygen is neglected. Inactivation by the other components (hydrogen 
peroxide, amine and the imine are discussed further).  
Stability of the biocatalyst at reaction conditions 
Biocatalyst stability could be influenced by reaction conditions (temperature, pH etc.) and the following 
section describes the results from stability studies carried out when no substrate was present over a period 
of 52 hours and the remaining activity measured by adding substrate to the reaction mixture. Since there 
was evaporation, the substrate concentrations at the start of the reaction was slightly higher in the flask 
incubated for 52h compared to the one where the substrate was added at t=0. This made the initial rate 
comparison faulty. Therefore, the substrate consumption profile was compared instead of just the initial 
rate (Figure 7-10). Comparison of the profiles indicates that there is no loss in stability at reaction 
conditions for 52h when no reaction is catalysed (Figure 7-10). 
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Figure 7-10: Stability of the biocatalyst at reaction conditions (37 oC, 150 rpm). Catalyst concentration of 5.65 gcdw/L (●) – No 
exposure, (▲) – 24h, (■) – 48h, (♦) – 52h exposure. 
 
Inactivation by hydrogen peroxide 
If the inactivation of the biocatalyst was caused by the hydrogen peroxide, removal of hydrogen peroxide 
should allow the reaction to proceed further. This can be achieved by adding an excess of catalase to the 
reaction system. 
 
Figure 7-11 indicates the effect of adding catalase to the reaction mixture to degrade the hydrogen 
peroxide produced during the reaction. This was tested with reactions catalysed by both whole-cells and 
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crude enzymes to eliminate concerns regarding the transfer of catalase into the cell (to the proximity of 
hydrogen peroxide). The results indicate that the degree of reaction does not improve by the external 
addition of catalase indicating that (at this concentration) hydrogen peroxide is not causing inactivation of 
the cells. This could be attributed to the presence of catalase in the E. coli cells. This result implies that the 
inactivation is caused by either the substrate or the product and further investigation is required in this 
regard. 
It is also noteworthy that the crude extracts and the whole cell reactions follow the same trend indicating 
that the mass transfer across the cell membrane is not limiting. The reaction is slower than the mass 
transfer rate across the membrane. 
 
 
Figure 7-11: Effect of catalase on the reaction progress. Substrate concentration: 15 g/L, Biocatalyst concentration: 5 gcdw/L, 
catalase concentration – 2.5 mg/mL. (◊) – whole-cells (control), (Δ) – crude extract, (□) – whole cell with catalase, (○) – crude 
extract with catalase. 
Inactivation by substrate (amine) 
Inactivation by the exposure to the amine is quite tricky because it is not possible to incubate the catalyst in 
the presence of oxygen and at the same time prevent the reaction from proceeding. Diluting the reaction 
mixture and adding competing amine substrates was considered. However, such a method makes it difficult 
to separate the effects of product inhibition (and inactivation) from substrate inactivation. Inactivation by 
substrate could be tested by incubating the enzyme in the presence of the substrate in the absence of 
oxygen (by sparging nitrogen). However, sparging might cause shear effects due to gas-liquid interface and 
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interfere with the results. Thus, a different method of estimating the substrate toxicity was adopted. We 
argue that if substrate inactivation was present, fed-batch addition of the amine would help maintain the 
stability of the biocatalyst. It is for this reason, a fed-batch reaction was run and the product profile 
compared to that of a batch (Figure 7-12). 
 
Figure 7-12: Stepwise feeding of the substrate to identify substrate toxicity. () represent fed-batch while () represent batch 
reaction. 
Figure 7-12 represents the ratio of area of the product to the area of the internal standard (sometimes 
known as relative response of the product) plotted against time. It can be seen that the profile of a fed-
batch matches that of a batch reaction. This indicates that the inactivation of the biocatalyst is not due to 
the substrate. Furthermore, since the inactivation is not caused by hydrogen peroxide, substrate or the 
reaction conditions (pH, temperature), it can be attributed to the inactivation by the product.  
Inactivation by product (imine) 
Preliminary tests indicate that when the biocatalyst was incubated in the presence of 0.12 g/L and 0.17 g/L 
of the imine at reaction conditions (37 ˚C, 150 rpm) about 4% and 8% of the activity was lost respectively, 
confirming that the inactivation is indeed caused by the presence of the product. Additionally, the loss in 
activity of the biocatalyst increases with increase in duration of exposure further confirming inactivation of 
the biocatalyst. The inhibition by the cyclic imine product has also been reported in a study where a similar 
amine was used69.   
Figure 7-13 represents the relative activity of the biocatalyst when exposed to 4mM and 8mM of the 
product for different period of time (0 h, 3 h, 6 h, and 24 h). From the figure it can be seen that the relative 
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activity is reduced by approximately 33% and 44% when the cells are exposed to the product of 4mM and 
8mM respectively for 24 h. Similarly, previous studies have shown that product toxicity is a function of both 
product concentration and duration of exposure69. In their study, the authors indicate a faster decay of the 
enzyme’s activity when exposed to higher concentration of the product (The catalyst lost ~85% of its 
activity at a product concentration of 32 mM). For the target system studied in this thesis, the reaction is 
severely product toxicity limited and the final product concentration achieved will be a combination of 
speed of product production and the tolerance of the biocatalyst towards product toxicity. 
 
 
Figure 7-13:  Figure represents the relative activity of the cells when exposed to the product for different durations of time. (♦) 
represents a reaction started with ~4mM product while (■) represents a reaction started with ~8mM of the product.  
7.3.5 Overcoming product toxicity 
In situ product removal technique using absorptive resins was suggested for removing the product. The 
separation technique employed was based on the fact that the charge of the substrate and the product is 
different at different pH (as explained previously).  The capacity of the resins to absorb the product was 
first tested and the % of product absorbed was plotted. Product absorbed was traced by the product left in 
the solution. It can be argued that the absorption might be overestimated because this approach does not 
take trimerization into account. However, this method offers a quick screening technique for the success of 
implementation of the resins for product removal. Arguably, since only uncharged molecules will be 
absorbed by the resin, the trimer should also be absorbed but this was not validated. Also, since the 
monomer and trimer exists in equilibrium, the trimer will convert to monomer as absorption occurs. 
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Figure 7-14: Test for resin capacity at pH 7.7 (■) and pH 9.5 (▲). Duplicate samples were taken and have been plotted. 
From Figure 7-14, it can be seen that about 50% of the product gets absorbed onto the resin at pH 9.5. 
While the product absorption is lower at the pH that is optimum for the reaction (pH 7.7), it is not 
significantly lower. This indicates that the resins can be used for product recovery.  
7.3.6 Test for oxygen limitation 
The reaction rate for any biocatalytic reaction is affected by the concentrations of the substrate(s) and the 
biocatalyst. For the target oxidation reaction, this rate is affected by the concentrations of the amine, 
oxygen and the biocatalyst. If the amine concentration and the oxygen supply rate are kept constant, the 
reaction rate is solely affected by the biocatalyst concentration in the system.  
The requirement of oxygen supply is set by the maximum rate achieved in the system during the course of 
the reaction. Initial rate of the reaction is considered here as the demand of oxygen supply is highest during 
the period over which initial rate is measured. By plotting the initial rate over various enzyme 
concentrations, one can determine the region where oxygen becomes limiting. When oxygen is not limiting, 
the initial rate linearly increases with the biocatalyst concentration, however, when oxygen becomes 
limiting, the rate is determined by the rate of oxygen supply and therefore levels off.  
0
10
20
30
40
50
60
0 1 2 3 4 5 6
%
 p
dt
 a
bs
or
be
d 
Resin loading (m/v%) 
106
Biocatalyst-related limitations –Characteristics of the biocatalyst 
91 
 
For the target system, since the rate of conversion of the substrate is rather low, oxygen was not expected 
to be limited. This was confirmed by performing experiments with increasing concentration of cells and 
measuring the initial reaction rate. The result shows a linear increase in the rate with the enzyme 
concentration (Figure 7-15), indicating that there is no oxygen limitation. The maximum oxygen transfer 
capacity for an un-baffled shake-flask has been shown to be around 10 mmol/h (corresponding to 1.48 
g/L/h) at a shaking speed of 150 rpm, with a 26 mL filling volume158. For a baffled shake flask, this is 
expected to be higher. Therefore, it is not surprising that the reaction is not oxygen limited in these 
conditions. The result obtained is in contrast to the study reported by Codexis69, where it was seen that the 
initial rate increased with the oxygen concentration. 
 
Figure 7-15: Reaction rate as a function of cell concentration at a substrate concentration of 6 g/L. 
7.3.7 Constraints identified 
From the above discussed results several constraints have been identified that prevent this system from 
being economically viable for large scale operation. The constraints identified are threefold (i) substrate 
inhibition, (ii) product inhibition (reversible loss of activity) and (iii) product toxicity (irreversible loss of 
activity). Likewise in a study by Zhang and co-workers69, on the oxidation of a similar amine with a different 
MAO mutant, similar constraints were identified to the ones presented in this study. In both these cases 
the system was severely affected by product inhibition, although substrate inhibition (by the amine) seems 
to be a more serious issue in the Codexis example.  
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Targets for pharmaceutical products have been set based on the economy of the process. For example a 
typical pharmaceutical product it will be necessary to have a target product concentration of 50-100 g/L, a 
whole-cell biocatalyst yield of 5-10 g/gcdw and a reaction yield greater than 95%127,159,160. A typical 
fermentation yield for E. coli is 50 gcdw/L. Hence it can be expected that for this process production of 
biocatalyst will not be a limitation. In fact a target biocatalyst concentration has been set at 25 gcdw/L, 
based on our experience with difficulty in sampling when running biocatalysis at such high concentrations 
of cells. Likewise, oxygen supply is limited to 14.8 g/L/h (corresponding to 100 mmol/L/h) when air is used 
to supply oxygen to the reactor97. Although oxygen can be supplied at a higher rate (up to 59.2 g/L/h) when 
pure oxygen is used instead of air, this would incur additional costs and appears unnecessary. It should be 
noted that agitation and mixing in larger vessels might be worse and have to be accounted for successful 
scale up of oxygen supply. 
Implications for oxygen requirements for the target system 
Oxygen requirement in this type of biocatalytic system is the highest when the rate of the reaction is 
maximum since stoichiometric amounts of oxygen is required by the system. The maximum rate for a 
biocatalytic reaction is the initial rate and therefore a plot of the variation of initial rate would give an 
indication of the maximum oxygen requirement for the system. As mentioned earlier, the limit for oxygen 
supply is about 14.8 g/L/h.  
 Also, when the concentration of whole cells used in a reactor is higher than 20 gdcw/L difficulties in 
product recovery was observed further advocating the use of lyophilised cells. Therefore, these limits can 
be marked-off on Figure 7-15.  By doing so, it is possible to obtain an operating region where the system is 
not oxygen limited (Figure 7-16). Such plots where a process constraint and process variable are expressed 
are commonly referred to as regime plots161. When the protein expression of the host system or the 
specific activity of the enzyme is improved, then the maximum rate achievable by the system increases. 
However, depending on the number of folds of increase, it is likely that the system would reach oxygen 
supply limits as expressed in Figure 7-16 (drawn based on the assumption that there is no mass transfer 
limitation of the substrate across the membrane). However, it is probably not critical that the process is 
operated at the oxygen limitation conditions for economic scale-up. Therefore, knowledge of the maximum 
rate that a process is required to operate at would make it easier to identify if efforts are required in terms 
of process development for improved oxygen supply.  
For example, in this system, if a product concentration of 50 g/L is desired in a time period of 24 h, one 
could operate the system as it is with a maximum specific activity of ~0.2 g/g/h at a biocatalyst 
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concentration of ~10 gcdw/L. However, if the biocatalyst is affected by stability i.e it loses stability after a 
few hours of operation, then it is desired that the reaction rate is increased. In such cases, it is desired that 
improved oxygen supply strategies are adopted to increase the rate at which the product is formed.  
 
 
Figure 7-16: Regime plot for oxygen requirement to the system. Dotted line represents the improved maximum specific activity 
of the biocatalyst when the expression is improved. 
From the biocatalyst-related limitations identified through experiments in this chapter, it is clear that use of 
whole-cell system for this specific case provide more challenges to the system. If the expression is 
increased, mass transfer of substrate would be limiting. Also, use of whole-cells makes product recovery 
difficult. Therefore, it is advisable to switch to the use of a cell-free extract or lyophilised cells for the 
process. It should be noted that the stability of a different biocatalyst formulation is likely to vary from 
using whole-cells and need to be evaluated. 
Further limitations to the reaction system have been identified in context of the economics of the process 
in the following chapter.  
7.4 Conclusions 
Biocatalyst-related limitations were quantified in this chapter. This indicates that there is no mass transfer 
limitation across the membrane for the substrate while half the product is trapped within the cell. As a 
result, it becomes advantageous to use lyophilised cells or cell-free extracts for the process. Furthermore, 
at the rate at which the reaction proceeds, it is not limited by oxygen and is therefore not a concern at this 
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very moment. However, with an improvement in the protein expression, the situation is likely different and 
the focus will shift from the expression to potentially the combined improvement, oxygen supply as well as 
the means to keep the biocatalyst stable.  
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 Analysis of process limitations 8.
Biocatalytic reactions are implemented to provide for the exquisite selectivity that the chemical 
counterparts cannot offer. However, implementation of the biocatalytic reactions at industrial scale is often 
a challenge in part due to the complex interaction between the reaction species and the biocatalyst. These 
interactions affect the activity and stability of the biocatalyst under industrially relevant conditions and 
consequently determine the economic feasibility of a process at scale. This chapter uses the results from 
the previous chapters where limitations to the target system were identified and uses this knowledge 
gained in conjunction with more experiments to make a more general assessment of the overall process to 
see which targets need to be met to make the process scalable. 
8.1 Introduction 
The success of a biocatalytic process is evaluated relative to the process targets such as biocatalyst yield or 
space-time yield, reaction yield and product concentration. The targets are set based on the market value 
of the substrate and product162. It is necessary that the process meets all these targets for a particular 
system. 
 The reaction yield of the process gives an idea about the efficiency with which the substrate is used. The 
reaction yield is stoichiometric when the substrate or product is not lost due to volatility. However, when 
the substrate or product is lost, or when the reaction suffers from thermodynamic limitations, the 
maximum reaction yield cannot be reached. 
The product concentration which represents the product produced per volume of the reactor places 
demands on the downstream processing. Biocatalysis operates in water-based systems which are often 
dilute and involve the separation of a large quantity of water163. Consequently, downstream processing 
costs contribute significantly to the process costs. To make the process more economically viable, it is 
essential to have high product titre coming out of the biocatalysis reaction and it is therefore critical to 
understand and estimate the maximum product concentration achievable in a process at different catalyst 
concentrations.  
Furthermore, since this process is based on non-metabolically active cells, the cost contribution from the 
biocatalyst (i.e. biocatalyst) becomes important. The cost contribution from the biocatalyst can be seen 
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from the biocatalyst yield. Biocatalyst yield is the amount of product produced per gram of biocatalyst and 
represents the biocatalyst cost contribution to the process. 
Additionally, since it is an oxygen-requiring process, oxygen supply can be a process constraint and 
therefore the maximum rate achievable (initial rate) by the system at different catalyst concentration is an 
important metric.  
The targets for the reaction system are set based on the market value for the product. Relative costs of the 
substrate to the product dictate the economics of the process. For the target reaction system considered in 
this thesis, the substrate can be purchased from AK Scientific at a cost of $5 per gram. Arguably a bulk 
purchase of the substrate could result in a cost that is an order or two lower. However, the product cannot 
be procured from the market. A quote for the synthesis of the product given by AK Scientific was $ 400 per 
gram. For the sake of process evaluation for economic feasibility, it is required to first set targets for a 
particular reaction system. It is noteworthy that the value of the product will be determined by the market 
and has to be evaluated carefully. In the following sections, the product is assumed to be a high value 
product of pharmaceutical relevance.  
Examples for targets for the economic metrics and are summarized for a pharmaceutical product in Table 
8-1.  
Table 8-1: Examples of targets for pharmaceutical product produced using whole-cell biocatalysis 
Parameter Examples of target 
Product concentration 50 g/L159 
Space time yield (STY) >2.5 g/L/h159 
Biocatalyst yield 10-35 gP/g dry cell weight116,160 
Reaction Yield  >90% 
 
For the target reaction catalysed by monoamine oxidase, the product toxicity and expression levels are 
identified as the potential (from experiments in Chapter 7). Most of the experiments conducted up to 
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Chapter 7 were carried out in a fixed catalyst concentration of 5 gcdw/L. However, changes in the reaction 
or process conditions would lead to changes in the performance of the reaction system. For example, by 
varying the catalyst and the substrate concentrations the effect of changing regimes on the process targets 
can be evaluated. That is, by varying the substrate and catalyst loads, further analysis of the impact of 
catalyst load and product toxicity to make an assessment of the potential for improvements in the process 
has been performed.  
In order to visualise the limitations of a process and the improvements attained, 2-D plots called regime 
plots have been used161. With regime plots, it is possible to identify the gain attained by relaxing the 
limitations present to the system. Combining the regime analysis with sensitivity analysis (where the effect 
of changes in variables on process constraints can be studied) would in turn allow for further process 
understanding and help identify operating conditions for the system164.  
Once the limitations and the effects of removing them on the target metrics are identified, two of the most 
significant economic parameters (for the target system) can be plotted against one another. The targets for 
the economic metrics can be plotted and the improvements on limitations can be visualised (Figure 8-1). 
 
Figure 8-1: Plot of one economic target against another. t1 and t2 represent the targets for the economic metrics 1 and 2. 
 
 The following sections in this chapter will discuss experiments that were carried out to quantify the 
process limitations based on previous Chapters. Following this, a sensitivity analysis on removing the 
process constraints were made and finally plotted against the economic target to identify where the efforts 
for improvement need to be placed. 
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8.2 Materials and methods 
All chemicals unless specified were purchased at Sigma Aldrich (Steinhiem, Germany) and used as 
purchased. The solvents used were GC grade while the salts were analytical grade. 
8.2.1 Plasmid and fermentation 
Plasmids (pET 16b vector) containing 3 different mutants of MAO genes derived from Aspergillus niger 
(wild-type) [Schilling & Berch, 1995] were kindly donated by University of Manchester (Professor N. J. 
Turner). 
The plasmid was transformed into competent BL21 strains and fermented as explained in Chapter 4.  
8.2.2 Biocatalysis 
Biocatalysis was carried out in baffled shake flasks with a final working volume 20mL of reaction mixture 
(substrate and biocatalyst (in whole-cell formulation) suspended in 500 mM phosphate buffer, pH 7.6) 
incubated at 37 ˚C and 150 rpm. 
The substrate, aza-bicyclo-octane HCl was procured from AK Scientific, (Union city, CA, USA). Samples were 
taken at t= 0, 1, 2, 4, 6, 8, 24, 27, 30, 48 and 52h. Samples were prepared and analysed as described in the 
following section. Similar experiments were performed with the same batch of cells (to avoid variation 
between batches).  
The cells from fermentation was harvested by centrifugation at 4500 rpm for 20 min and re-suspended in 
phosphate buffer (used for the reaction) to achieve a concentration of ~50 gcdw/L. Dilutions of this 
suspension were used to achieve desired concentration for the reaction.  Biocatalysis was carried out at 
different cell concentration (1.25, 2.5, 5, 10, 20 gcdw/L) to react different substrate concentrations (2.6, 7 
and 14 g/L).  
For biocatalysis using biocatalyst concentrations of 10, 15 and 20 g/L, the reaction was repeated and 
substrate (approx. 0.11 g) was added to the reaction mixture at 24h. 
8.2.3 Sample preparation 
200 μl of samples of reaction mixture were added to Eppendorf tubes containing 10 μL of 10 M sodium 
hydroxide and 100 μL of 1% (v/v) 1-phenyl ethyl amine (PEA) (Merck, Germany). To this, 1 mL of methyl 
tert-butyl ether (MTBE) was added. The tubes were vortexed for approx. 20 seconds and subsequently 
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centrifuged (Eppendorf, Horsholm, Denmark) at 14100 rpm for 5 min. The supernatant was then 
transferred to another Eppendorf tube and dried with sodium sulphate. This was then also vortexed and 
centrifuged in an equivalent manner. Finally, 200 μL of the organic phase was transferred to GC vials for 
analysis. 
8.2.4 Gas chromatography 
The organic substrate and product were analysed in a J&W CAM column (Agilent Technologies, Horsholm, 
Denmark) by Clarus 600 GC-FID (Perkin Elmer, Skovlunde, Denmark) with a split injection, using a split ratio 
of 50:1. An isothermal method with column, injector and detector temperatures of 110 ˚C, 250 ˚C and 250 
˚C, respectively, was used. The carrier gas (nitrogen) flow-rate was set to 1.6 mL/min. Flow rates of 350 
mL/min and 45 mL/min were used for the detector gases air and hydrogen, respectively. 
8.3 Results and discussion 
The following sections discuss the results from more experimental work for identifying limitations, 
specifically product toxicity as a function of catalyst concentration. Furthermore, an analysis the impact of 
alleviating the limitations on the reaction system has been described. 
8.3.1 Product-time profiles at different biocatalyst concentration  
Product-time data were procured for different substrate and catalyst concentrations to understand process 
limitations such as loss in biocatalyst stability (which can be seen if no further conversion is achieved at 
substrate non-limiting regimes). For the target reaction system the maximum theoretical yield based on 
stoichiometric conversion is 0.7 g product per g substrate. The yield appears to be low, but this is a result of 
using a hydrochloric salt as a substrate making the molecular weight of the substrate 148 g/mol. Figure 8-2 
represents the product-time profiles for reactions catalysed at different substrate and product 
concentrations. The product concentrations plotted here are calculated from substrate conversion, 
assuming stoichiometric yield (i.e. 1 mol of substrate forms 1 mol of product).  
It can be seen that at low substrate concentration (Figure 8-2a), the maximum product concentration 
achievable is limited only by the duration of the reaction, that is, all of the substrate is converted to product 
as long as enough time is provided for the reaction. At increasing substrate concentrations, full conversion 
is not consistently achieved (Figure 8-2b, Figure 8-2c). For high enzyme concentrations (>10 gcdw/L), all the 
substrate is converted to product. Figure 8-2c indicates that the conversion for biocatalyst concentration of 
1.25 and 2.5 gcdw/L has stopped after 30 h.   
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Figure 8-2: Product profiles at different enzyme (●) – 20 gcdw/L, (■) – 10 gcdw/L, (▲) – 5 gcdw/L, (♦) – 2.5gcdw/L and (○) – 1.25 
gcdw/L and substrate concentrations (a) 2.6g/L, (b) 7 g/L and (c) 14 g/L.   
Based on the final yields represented in Figure 8-2, the achievable reaction yields can be plotted as a 
function of cell concentration (Figure 8-3). In all reactions represented in Figure 8-2, complete conversion 
of substrate was observed at high biocatalyst concentration (biocatalyst concentration ≥10 gdcw/L) (Figure 
8-3). In order to check for the activity remaining in the biocatalyst after complete conversion of the 
substrate, when the substrate is not limited (at cell concentration > 10 gcdw/L), substrate was added to the 
flask at the end of 24 h. The substrate added was in solid form and then the consumption was traced until 
no further conversion or all of the substrate was used was tracked (Figure 8-4).  In the reaction with a 
biocatalyst concentration of 10 gcdw/L, it was observed that no further conversion was seen (after 48 h) 
indicating that the biocatalyst lost all activity. But with a cell concentration of 15 and 20 gcdw/L, most of 
the substrate was used. Therefore, the final product concentration achieved cannot be assumed to be the 
maximum possible product concentration achieved at these biocatalyst concentrations. 
For obtaining the final product concentration achieved by the target reaction system at high cell 
concentrations, the substrate has to be fed in such a way that the substrate concentration is below the 
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toxicity limit. Furthermore, the biocatalyst is affected by a time-dependant product inactivation (as seen in 
Chapter 7). As a result, the method adopted for feeding the substrate becomes important for the product 
concentration achieved. Therefore, though a step feed has been adopted in this study, it is likely not the 
best strategy for using the entire potential of the biocatalyst. Continuous feeding would prove more 
advantageous in such scenario.  
 
 
Figure 8-3: Reaction yield plotted as a function of cell concentration for reactions started with a substrate concentration of (♦) 
2.6 g/L, (▲) 7 g/L and (■) 14 g/L. 
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Figure 8-4: Reaction catalysed by biocatalyst at concentrations of (▲) – 10 gcdw/L, (■) – 15 gcdw/L and (●) – 20 gcdw/L. The 
reaction was fed with a substrate concentration of approx. 10 g/L at 24h. 
8.3.2 Reaction rate and oxygen transfer limit 
The results shown in Figures 8-2 and 8-3 indicate that the reaction suffers from limitations preventing the 
maximum theoretical yield from being achieved. The lower yield achieved by reactions with low catalyst 
concentrations can be a result of some limitation.  
Plotting catalyst*time against product concentration (known as Selwyn’s test) for identification inactivation 
of the biocatalyst over the course of the reaction has been proposed previously165. This plot can be used as 
a means for identifying rate limitations in the reaction system. If the rate of the reaction does not linearly 
scale with biocatalyst concentration during any part of the reaction curve, the profiles for the different 
biocatalyst concentrations would not superimpose on one another. Furthermore, the plot can be used for 
separating rate limitations that are caused by catalyst deactivation from those caused by mass transfer 
limitation166. 
For example, if the limitation is due to loss in stability of the biocatalyst, then the deviation would be 
observed in the lower catalyst concentrations. For example, for a system with product inhibition, the initial 
conditions would superimpose for all catalyst concentrations but as the reaction proceeds, inactivation 
occurs and deviations will be observed.  
On the other hand, if the limitation is arising from the mass transfer limitations of oxygen, the deviations 
would be observed for higher catalyst concentration. This is because oxygen is required in stoichiometric 
amounts for the reaction. Therefore, initial rate would give an idea about oxygen limitation.  
Therefore, to identify the type of limitation (for reaction system), the product concentration was 
normalized against enzyme concentration to obtain a product concentration against cell concentration * 
time plot (Figure 8-5). 
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Figure 8-5: Product concentration achieved in a reaction where a substrate concentration of 14.8 g/L was converted as a function 
of reaction time and biocatalyst concentration. Biocatalyst concentration: (●) – 20 gcdw/L, (■) – 10 gcdw/L, (▲) – 5 gcdw/L, (♦) – 
2.5gcdw/L and (○) – 1.25 gcdw/L.  
In Figure 8-5, the trends for the different biocatalyst concentration overlap in the initial part of the curve, 
indicating that initial rate is not limiting for the catalyst concentrations tested in this case. With the current 
expression levels, the initial rate of biocatalysis is not seen to be limiting implying that oxygen is not limited 
in this reaction at the conditions tested. Since oxygen can be supplied at a rate of 100 mmol/L/h 
(corresponding to 14.8 g/L/h) and the current reaction rate for a reaction with 14 g/L of substrate 
concentration and 20 gcdw/L is 2.11 g/L/h, there is scope for increasing the rate at least by five times 
before oxygen becomes a limiting factor. A linear increase in reaction rate with cell concentration was 
shown also in Chapter 7 indicating that the oxygen is not the limiting factor. Similar plots were made for the 
reactions with lower substrate concentrations and verified that reaction is not limited by rate (see 
Appendix VII). 
Figure 8-5 shows that the final product concentration achieved at biocatalyst concentrations of 1.25 gcdw/L 
and 2.5 gcdw/L are lower than the maximum possible product concentration. This indicates that the 
reaction suffers from loss of biocatalyst stability. 
8.3.3 Product concentration limit 
The final product concentration achieved at a particular biocatalyst concentration was plotted (Figure 8-6) 
to identify the maximum product concentration achievable in the system. From Figure 8-6, it can be seen 
that the product concentration increases linearly with increase in biocatalyst concentration until a certain 
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point (until biocatalyst concentration 10 gdcw/L) after which there appears to be a levelling off. The linear 
part of this curve depicts the total turnover number (TTN) for the biocatalyst at its current performance.  
From the substrate feeding profiles, it can be seen that at a catalyst concentration of 20 gcdw/L all of the 
substrate was converted and therefore, this trend can be because of the unavailability of the substrate and 
the region has been marked as “substrate limited”. Substrate limitation could in principle occur when the 
substrate is volatile. However, for the current case study, the substrate conversion profiles indicate the 
presence of the substrate and hence volatility can be neglected. 
 The linear region where the product concentration increases with increase in biocatalyst concentration can 
when there is a biocatalyst limitation and is represented by the term “biocatalyst limited” (Figure 8-6). As 
an extension, if only the linear region of the plot is considered, then the area above the curve is biocatalyst 
limited (i.e. the entire potential of the biocatalyst has been used) and when the system is operating in the 
area below, it is limited by the availability of the substrate.  
The biocatalyst limitation can occur either due to inactivation of the biocatalyst due to product toxicity or 
due to loss in stability of the biocatalyst over time at reaction conditions (i.e. interaction of components 
from the reaction mixture that is not related to the substrate or the product). From Figure 7-10 it can be 
concluded that the biocatalyst is stable at the reaction conditions for 52 hours. Therefore, loss of activity 
within that time should be linked to either the substrate or product toxicity. Substrate toxicity was tested 
for by running a fed-batch reaction and comparing it to a batch (Figure 7-12). This test indicates that the 
reaction is not limited by substrate toxicity. However, from Figure 7-13 it can be seen that the biocatalyst is 
severely affected by product toxicity and toxicity is a function of duration of exposure and the product 
concentration. Therefore, the final product concentration attained at low cell concentrations represented 
in Figure 8-6 is a function of product toxicity. In a Bayer Villiger Monooxygenase (BVMO) system, it was 
seen that the product concentration increased linearly with product concentration and levelled off when 
the toxicity became predominant164. Such a trend can be expected in the target system at higher biocatalyst 
concentrations (≥ 15 gcdw/L). 
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Figure 8-6: Product concentration as a function of biocatalyst concentration. 
8.3.4 Implication of the results 
The process metrics i.e. product titre, biocatalyst yield and maximum rate are all affected by the biocatalyst 
concentration. Therefore, these metrics were plotted against the cell concentration to obtain Figure 8-7. 
Biocatalyst yield is obtained by dividing the product concentration to the catalyst concentration. 
The initial rate is obtained for a reaction with 14 g/L substrate concentration. It can be seen that the initial 
rate can be increased by approx. 7.4 times before the system reaches an oxygen supply limit. Improving the 
expression under this limit would in turn improve the product concentration and consequently the 
biocatalyst yield until product toxicity becomes limiting. The initial rate of the reaction can be increased by 
either increasing the amount of enzyme in a gram of cell or increasing the specific activity of the enzyme. 
However, the SDS experiment represented in Appendix III indicates that protein was not detected. It can be 
inferred that the protein per g of cell is very low and is possibly the parameter that can be improved.  
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Figure 8-7: Representation of the targets and limitations for the reaction system. (●) represents the product concentration as a 
function of cell concentration; (♦) represents the maximum rate of the reaction as a function of cell concentration and (■) 
represents a plot of one economic target (product concentration) against another (biocatalyst yield). 
An improvement in the initial rate would in turn change the profile of product produced per mass of cell. 
Since product toxicity is established as a time and concentration based phenomena (Chapter 7), an 
increased reaction rate would lead to an increase in product concentration achievable at a certain 
biocatalyst concentration. Therefore a change in the expression level would not only cause a change in the 
product concentration but also a change in the biocatalyst yield obtained. Similarly, improvement of 
product tolerance or adopting ISPR would lead to an improvement in the product concentration attained by 
a particular cell concentration. Hence, both the approaches have the potential for bringing the process 
closer to the economic targets. In order to choose one method over another, the benefits attained in the 
economic targets can be assessed. This is done in the following sections. 
8.3.5 Effect of adopting a successful ISPR 
As mentioned earlier, product toxicity can either be overcome by employing a robust ISPR technique or by 
protein engineering. Ideally, one of the two strategies may be able to overcome the issue of product 
inhibition, but a combination of these techniques is often necessary. Although ISPR is a very valuable tool, it 
is often difficult to employ. In order to assess the improvement achieved in the system by removing 
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product inhibition, data set from a successfully implemented ISPR technique is necessary. However, since 
this data is unavailable for this system, the improvement is estimated based on several assumptions.  
To make a best-case estimate for the potential of a process implementing ISPR, the following assumptions 
have been made - (i) the duration of a batch is assumed to be 24 h  (ii) the biocatalyst is stable during this 
period (chapter 5) (iii) feeding of substrate is employed such that the substrate concentration is a constant 
over a period of time (iv) feeding of the substrate does not cause dilution (v) an ideal ISPR is employed 
which removes all the product as and when it is formed and (vi) as a consequence of iii-v, the initial rate is 
the rate throughout the duration of the batch.  
Improvement in product concentration from employing a successful ISPR 
Based on the above-mentioned assumptions, plots of product concentration achieved at the end of 24 h 
and biocatalyst yield against cell concentration are represented in Figure 8-8 for both the base case and the 
case where ISPR is employed. Biocatalyst yield is calculated by taking the ratio of the product concentration 
to the biocatalyst concentration. The target biocatalyst yield as represented in Table 8-1 is 10-35 
KgP/Kgcdw. However, since the biocatalyst is a speciality biocatalyst and is in development stage, a target 
of 10 gP/gcdw was chosen as the required biocatalyst yield.    
In order to calculate the product concentration when ISPR has been successfully implemented, the initial 
rate achieved at different cell concentrations (in the base case) was multiplied by the duration of the batch 
(24 h).   
 
Figure 8-8: Effect of employing successful ISPR on the final product titre and biocatalyst yield. Blue line indicates the current 
scenario for the reaction system while the red line indicates the scenario when ISPR is adopted. 
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From Figure 8-8, it can be inferred that the product concentration can be increased by adopting ISPR and 
depending on the duration for which the initial rate can be maintained, the final product titre achieved can 
be varied.  However, the biocatalyst yield is still 2-folds lower than the target biocatalyst yield. Therefore an 
improvement on the biocatalyst yield is required to make the cost contribution from the biocatalyst lower.  
8.3.6 Effect of improving protein expression  
The expression of an enzyme can be increased by either increasing the specific activity or the amount of 
protein per unit cell mass. While increasing the specific activity involves changing the protein structure, the 
increase in protein can be achieved by increasing the copy number. Both these strategies will influence the 
product concentration achieved in the end in different ways. Increase in protein concentration can only be 
done so long as inclusion bodies (yielding unusable protein) are not formed. Increasing the specific activity 
on the other hand increases the number of catalytic cycle per unit enzyme and therefore might lead to a 
lower stability of the catalyst. For further analysis, on product concentration and biocatalyst yield, a region 
where oxygen limitation does not exist has been chosen. At regions where oxygen becomes limiting, 
oxygen has to be supplied externally. In turn, this would cause changes in the biocatalytic reaction (for 
example changes in stability of the biocatalyst).  
In the following discussion, it is noteworthy that an assumption has been made that the expression has 
been improved 5-folds and all the protein obtained is active. 
However, a 5-fold improvement in expression will not translate to an improvement in the reaction rate by 5 
folds because the system will likely run into mass transfer limitations when the expression is improved (as 
seen in Chapter 7). Only 10% of the substrate was observed within the cell, therefore when the conversion 
rate is increased, the mass transfer of the substrate across the membrane would become limiting. The mass 
transfer issues can be overcome by operating with lyophilised cells and the analysis described further will 
be carried out with lyophilised cells to avoid mass transfer issues.  
An additional uncertainty that arises with improved expression is because of the nature of product toxicity 
(i.e. product toxicity is a function of duration of exposure and the product concentration). Partitioning of 
the product was found to be such that 50% of the product was trapped within the cells (or associated with 
the cell membrane). Hence, when lyophilised cells with its expression improved are used, it is likely possible 
that the product concentration in the microenvironment of the biocatalyst is lower, consequently there will 
be an improvement observed in the stability profiles.  
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However if we assume the use of lyophilised cells which exhibit the same stability profiles, the product 
concentration achieved in the linear region observed in Figure 8-6 can be used for predicting the product 
concentration. For an improvement in expression by 5 folds, the product concentration obtained from 1 
gdcw/L would be equivalent to that obtained with a biocatalyst concentration of 5 gdcw/L in the base case. 
Therefore, improvement in expression would potentially lead to the use of a lower cell concentration, 
consequently improving the biocatalyst yield.  
8.3.7 Improvement on process metrics achieved 
It is a common practice to represent the biocatalyst yield and the product concentration to depict the 
current scenario of the process160. In this case however, it can be seen that the biocatalyst yield varies with 
the cell concentration in both the base case as well as when the expression is improved. The product 
concentration achieved in both cases is also dependent on the catalyst concentration. In order to compare 
the improvements offered by each strategy, the catalyst concentration has been fixed based on the target 
biocatalyst yield (10 gP/gbiocatalyst) and the product concentration (50 g/L) to 5 gdcw/L.  
In Figure 8-8, it can be seen that the successful implementation of the ISPR leads the increase of the 
product concentration and biocatalyst yield from 2 g/g and 10 g/L to 2.5 g/g and 12.5 g/L. The base case 
values and the improved ISPR have been plotted in Figure 8-9. 
 
Figure 8-9: Representation of the effect of adopting ISPR and/or improved expression on the economic targets. (■) Base case at a 
catalyst concentration of 5 gcdw/L, (a) Effect of improving product tolerance through ISPR (b) represents the effect of improving 
both the product tolerance and the expression levels in a cell-free extract. 
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From the plot (Figure 8-9), it can be observed that the extent of improvement in biocatalyst yield and 
product titre achieved varies with the approach taken. Improving product tolerance seems to increase the 
product titre, albeit very little. But on adopting an improvement of both these strategies, the reaction 
system reaches the required targets. 
Of the two targets, it could be argued that the product concentration is seemingly the most important one 
as the cost and the ease of the downstream processing for the product is directly affected by the product 
concentration. As a result, it is desired that a high product titre is obtained from a reaction. Consequently, a 
stable biocatalyst that can handle high product concentrations should be available for a target reaction.  
8.4 Conclusion 
A systematic analysis of the limitations for the target system has been established. The analysis presented 
can be extended to other oxidase based biocatalytic processes to identify process limitations. In order to 
identify the key process limitation however, knowledge on the cost benefits is required to be coupled with 
the above presented methodology. In this particular case, both the biocatalyst tolerance to the product and 
the biocatalyst expression has to be improved to make the process economically viable.  
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 Biocatalyst washing  9.
In order to save on the cost-contribution from a biocatalyst, it is desired that the biocatalyst is employed in 
the crudest form possible and it is for this reason that the rational choice of biocatalyst would be a whole-
cell (when cells cannot be used in growing state). When using resting cells for biocatalysis, it is important to 
take care in the washing steps downstream of cell harvest. This chapter describes the technique involved in 
handling of the biocatalyst downstream of fermentation. 
9.1 Introduction 
It is desired that the biocatalyst is employed in the crudest form possible and it is for this reason that the 
rational choice of biocatalyst would be a whole-cell167. Whole-cell biocatalysts are used in cases where 
there is a need for co-factor regeneration. Additionally, the enzymes in whole-cells tend to be more stable 
because they are surrounded by their natural environment17,168. 
There are two common modes of operating a whole-cell based biocatalytic reaction (Figure 9-1). The 
former deals with combining the fermentation and the biocatalysis into a single step and the latter where 
the fermentation is separate from the biocatalysis. Host cell proteases are produced during the 
fermentation process which can break down the protein of interest169. By separating the residual 
fermentation media prior to biocatalysis, extracellular proteases produced by the cells can be removed. 
Also, when the biocatalysis is operated separate to the fermentation, more flexibility in terms of 
operational conditions can be achieved for these independent processes. Examples of the flexibility 
achieved include changing catalyst concentration that goes into biocatalysis, use of different temperature 
and pH criteria in fermentation and biocatalysis for achieving optimum concentrations in each of these 
individual steps. Therefore it is of significant advantage to de-couple the fermentation from the 
biocatalysis. Several biocatalytic processes employ this strategy. However, the handling of cells 
downstream of fermentation is quite different. Some investigations report the direct use of the cells after 
harvesting in the biocatalytic process in quesiton153,157,170, cells have been washed in buffer prior to use in 
other cases171-175. The reason for the practice of washing cells prior to biocatalysis is often not documented 
and we believe that it is intuitively done to remove residual media components and metabolites produced 
during fermentation.  
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In this chapter, the differences in activity of the whole-cell biocatalyst before and after washing for the 
target reaction system are presented. 
Fermentation
Waste
Cells
Cell
separation Biocatalysis
Substrate
Oxygen
Off-gasMedia
Innoculum
B. Resting-cell biocatalysis
A. Growing-cell biocatalysis
Off-gas
Media
Innoculum
Substrate for biocatalysis
Oxygen
 
Figure 9-1: Modes of operation of whole-cell biocatalysis. (A) Growing-cell biocatalysis (B) Resting-cell biocatalysis. 
  
9.2 Materials and Methods 
All chemicals unless specified were purchased at Sigma Aldrich (Steinhiem, Germany) and used as 
purchased.  The solvents were GC grade while the salts were analytical grade.  
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9.2.1 LB broth and plates 
LB broth was made with 10 g/L tryptone (Nordic biolabs AB, Täby, Sweden), 5 g/L yeast extract (Nordic 
biolabs AB, Täby, Sweden) and 10 g/L sodium hydroxide. To this, 2% (w/v) agar was added for making 
plates. The broth was autoclaved and ampicillin (filter-sterilized) was added to the broth (100 μg 
ampicillin/mL media) prior to use and the agar just prior to plating (100 μg ampicillin/mL media). 
9.2.2 TB broth 
TB broth was prepared by mixing 12 g/L tryptone (Nordic biolabs AB, Täby, Sweden), 24 g/L yeast extract 
(Nordic biolabs AB, Täby, Sweden), 4 mL/L glycerol, 12.54 g/L potassium mono-hydrogen phosphate and 
2.31 g/ potassium di-hydrogen phosphate.  
9.2.3 Biocatalyst production  
 Pre-culture 
Cells were streaked from a glycerol stock onto LB plates containing ampicillin. The plate was incubated at 
37 oC overnight. 5 mL of LB broth containing 100 μg/mL of ampicillin was inoculated with a colony from the 
LB-Amp plates. The culture tube was incubated at 30 oC in a shaker at 150 rpm for about 4 hours (OD600 0.6-
1.0).  
Fermentation 
All fermentations were carried out in un-baffled shake flasks. To 100 mL of media containing ampicillin, 1 
mL of pre-culture was added (1% inoculum). The flask was incubated at 30 oC, 150 rpm. Cells were 
harvested after 20 h of growth by centrifugation at 4000 rpm, 20 min and 4 oC.  Fermentation was carried 
out prior to each biocatalytic reaction.  
9.2.4 Biocatalyst washing 
Biocatalyst obtained from TB and LB media by centrifugation was weighed and re-suspended with 100 mM 
phosphate buffer containing mono and di-basic potassium salts at pH 7.6 (25 oC). Subsequently, the cells 
were centrifuged again and the supernatant discarded. The pellet was re-suspended in phosphate buffer to 
get a concentration of ~50 gcdw/L. This concentrate was diluted to perform the biotransformations. 
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9.2.5 Biocatalysis 
Biocatalytic reactions with whole-cells obtained from fermentation carried out in LB and TB media were 
carried out in baffled shake-flasks with 20 mL working volume (substrate and biocatalyst suspended in 100 
mM phosphate buffer, pH 7.6) incubated at 37 oC and 150 rpm. The substrate, aza-bicyclo-octane HCl was 
procured from AK Scientific, (Union City, CA, USA). The sampling frequency and duration varied depending 
on the experiment. Samples for gas chromatography were prepared and analysed as described in Chapter 
4145.  
9.2.6 Sonication 
In order to obtain crude cell extract from cells grown in TB media, the cells were harvested by 
centrifugation and re-suspended in phosphate buffer to get a final concentration of ~500 gcww/L. 5 mL of 
this solution was further diluted to 10 mL with phosphate buffer. The cell suspension was then sonicated at 
50% amplitude and 0.5 s cycles for 7 min. This suspension was directly used for biocatalysis.  
9.2.7 Effect of glycerol on the biocatalysis 
Biocatalysis was carried out using whole-cell biocatalyst obtained from LB media. The cells were harvested 
after shake-flask fermentation as explained previously. Different quantities of glycerol were added to 
baffled-shake flasks with a total working volume of 20 mL of reaction mixture such that a final 
concentration of glycerol was 0.025, 0.05, 0.1% (v/v). Samples were taken at 0, 15, 30, 45 min., 1, 2, 4, 6, 24 
hours and analysed in GC. Initial rates were calculated.  
Biocatalysis was performed before and after washing and the conversion of the substrate compared. 
9.3 Results and Discussion 
Several whole-cell oxidation reactions have been documented which include oxidases, oxygenases and 
monooxygenases. The drive for using a whole-cell for biocatalysis is either the need for co-factor 
regeneration, a need for a redox partner or the need to maintain the stability of the biocatalyst176. A major 
part of the cost of biocatalysis depends on the catalyst cost167. This in turn is dependent on the 
fermentation yield and the amount of active protein within the cell. For the monoamine oxidase system 
chosen for this reaction, the enzyme is soluble51 and the protein is constitutive (i.e. the enzyme is produced 
along with cell growth and does not need to be induced, Appendix III). Consequently, the protein content 
per g dry cell weight is low. Thus, in order to ensure enough biocatalyst is present in the system, it is 
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desired to use a large quantity of cells containing MAO for biocatalysis. As a result, it is necessary to 
produce high concentrations of cells during fermentation. Catalyst concentration can then be adjusted by 
concentration or dilution to fit the need of the biocatalysis. 
 9.3.1 Biocatalysis in LB and TB media 
In order to obtain higher biomass concentrations from the fermentation, it was desired that the media be 
changed to include a carbon source and eventually move to a fed-batch mode of fermentation. To assess 
the effect of growing the cells in the presence of a carbon source, preliminary shake-flask fermentation of 
cells grown in TB media with glycerol as a carbon source was performed. The switch from LB media to TB 
media caused an increase in cell mass obtained (in shake-flasks) from ~1 gdcw/L for cells grown in LB to 
~1.5 gcdw/L for cells grown in TB. Following cell harvest by centrifugation, the cells were suspended in 
phosphate buffer to obtain a biocatalyst concentration of ~5 gdcw/L (i.e concentrated) and the biocatalysis 
was followed as substrate conversion (substrate conversion is traced instead of product formation to 
account for the trimerization of the product as discussed in Chapter 6) and plotted (Figure 9-2). It can be 
seen from Figure 9-2 that conversion is affected when the biocatalyst was grown in TB media. Both the final 
conversion (achieved at the end of 24 h) and the rate of substrate conversion are affected (lower for 
biocatalysis with cells grown in TB media). 
 
Figure 9-2: Conversion profile of biocatalysis carried out by cells grown in LB media (■) and TB media (▲).Cell concentration of 5 
gcdw/L and substrate concentration of 2.96 g/L. 
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It was speculated that the results could arise from two separate phenomena (i) the cells when grown on TB 
or semi-defined media have a defined cell membrane causing a mass transfer limitation and (ii) media 
components cause inhibition to the biocatalyst.  
In a study with yeast cells, it was seen that when the cells were grown in nitrogen limited conditions, the 
cell membrane was more porous than when it was limited by carbon source (glucose)177. It was therefore 
speculated that membrane porosity and consequently the mass transfer across the membrane could affect 
the biocatalysis. In order to test mass transfer limitations due to cell membranes, the cells were sonicated 
and used for biocatalysis (Figure 9-3). The trend for conversion for cells grown in TB media was similar to 
the cells grown in LB indicating that the mass transfer limitations could arise from a more developed 
membrane. However, the rate was a little lower than when cells were grown in TB media although the final 
conversion achieved was the same (It is noteworthy that the catalyst concentration is the same in both the 
biocatalytic reactions). It was speculated that the media components could cause inhibition which leads to 
such a phenomena and this is discussed further. 
 
Figure 9-3: Conversion of substrate by cells grown on LB media (■) and crude extract on TB media (♦). Duplicates were made for 
the reaction with crude extract and the error bars drawn are indicating the standard error between the duplicates. 
9.3.2 Test for media component inhibition 
In order to test for inhibition from media components, the cells were washed with phosphate buffer to 
remove any media components from the cell suspension. The reaction profiles indicate that the washed TB 
cells perform as good as the LB cells that were also washed with phosphate buffer (Figure 9-4). This test 
further indicated that media components from fermentation broth might be influencing the biocatalysis 
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reaction. It should be noted that the washing step involves using phosphate buffer to re-suspend the cells 
after harvest by centrifugation followed by another round of centrifugation and re-suspension before the 
cells are used for biocatalysis. This procedure is believed to cause some damage to the cells (through lysis 
of the cell membrane) causing some of the biocatalyst to be lost during the centrifugation step). Therefore 
it is necessary to handle the catalyst from LB- and TB-grown cells in the same way to avoid differences that 
arise from the loss of biocatalyst.  Washing the whole-cells after fermentation seems to improve the 
conversion for cells grown in TB media (see Figure 9-2 and Figure 9-4). Therefore, the effect of residual 
media components on biocatalysis was tested by adding media component that is different between the 
two media (LB and TB) back to the biocatalytic reaction mixture. 
 
Figure 9-4: Comparison of substrate conversion profiles from cells grown in LB (□) and TB (◊) media that were washed prior to 
biocatalysis. 
The primary difference between LB and TB media is that the TB media has an additional carbon source 
(glycerol). The cells were grown by shake-flask fermentation prior to biocatalysis. Hence it was speculated 
that there might be residual glycerol in the reaction media that can cause a negative impact to the reaction. 
Trace amount of glycerol was added to the reaction mixture and the reaction progress was measured. 
Glycerol is expected to be consumed by the cells during fermentation, however since the cells were grown 
in shake-flasks, complete utilization of glycerol may not occur, therefore, only trace quantities of glycerol 
were added to the reaction mixture. The overall reaction trends were similar and all the reactions reached 
complete conversion (Figure 9-5). However, there was a significant difference in the initial rate was 
observed when the glycerol concentration was increased (Figure 9-6). This indicates that media 
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components (glycerol in this case) can affect biotransformation reactions and it is important to wash cells 
prior to catalysis.   
 
Figure 9-5: Biocatalysis in the presence of glycerol. Different concentrations (●) – 0%, (■) – 0.025%, (▲) – 0.05% and (♦) - 0.1% of 
glycerol were assessed. 
 
 
Figure 9-6: Effect of glycerol on the initial rate of the biocatalysis. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 5 10 15 20 25
Co
nv
er
si
on
 
Time (h) 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 0.02 0.04 0.06 0.08 0.1 0.12
In
iti
al
 ra
te
 (g
/L
/h
) 
Glycerol concentration (%v/v) 
136
Biocatalyst washing 
121 
 
9.3.3 Implications for operating with whole-cell biocatalysts 
Crudest possible form of enzyme (whole cells or crude extract) is desired to operate biocatalytic process as 
a rule of thumb to help reduce the cost contribution from the biocatalyst178. Whole-cell biocatalysis can be 
operated with either growing cells (fermentation and the biocatalysis occur simultaneously) or using resting 
cells (fermentation is separated from biocatalysis). Use of resting cells gives process flexibility in the sense 
that the ideal operating conditions for biocatalysis can be used as opposed to operating at conditions that 
is a compromise to both the fermentation and biocatalysis179. Considering a process is operated such that 
the fermentation is separated from the biocatalysis, we cannot simply dilute or concentrate the cells 
derived from the fermenter as discussed earlier. It might be necessary to wash the cells to remove residual 
media components and/or by-products from fermentation, which may interfere with biocatalysis180. A flow 
sheet of the process from fermentation to biocatalysis is presented in Figure 9-7. The cells obtained from 
fermentation are separated either by filtration or centrifugation and the cells are then washed with buffer 
to remove residual media components, followed by a cell separation stage. Following this the cells are 
suspended in buffer or water to obtain the desired biocatalyst concentration for the reaction. It should be 
noted that the addition of an extra step downstream of fermentation (which includes biocatalyst washing 
and an additional separation stage) would add to the cost contribution of the biocatalyst.  
In Figure 9-7 the cell concentrations are depicted as cf, cfc, cw, cb. It is noteworthy that the first cell 
separation would lead to an increase in cell concentration up stream of fermentation. Following this, one 
can wash the biocatalyst and separate the waste from the washing step from the cells (resulting in another 
concentrated cell solution). Finally the cells are suspended in the reactor used for biocatalysis to obtain the 
concentration desirable for biocatalysis.  
 
Figure 9-7: Whole-cell biocatalyst handling from fermentation to biocatalysis. Cf, cfc, cw, cb represent the biocatalyst 
concentrations coming from each unit operation. 
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9.4 Conclusions 
In this study, it has been shown that washing of cells is necessary for biocatalysis especially when cells are 
grown in media with additional carbon source (such as TB). Although this study has been carried out using 
E. coli cells, this phenomenon of media component influencing the performance of biocatalysis might be 
true for other organisms as well. It is also noteworthy that washing procedure (quantity of buffer used for 
washing with respect to the biomass produced) needs to be assessed and could vary dependent on the cells 
and the ease of separation of the residual media components. Also, it is important to consider the necessity 
of intact cell membranes for the biocatalytic process. Introducing a washing step would cause changes in 
cell membrane integrity which may affect the biocatalysis. Finally, the effect of the media components on 
the biocatalysis could be detrimental and motivates the need for de-coupling fermentation from the 
biocatalysis. 
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 Discussion 10.
Summary 
In this chapter, general discussions on oxidase-based biocatalytic processes based on the case study have 
been described. A part of this chapter presents the work in this thesis and explains how they can be 
extended to other biocatalytic oxidations. Concerns from the analysis of the experimental results have 
been raised whenever needed and forms a basis for future perspectives, which will be listed in Chapter 12.  
10.1 Process development  
The monoamine oxidase case study in part was dedicated to process development. Based on the results 
from identification of the constraints in this system through in silico analysis and further  from experimental 
validation, suggestions for improvement to make the process economically feasible have been identified.  
10.1.1 Methodology for process development of oxidases 
Biocatalytic reactions have two major considerations that need to be taken into account for process 
development. The first is what a biocatalyst can provide (and what its limitations are) and secondly how 
process engineering can assist in improving the process. Initial work on process development has focussed 
on fitting the process to the biocatalyst. However, the field of protein engineering has seen tremendous 
improvement making it possible to fit the enzyme to the limitations of the process120,181-183. However, 
certain limitations such as volatility of the substrate(s) and product(s) or thermodynamic equilibrium 
limitations of the reaction cannot be overcome by protein engineering and can only be overcome by 
process engineering or reaction engineering.  Therefore, it is desired that that biocatalyst development and 
process development must go hand-in-hand to overcome the limitations of a particular system. A combined 
effect of process development has been suggested by Ramos et al154. 
In this thesis, process development was made for the case study (MAO) where most of the published 
results were either in a patent or in the supplementary information of a manuscript by Köhler and co-
workers57,184.  It was therefore interesting to study the process aspects and the limitations for this bio-
oxidation for scale-up.  
141
Discussion 
126 
 
In order to get to process development, a systematic approach has been described. Firstly, a limited 
number of mutants (three) of the biocatalyst were available to test for the target system. The three 
enzymes were first used and the best mutant was selected for characterisation. The process targets for the 
system were set which include product titre and the biocatalyst yield.  
Following this, the most important step was to make an in silico analysis of the limitations of the target 
system to guide the experimentation and thereby help in making smarter choices between the process 
options available for the target system. In silico analysis also helps identify the potential limitations of the 
system prior to experimentation. For example, the differences in product and substrate properties will 
dictate the efficiency of product removal. The efficiency of product removal in turn will affect the product 
concentration that is required for separation and the cost of the downstream processing.  
Form the work of this thesis, a methodology for process characterisation for resting-cell, oxidase-based 
biocatalytic reaction can be derived and is presented in Figure 10-1.  
For the current system, in silico analysis provided vital information about the necessity of pH control in the 
target system as well as indicated the potential for substrate inhibition. Oxygen requirement was found to 
not be limiting for the target system. The experiments conducted were in part to validate the identified 
limitations from the analysis followed by quantification of other expected limitations such as product 
toxicity to the biocatalyst. Other limitations arising from the product have been discussed in Chapter 6. 
Finally a process limitation analysis has been conducted in Chapter 8, which goes to identify the bottleneck 
of the current process which is discussed in the following section.   
The methodology worked for the monoamine oxidase case study where the substrate had high solubility. In 
cases where substrate solubility is limited, there will be an additional limitation arising from the mass 
transfer of the substrate (in the second phase) to the cells. This would need to be addressed. The critical 
concentration of the substrate (with low solubility) will determine the necessity for substrate solubilisation 
efforts. If the substrate is toxic below the solubility limit, then solubilisation would not help improve the 
performance of the system. However, if the substrate is toxic above the solubility limit, then solubilisation 
of the substrate using a co-solvent would help improve the substrate mass transfer. If a co-solvent is used, 
then the stability of the biocatalyst in the co-solvent needs to be assessed.  
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Figure 10-1: Methodology for process development for oxidases using resting cells. 
To summarize, in the result presented in this thesis follow up from identification of target system down to 
identifying the cause for deactivation of biocatalyst. Implementation of a successful ISPR technique and 
scale-up remain to be achieved. 
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10.1.2 Process limitation analysis 
For a biocatalytic process with resting cells, the cost contribution from the biocatalyst (biocatalyst yield) 
and the product titre are the most important economic targets that need to be fulfilled. Since the 
monoamine oxidase example is an oxygen requiring system, oxygen has to be supplied in sufficient 
quantities to cope with the maximum rate of the reaction. Therefore, maximum rate is introduced in this 
thesis as a constraint to the system.  
To make a process limitation analysis, the effect of the catalyst concentration on the process limitation can 
be analysed as explained in Chapter 8. In Chapter 8, the maximum product concentration reached for a 
given cell concentration was studied and it was inferred that product concentration achieved was a linear 
function of cell concentration. It was also seen that the product toxicity limit is a function product 
concentration and the duration of exposure. Product toxicity can be overcome by adopting biocatalyst 
engineering182 for improving product tolerance or by removing the product from the microenvironment of 
the biocatalyst (such as by implementation of ISPR)155,185. Additionally, sensitivity analysis on the effect of 
overcoming the process limitations on process metrics revealed that the removing product toxicity alone is 
not enough to make the process economically feasible. The expression of the cells also needs to be 
improved to make the biocatalyst cost contribution reasonable. Expression of biocatalysts can be improved 
by biocatalyst engineering. 
When the expression levels are increased, then the potential initial rate of the reaction is also increased so 
long as mass transfer across the membrane is not limited. The system can go from being limited by the 
expression levels to limitation on transport across the membrane. However, several methods of 
permeabilization of the cell membrane are available and can be used150,186. Hence, transport across the 
membrane was not considered as a potential limitation to the system. Due to mass transfer limitations, it 
becomes advantageous to use cell-free extract or lyophilised cells.  
Increase in expression, would in turn have an effect on the oxygen demand from the process (since one mol 
of oxygen is used for every mol of substrate converted) as long as mass transfer across the membrane is 
not limiting. With the current system (i.e. at the current expression limit), oxygen has been identified to not 
be a constraint, however, when the expression is improved, it might become a problem. Operating at high 
cell concentrations will in turn shift the regime to oxygen limitation. It is noteworthy that although the 
system might run into oxygen limitation when rates over 100 mmol/L/h are achieved, it might not be 
necessary to operate the reaction at rates higher than that to achieve the product titre required within the 
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duration of a batch. Also the effects of oxygen supply and oxygen concentration on the stability of the 
biocatalyst need to be examined. 
Finally, substrate limitation was observed in this case study, and this has been listed as the last limitation. 
Various substrate supply strategies have been successfully implemented123,187,188. Therefore, it is not 
considered as a major limitation and listed as the last constraint. 
To summarize, from the results in Chapter 8, it was seen that the expression of the biocatalyst need to be 
improved even if product toxicity is overcome in order to achieve the targets for the biocatalyst yield. 
Following the expression limitation, product toxicity affects the reaction system severely. Thus, an order for 
the process limitations specific to the monoamine oxidase case can be arrived at and is depicted in Figure 
10-2. The figure has been drawn based on the assumption that there is no mass transfer limitation across 
the membrane.  
The limitations that arise in other oxidase systems would likely have a different order of occurrence. In 
principle, the order of the limitations can be identified based on the improvement gained on the process 
metrics by overcoming the process limitations that are identified for the system.  
 
 
Figure 10-2: Order for process limitations of the current system assuming that the increase in expression does not cause mass 
transport limitation of the substrate and product from the bulk across the membrane.  
Limitation 1 
• Expression level of the biocatalyst 
Limitation 2 
• Product toxicity 
Limitation 3 
• Oxygen supply 
Limitation 4 
• Substrate inhibition 
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10.1.3 Catalyst formulation 
All most all of the experiments in this study have been carried out using whole-cells. It is desired to operate 
a biocatalytic process with the crudest possible enzyme in order to save on the cost contribution from the 
biocatalyst. Use of whole cells from fermentation saves cost on the downstream of fermentation since 
protein isolation steps are avoided.  Also, the use of whole-cell protects the enzymes by keeping them in 
their natural environment and protects the target proteins from shear forces189,190. Whole-cells are often 
seen to be advantageous when co-factor regeneration is required, when a fusion-construct of a protein is 
desired (like in the case of P450s) or when de novo pathways of the cells are required for the biocatalytic 
process176.  
However, use of whole-cells can cause mass transport limitations of substrate and product across the cell 
membrane. While molecules that are nutrients for the cells are usually taken up by active transport. 
Transport of substrate molecules usually used for biocatalysis do not have active transport mechanisms and 
have to be transported by passive diffusion191. Therefore, cells need to be permeabilized in order to allow 
for transport across the membrane and prevent mass transfer limitations192. 
 Furthermore, when employing whole-cells for biocatalysis, product recovery becomes more complicated 
due to the product being trapped inside the cell (this has also been seen in our experimental results)193. It 
was seen that 50% of the product was associated with the cell membrane which could potential imply that 
there is a high product concentration in the microenvironment of the enzyme. By using a lyophilised 
system, the product concentration at the microenvironment would be lower, reducing product toxicity. It 
should be noted that the catalyst recovery is made more difficult when lyophilised cells are used. 
For the target system, experimental results have shown that the stability of the crude extract is as good as 
the whole-cells (which is often not the case in other oxidase systems, particularly amino acid oxidase). Also, 
there is no need for co-factor regeneration systems (since FAD is tightly bound to the enzyme). And finally, 
the expression levels of the enzyme are low and hence use of high catalyst concentration which causes 
downstream limitations in terms of product recovery.  
For the current process therefore, it could be more useful to use crude extracts which opens up the 
possibility of loading more catalyst in the reactors and possibly ease the separation of the product from the 
reaction mixture. Some studies have also reported higher activities for isolated enzymes compared to 
whole-cells194. Thus, if the expression of the system was improved, it would possibly be more advantageous 
to shift to isolated enzyme formulation.  
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10.1.4 Process outlook 
For the monoamine oxidase catalysed reaction, the following limitations have been identified – substrate 
and product inhibition, product toxicity, low expression levels and pH shift during the reaction.   
The first limitation to overcome has been identified as low expression level. The consequences of improving 
the expression levels have been explained in the previous section. In order to avoid mass transfer 
limitations across the membrane, use of lyophilised cells has been suggested.  
In order to lower the costs of biocatalyst production, it is desired that high cell densities are obtained from 
the fermentation. This necessitates the use of semi-defined media such that the fermentation is operated 
in a fed-batch mode. Consequently, it becomes necessary to wash the cells downstream of fermentation to 
remove residual media components and fermentation by-products (as seen in Chapter 9, use of high cell 
density media causes inhibition of the enzyme lowering its activity). 
Chapter 6 indicated that a pH shift should be expected for the target reaction system. Therefore, pH control 
is required for the process to be successful. 
In Chapter 7, it was seen that the biocatalyst was limited by product toxicity. To overcome product toxicity, 
ISPR using absorbent resins have been suggested.  Also, the optimum pH for separation was identified to be 
different from the pH optima for the reaction. As a result, pH adjustment is required before and after ISPR 
operation.  
From the above discussed constraints and assuming that the expression of the system is improved and ISPR 
operation using resins is successfully implemented, the process outlook from the biocatalyst production to 
product recovery can be depicted in Figure 10-3. First, the cells will be produced in a fed-batch mode of 
fermentation (to obtain high cell densities) followed by cell separation. Following this, the cells need to be 
washed to remove residual media components and the cells disrupted to get crude extracts. The crude 
enzyme would be used in a stirred tank reactor where oxygen supply, oxygen monitoring and pH control 
will be employed. Following the reaction vessel, an external packed bed with absorbent resins will be used 
for product removal. pH adjustment has to be made before ISPR to ensure that the process is operating at 
optimum conditions. A reverse osmosis step after the second pH adjustment is employed to prevent 
dilution of the reaction system. 
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Figure 10-3: Process outlook for monoamine oxidase catalysed biocatalysis assuming that the expression of the biocatalyst has 
been improved. 
The process can be extended to other biocatalytic processes. While the fermentation is preferably carried 
out in fed-batch mode, the catalyst formulation used depends on a case to case basis. For example, an 
extracellular protein or a whole-cell resting state based biocatalysis would not require cell disruption 
techniques.  
For biocatalytic processes, high processing intensities are usually desired. As a consequence, it is desired to 
operate at high substrate concentrations. While substrate inhibition and toxicity levels can vary, they will 
likely be present for biocatalytic processes and therefore a fed-batch mode of operation is desired.  
Similarly, to help the biocatalyst cope with high product concentrations, product removal strategies have to 
be applied. Depending on a case to case basis, the product removal strategy adopted would vary. 
10.2 Oxygen sensors as tools for oxidase-based biocatalytic processes 
The work presented in Chapter 4 describes the use of oxygen sensors for measuring Kla and for obtaining 
substrate inhibition profiles. The sensors in extension could be used when there is a change in oxygen 
concentration to track the progress of the reaction as well as for cases where kinetics for oxygen requiring 
reactions is desired. Nevertheless, care should be taken when implementing these sensors when the 
oxygen is produced or consumed by a side-reaction. For example, in a biocatalytic oxidation, if catalase is 
present in the enzyme formulation, it is desired to quantify the activity of the catalase and account for the 
oxygen produced during the degradation of hydrogen peroxide. Similarly, when product is labile or is 
substrate is used in side-reactions, it is likely that the oxygen sensors cannot be used for quantitation of the 
reaction. In these cases, it is necessary to make more experiments. The implementation of such sensors in 
biocatalytic oxidations can nevertheless provide a valuable tool for monitoring and control of the process.  
The following chapters would describe the conclusions of the thesis and some directions for future work.
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 Conclusions 11.
Biocatalysis has moved from a time where there was a lot of scepticism around the industrial application of 
biocatalytic reaction to where there are over 150 industrial reactions implemented at industrial scale17,195. 
Particularly, biocatalytic oxidations have been advocated in light of high biocatalytic selectivity and 
specificity. This is not without sound reason. Oxidases in particular have harnessed interest for industrial 
applications. The potential of oxidase reactions can be seen from the industrially implemented processes 
that employ oxidases (amine oxidase, amino acid oxidase and glucose oxidase).  
This thesis has focussed on process development for oxidase-based biocatalysis. Here, the biocatalyst was 
used in a whole-cell formulation (in resting mode) for catalysing the oxidation of a secondary amine to an 
imine (which is used as a building block for a drug to treat Hepatitis C). 
The significant conclusions from the MAO catalysed reaction system have been classified and listed. 
x A methodology for process development of oxidase based reaction has been arrived at in this 
thesis. The methodology includes the use of property prediction tools to gain process knowledge 
prior to experimentation. It was identified that oxygen supply will likely not be a problem for this 
system. While substrate inhibition and (co)product inhibition are potential limitations. The use of in 
silico analysis of the reaction system helped direct experimental work for the thesis.  
x In silico analysis of the substrate toxicity indicated that the substrate is toxic at concentrations over 
100 mM (~14.8 g/L) and was in line with experimental results. 
x Following this, experimental evaluation has been adopted to quantify the limitations that are 
present in the system. From the experimental evaluations co-product inhibition from the hydrogen 
peroxide was identified to be unproblematic due to the presence of catalase to cope. Product 
toxicity was identified as a potential limitation. Product toxicity has been established as a 
phenomenon that is time and catalyst concentration dependent for example exposure to 
approximately 1 g/L of product for 24 hours caused the activity of the biocatalyst to decrease by 
about 50%. 
x pH control was established as a critical process parameter that needs to be closely controlled. The 
biocatalyst lost ~50% of its activity with a pH shift of 1 unit.  
x The product produced in the target reaction system was identified to co-exist as a trimer which was 
not detectable by GC. 
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x Partitioning of the substrate and product within the cell and the reaction media is highly critical for 
whole-cell biocatalytic systems. About 10% of the substrate is within the cells while 50% of the 
product is trapped within the cells. Therefore, the product trapped in the cell should be considered 
for implementation of ISPR.  
x When fermentation is carried out for high cell-density cultures, it is of critical importance to wash 
the cells with buffer to remove residual media components that hamper the activity of the 
biocatalyst. 
x For the target reaction system, product toxicity and level of expression were identified as central 
hurdles that prevent the reaction from scale-up. Evaluation of the bottleneck revealed that while 
improvement in product tolerance would enable the target for product titre to be reached, it is 
imperative to improve the expression levels of the biocatalyst to reach the target biocatalyst yield. 
A combination of improvement of the expression of the biocatalyst in combination with the 
product tolerance is important for reaching the targets for the reaction. 
x Oxygen sensors have been used as a monitoring tool in the presence of solvents. The sensors have 
been shown to work in the presence of solvents are a highly versatile tool for online monitoring. 
The sensors can also be used as a screening tool.  
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 Future Perspectives 12.
Based on the work performed in this thesis and some directions for future work are proposed. 
Furthermore, further development of the biocatalysts or the tools that are available for biocatalytic 
reactions can have a significant impact on the perspective of operating oxidase-based reactions. Some of 
these improvements required are presented in this chapter.   
12.1 Future work specific to case study 
Development of a feeding strategy – In this study, to identify the potential bottlenecks to the process, 
substrate was fed after a certain amount of time. However, this is not an efficient feeding strategy. If the 
substrate is fed at the rate at which it is converted, there is a potential of improving the product titre in the 
end (as the product toxicity limit is also dependent on the duration of exposure). 
Catalyst development – During the bottleneck evaluation, it was seen that there is a need to improve the 
expression levels of the biocatalyst in order to operate the process within the cost contribution limit from 
the biocatalyst. Therefore, the expression of the biocatalyst should be improved. Since oxidases can 
operate outside the cell with remarkable stability, it could be an option to make the protein extracellular 
using a different expression system. This would allow for overexpression as well as easy recovery of the 
protein. 
Development of a method to track the trimer form of the product – One of the most important parts of 
process development is to keep track of the mass balances in the system. One of the limitations in the 
present system is that the detection method cannot identify the product trimer. As a result, it was never 
possible to verify if all the substrate was being converted into the product. Therefore, it is important to 
develop a method to quantify both forms of the product molecules. LC-MS could be a powerful tool for 
such an analysis. 
Overcome product toxicity – An attempt of ISPR using absorptive resins has been made in this thesis. While 
in principle this should work, but because most of the product (50%) was still trapped inside the cell, 
implementation of ISPR was difficult. For this reason, it is necessary to test the ISPR method suggested in 
this thesis or develop a new method using cell-free extracts to overcome the need for transport of the 
product across the cell membrane. Alternatively, the cells can be modified to be tolerant to high product 
concentrations.  
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Reactor engineering – Oxidases are enzyme that require oxygen supply. Some of these experiments for 
characterization have been carried out in shake-flasks and there is no difference in the biocatalysis profile 
between the shake-flask and the reactor. However, this is only true because of the low expression levels in 
the current system. On improving the expression, the supply of oxygen will become important and the use 
of reactors where air is sparged will become a necessity to harness the full capacity of the biocatalyst. 
Stability – This thesis has only assessed the stability of the enzyme when there is no reaction being carried 
out by it (i.e. storage stability). However, stability under reaction conditions has not been assessed. This 
could be done by operating the system under a continuous system and tracing the conversion loss over a 
period of time.  
Methodology development – A methodology for process development has been proposed in this thesis. 
However, the methodology does not include the cases where the substrate has low solubility. Also, the 
requirement of the cells metabolic activity has not been discussed or included. While solubility issues can 
occur in oxidases system, the requirement of cell’s metabolic activity is more common for other oxygen 
requiring systems (e.g. oxygenases).  
Economic evaluation and scale-up – The target monoamine oxidase system discussed in this thesis has not 
been scaled-up because of the need for improvement in the expression and product tolerance required to 
make the process economically viable. However, when these are circumvented, economic evaluation and 
scale-up become the apparent next step for the process.  
Furthermore, some general future work can be described for oxygen-requiring biocatalytic processes. 
Property prediction tools – While there are some property prediction tools available for academic use, 
they operate under certain assumptions (for example, solubility data available is usually presented in water 
at 25 oC) which may not be relevant under experimental conditions (where the solubility measurements 
vary due to presence of salts and the temperature is usually higher). Therefore, there is a need to develop 
property prediction tools which will make the in silico analysis more robust and consequently reduce the 
effort in terms of experimentation.  
Modelling – It is desirable to have models for the prediction of the biocatalytic oxidation. By developing 
such a model (including kinetics of the enzyme) and by including the entire process (i.e. substrate supply 
and product removal), the effect of implementing these technologies can be identified, and would be a 
valuable tool.  
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Development of oxygen supply technologies – Since oxidases are highly efficient enzymes that require 
oxygen for catalysis, it is necessary to develop oxygen supply strategies that are effective. Currently, oxygen 
supply is done with air at the rate of 100 mmol/L/h but depending on the choice of oxidase, higher oxygen 
concentrations maybe desired to keep up with the oxygen demand. Hence development of new oxygen 
supply technologies could be a useful tool for oxygen requiring biocatalysis. It should be kept in mind that 
the oxygen concentration could alter the stability of the biocatalysts and will need to be evaluated. 
Sensor development – The solvent-resistant oxygen sensors have been shown to be excellent tools for 
monitoring of oxygen requiring reactions that need to operate in the presence of solvents. However, the 
life-time of the sensor is currently short and need to be re-calibrated often. This is a disadvantage in 
operating with these systems especially in continuous reactors. Therefore, there is still some need to 
improve the stability of the sensors.  
Use of oxygen sensor as tools for oxygen requiring reactions – The sensors can also be used in two-phase, 
oxygen-requiring systems that involve the presence of an emulsion of the solvent and the aqueous phases. 
These reactions are often run (for example to achieve substrate supply or product removal). The sensor 
system discussed here has been used with a catalyst formulation that does not contain catalase. In 
principle, when catalase is present, they would degrade the hydrogen peroxide produced to oxygen and 
water and would influence the concentrations. These effects need to be considered when using the system 
for other operations. 
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Appendix I – Calibration curve 
Calibration curve for substrate 
A substrate stock of 200 mM solution was made and different volumes of the substrate solution were taken 
in an eppendorf tube to obtain different concentrations of the substrate as represented in Table A1. The 
volume of the sample was made up to 200 μL using phosphate buffer at pH 7.6. Sodium hydroxide was 
added to make the pH alkaline (this ensures that the substrate and product molecules are uncharged). To 
this 1mL of MTBE was added and the sample extracted to the MTBE phase. The solvent phase was dried 
with sodium sulphite and analysed in the GC. Triplicates were made and plotted (Figure A1). 
Table A 1: Volumes of stock solutions used to obtain the various concentrations 
Volume of stock 
(μL) 
Vol of 
buffer 
(μL) 
Vol of IS 
(μL) 
Volume of 
10M NaOH 
(μL) 
Conc 
(mM) 
200   100 100 200 
150 40 100 100 150 
80 120 100 100 80 
40 160 100 100 40 
30 170 100 100 30 
20 180 100 100 20 
10 190 100 100 10 
5 195 100 100 5 
2.5 197.5 100 100 2.5 
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Figure A 1 : Calibration curve obtained for the substrate. Triplicates were made and the accuracy determined. 
 
Test for instrumental error 
In order to check for instrumental error in injection, multiple injections were made from the same vial and 
this was tested with different substrate concentrations. The instrumental error on the injection was <1%.  
Table A 2: Multiple injections from the same vial to determine instrumental error 
 
 
Standard curve for product 
Product was synthesised at University College of London (UCL) and provided as a solid. The weight of the 
imine used for the standard curve is 0.02 g. The solid was first dissolved in 100 μL of concentrated HCl (6M) 
and then the volume was made up to 5 mL using phosphate buffer. This was used as the stock solution and 
the product concentrations were varied with buffer. The product was extracted to MTBE and the solvent 
phase was analysed. 
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1 2 3
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Table A 3: Volume of stock solutions of product used for obtaining different product concentrations 
Volume of stock 
(uL) 
Vol of 
buffer 
(uL) 
Vol of IS 
(uL) 
Volume of 
10M 
NaOH (uL) 
Conc 
(mM) 
200 0 100 10 12.21 
80 120 100 10 4.885 
40 160 100 10 2.443 
20 180 100 10 1.221 
10 190 100 10 0.611 
5 195 100 10 0.305 
 
 
Figure A 2: Calibration curve for the product 
Because the product forms a trimer which cannot be identified in the GC, this calibration curve was not 
generally used, but the reproducibility in the areas and concentration indicate that equilibrium in the 
solvent phase is constant at a given product concentration.   
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Appendix II – DCW measurements 
 
A standard curve was made to convert wet cell weights obtained in fermentation and the stock solution 
obtained after concentration to determine the corresponding dry cell weights. Dry cell weight was 
measured by filtering the cells (using a vacuum pump) and drying them in a microwave (low power, 20 
min). The dried filter paper was then left in the desiccator for at least an hour before the weight was 
measured. 
Fermentation yield 
In order to assess the fermentation yield in LB media, cells were grown in LB media and samples were taken 
at regular intervals. The OD and the dry cell weights were measured and plotted (Figure A 3). 
 
Figure A 3: Fermentation yield obtained from growing cells in LB media 
Conversion to dry cell weight 
In order to use the cells for biocatalysis, the cells needed to be concentrated. Therefore, the cells from the 
shake-flasks were harvested (by centrifugation) and resuspended in phosphate buffer to obtain a stock at a 
concentration of 500 gcww/L. This stock was then diluted to obtain the different cell concentrations. 1 mL 
of the suspension was filtered and used for dry cell weight measurements.  
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Figure A 4: Conversion of wet cell weight to dry cell weight. Triplicate measurements were made and plotted. 
It should be noted that the dry cell weight is about one-tenth of the wet cell weight (Figure A 4). This could 
be because of the water trapped in the cell pellet which adds to the wet cell weight.  
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Appendix III – Biocatalyst 
characteristics 
SDS PAGE 
In order to check for the protein production in E. coli BL 21 (DE3) strains, SDS PAGE was run (Figure A 5). 
 
Figure A 5: SDS PAGE of cell pellet (right of molecular marker) and supernatant (left of molecular marker) of lysed E Coli BL21 
cells to check for protein.  
The molecular weight of the protein is about 55 kDa (Nick Turner, personal communication). The gel 
indicates that the protein is barely seen around a molecular weight of 55 kDa, indicating that the 
fermentation yield for the protein is low (expression level).  
Test for plasmid leak 
To verify if the insert is being lost from the plasmid, we tried to isolate and clone the plasmid onto an HMS 
strain where we expected better plasmid integrity. After the cloning, both strains were fermented in LB 
media and used for biocatalysis and the substrate conversion measured and plotted Figure A 6. 
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Figure A 6: Comparison of biocatalysis profile when the enzyme was expressed in BL21 and HMS strains.  
From the above figure, it can be seen that both the BL21 and HMS strains have very similar reaction profiles 
indicating no change in shifting from one strain to another.  
Then, we decided to check for induction of the protein production using IPTG in the HMS strains to test for 
effect of induction Figure A 7. 50 μl of 100 mM IPTG was added when the OD 600 reached a value of 0.9. The 
test indicated that there is little difference in reaction profiles when induced with IPTG. This indicates that 
the induction does not help to produce more biocatalyst. This might be due to the protein being 
constitutive.  
 
 
Figure A 7: Test for induction of MAO production using IPTG. 
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Test for constitutive expression of the protein 
In order to check for constitutive expression of the protein, cells were harvested at different times of 
fermentation and used for carrying out a standard reaction. 1mL of the broth was harvested and the pellet 
was resuspended in 2mL of phosphate buffer when the cells had been growing for 4h and 6h. In order to 
get a comparison to the standard reaction the cells harvested after 18h of fermentation (fermentation was 
carried out without IPTG) was resuspended in phosphate buffer and used for biotransformation at a 
concentration of 5 gcdw/L. The conversions obtained at these conditions are reported in Table A 4. 
Table A 4: Conversions obtained by HMS cells grown for different times and a reaction with 10mM of substrate was carried out 
and conversion measured at 21h. Duplicates were represented in the table below. 
Experiment number Biocatalyst harvested 
after fermentation at 
times t= (h) 
Conversion at 21h of 
biocatalysis (%) 
Experiment 1 4 8.07 
Experiment 1 4 7.37 
Experiment 2 6 14.49 
Experiment 2 6 16.30 
Experiment 3 24 95.33 
Experiment 3 24 92.51 
 
These results indicate that the protein is produced constitutively inside the cells. 
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Appendix IV – Charge of substrate and 
product with respect to pH 
 
In order to assess the differences in properties of the substrate and product in terms of charge, a plot of 
the ratio of uncharged substrate species to the charged substrate and the corresponding pH was plotted 
(Figure A 8). Plot was obtained using the Hassel-Bach equation and the pKa values of the substrate and the 
product. The plot indicates that the product is completely uncharged around pH 9.5 while all of the 
substrate at this pH is charged. This difference in charges can be exploited for product removal strategies.  
 
 
Figure A 8: Effect of pH on the charge of the substrate and the product
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Appendix V – Product extraction 
 
In order to obtain product for NMR analysis, three extraction steps with MTBE were made. To determine if 
the entire product was extracted, the MTBE phase before and after extraction was measured. A plot of the 
relative response of the product to the number of extraction steps was obtained (Figure A 9). This indicated 
that the entire product produced during the reaction has been extracted with three steps of extraction.  
 
 
Figure A 9: Extraction of product with MTBE for isolation of product. 
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Appendix VI – NMR analysis 
 
To confirm the presence of a trimer, NMR analysis was performed. 1H NMR (300 Hz) of the substrate, 
isolated product and extracts from during the reaction were performed to obtain an idea about the 
presence of a trimer. NMR obtained was then compared to that from the literature57. 
NMR of Substrate 
 
Figure A 10: NMR spectra of pure substrate (3-aza bicycle octane [3,3,0] HCl 
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 NMR of isolated product 
 
Figure A 11: NMR spectra of isolated product  
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NMR from biotransformation 
The reaction mixture was harvested at t=4h and t=24h. 
NMR from biotransformation (t=4h) 
 
Figure A 12: NMR spectra of biotransformation mixture at t=4h  
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NMR from biotransformation (t=24h) 
 
Figure A 13: NMR spectra of biotransformation mixture at t=24h  
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Appendix VII – Test for rate limitation  
To test for rate limitation at different cell concentrations and substrate concentrations, the product 
concentration obtained was plotted as a function of cell concentration and time. By doing so, the reaction 
rate is normalised to the biocatalyst concentration. If the reaction system becomes rate limited, the 
reaction profiles for the different biocatalyst concentrations would not overlap. The figure indicates that 
the biocatalytic reaction is not oxygen limited at these biocatalyst concentrations. 
 
 
 
Figure A 14: Product concentration achieved in a reaction where a substrate concentration of (a) 2.6 g/L, (b) 7 g/L was converted 
as a function of reaction time and biocatalyst concentration. Biocatalyst concentration: (●) – 20 gcdw/L, (■) – 10 gcdw/L, (▲) – 5 
gcdw/L, (♦) – 2.5gcdw/L and (○) – 1.25 gcdw/L. 
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